<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vani="http://vivani.com/20251231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vani-20251231.xsd" xlink:type="simple"/>
    <context id="D20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="I20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="D20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="D20240229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="D20240528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2024-05-28</startDate>
            <endDate>2024-05-28</endDate>
        </period>
    </context>
    <context id="D20240904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2024-09-04</startDate>
            <endDate>2024-09-04</endDate>
        </period>
    </context>
    <context id="D20230201_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="D20240926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <context id="D20240703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2024-07-03</startDate>
            <endDate>2024-07-03</endDate>
        </period>
    </context>
    <context id="I20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20221231_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="D20221208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2022-12-08</startDate>
            <endDate>2022-12-08</endDate>
        </period>
    </context>
    <context id="D20251231_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20241231_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20231231_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="D20251231_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="I20251231_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="D20251231_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="I20241231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20241231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20241231_MoneyMarketFundsMember_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_MoneyMarketFundsMember_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_MoneyMarketFundsMember_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_MoneyMarketFundsMember_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_FurnitureAndFixturesMember_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_FurnitureAndFixturesMember_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_ComputerEquipmentMember_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20231231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="D20251231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="I20251231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="D20251231_RightOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vani:RightOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="I20241231_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_ComputerEquipmentMember_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="D20251231_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20241231_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20231231_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20251231_EquipmentMember_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_EquipmentMember_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20231231_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="D20241231_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20240301_SecuritiesPurchaseAgreementMember_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="I20251231_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="D20251231_MinimumMember_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_MaximumMember_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_MinimumMember_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_MaximumMember_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20240301_WarrantMember_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="D20240301_SecuritiesPurchaseAgreementMember_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="I20240422_SalesAgreementMember_JefferiesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="I20251231_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241108_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-08</instant>
        </period>
    </context>
    <context id="D20241108_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-08</startDate>
            <endDate>2024-11-08</endDate>
        </period>
    </context>
    <context id="I20251231_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20251231_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241219_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="D20251231_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20240301_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="D20251231_CommonStockMember_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="I20240930_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20240930_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20221121_AlamedaCAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:AlamedaCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="D20221121_ValenciaCAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:ValenciaCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="D20251231_BiopharmDivisionMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vani:BiopharmDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_NeurostimulationDivisionMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vani:NeurostimulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_BiopharmDivisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vani:BiopharmDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_NeurostimulationDivisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vani:NeurostimulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20230201_SubleaseStorageSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:SubleaseStorageSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="D20230201_LessorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:LessorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="I20251231_EquityIncentivePlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vani:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="D20241231_StockOptionsWithServiceVestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vani:StockOptionsWithServiceVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20251231_NanoPrecisionMedicalIncWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vani:NanoPrecisionMedicalIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="D20251231_EquityIncentivePlansMember_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vani:EquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_LessorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:LessorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="I20251231_LessorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:LessorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="D20251231_WarrantMember_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20221231_CortigentIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">vani:CortigentIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="I20241231_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_CertificatesOfDepositMember_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_CertificatesOfDepositMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_CertificatesOfDepositMember_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20221121_AlamedaCAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:AlamedaCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="D20250930_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250326_EntityAffiliatedWithDirectorMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="D20250326_EntityAffiliatedWithDirectorMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-26</startDate>
            <endDate>2025-03-26</endDate>
        </period>
    </context>
    <context id="I20250512_IndependentDirectorOneMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vani:IndependentDirectorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="D20250512_IndependentDirectorOneMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vani:IndependentDirectorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="I20250512_PrivatePlacementMember_EntityAffiliatedWithDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="D20250811_PrivatePlacementMember_IndependentDirectorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vani:IndependentDirectorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="I20251231_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20241231_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20191231_NanoPrecisionMedicalIncWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vani:NanoPrecisionMedicalIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D20201231_NanoPrecisionMedicalIncWarrantMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vani:NanoPrecisionMedicalIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="D20211231_NanoPrecisionMedicalIncWarrantMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vani:NanoPrecisionMedicalIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="D20231231_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="D20231231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="I20260715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2026-07-15</instant>
        </period>
    </context>
    <context id="I20240422_SecuritiesPurchaseAgreementMember_JefferiesLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="I20250811_EntityAffiliatedWithDirectorAndInvestorMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="I20250811_IndependentDirectorOneMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vani:IndependentDirectorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="D20251001_SubleaseForManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">vani:SubleaseForManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="D20240126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2024-01-26</startDate>
            <endDate>2024-01-26</endDate>
        </period>
    </context>
    <context id="I20251231_BiopharmDivisionMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vani:BiopharmDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20251231_NeurostimulationDivisionMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">vani:NeurostimulationDivisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="I20260325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <instant>2026-03-25</instant>
        </period>
    </context>
    <context id="D20251231_StockOptionsWithServiceVestingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vani:StockOptionsWithServiceVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_EntityAffiliatedWithDirectorAndInvestorMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_CommonStockMember_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20250917_CortigentIncMember_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">vani:CortigentIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vani:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <context id="D20250917_CortigentIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">vani:CortigentIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <context id="I20250917_CortigentIncMember_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">vani:CortigentIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vani:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-17</instant>
        </period>
    </context>
    <context id="I20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-25</instant>
        </period>
    </context>
    <context id="I20260125_SubsequentEventMember_ThinkEquityLlcMember_PlacementAgencyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:ThinkEquityLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vani:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-25</instant>
        </period>
    </context>
    <context id="D20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-25</startDate>
            <endDate>2026-01-25</endDate>
        </period>
    </context>
    <context id="D20260125_SubsequentEventMember_PlacementAgencyAgreementMember_ThinkEquityLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:ThinkEquityLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vani:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-25</startDate>
            <endDate>2026-01-25</endDate>
        </period>
    </context>
    <context id="D20251231_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_CH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20251026_CommonStockMember_EntityAffiliatedWithDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-26</instant>
        </period>
    </context>
    <context id="I20251026_ThinkEquityLlcMember_PlacementAgencyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:ThinkEquityLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vani:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-26</instant>
        </period>
    </context>
    <context id="D20251026_ThinkEquityLlcMember_PlacementAgencyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:ThinkEquityLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vani:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-26</startDate>
            <endDate>2025-10-26</endDate>
        </period>
    </context>
    <context id="D20251026_ThinkEquityLlcMember_PlacementAgencyAgreementMember_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:ThinkEquityLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vani:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-26</startDate>
            <endDate>2025-10-26</endDate>
        </period>
    </context>
    <context id="D20251026_CommonStockMember_EntityAffiliatedWithDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:EntityAffiliatedWithDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-26</startDate>
            <endDate>2025-10-26</endDate>
        </period>
    </context>
    <context id="D20251231_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_WarrantMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_EmployeeStockOptionMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_RestrictedStockUnitsRSUMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_WarrantMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_EmployeeStockOptionMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20241231_RestrictedStockUnitsRSUMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_LicenseAndSupplyAgreementMember_OkavaPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:OkavaPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vani:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_ThinkEquityLlcMember_PlacementAgencyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vani:ThinkEquityLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vani:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_NanoPrecisionMedicalIncWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">vani:NanoPrecisionMedicalIncWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20250805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2025-08-05</startDate>
            <endDate>2025-08-05</endDate>
        </period>
    </context>
    <context id="I20241231_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20251231_CH_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="D20251231_43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001266806</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Week">
        <measure>utr:WK</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="N">
        <measure>vani:Number</measure>
    </unit>
    <unit id="ITEM">
        <measure>vani:ITEM</measure>
    </unit>
    <unit id="SEGMENT">
        <measure>vani:Segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="D20251231" id="Tag3">0001266806</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="D20251231" id="Tag4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="D20251231" id="Tag5">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="D20251231" id="Tag6">2025</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag contextRef="D20251231" id="Tag7">false</dei:AmendmentFlag>
    <dei:EntityAddressStateOrProvince contextRef="D20251231" id="Tag8">CA</dei:EntityAddressStateOrProvince>
    <vani:ShareBasedPaymentAwardPercentageOfAwardShallVestOnHurdleAchievementDateSubjectToAchievementOfPerformanceCondition
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag9"
      unitRef="Pure">0.33</vani:ShareBasedPaymentAwardPercentageOfAwardShallVestOnHurdleAchievementDateSubjectToAchievementOfPerformanceCondition>
    <vani:ShareBasedPaymentAwardPercentageOfAwardShallVestFirstAnniversaryAfterHurdleAchievementDateSubjectToAchievementOfPerformanceCondition
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag10"
      unitRef="Pure">0.33</vani:ShareBasedPaymentAwardPercentageOfAwardShallVestFirstAnniversaryAfterHurdleAchievementDateSubjectToAchievementOfPerformanceCondition>
    <vani:ShareBasedPaymentAwardPercentageOfAwardShallVestSecondAnniversaryAfterHurdleAchievementDateSubjectToAchievementOfPerformanceCondition
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag11"
      unitRef="Pure">0.33</vani:ShareBasedPaymentAwardPercentageOfAwardShallVestSecondAnniversaryAfterHurdleAchievementDateSubjectToAchievementOfPerformanceCondition>
    <vani:ShareBasedPaymentAwardPercentageOfAwardShallVestOnHurdleAchievementDateSubjectToAchievementOfPerformanceCondition
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag12"
      unitRef="Pure">0.33</vani:ShareBasedPaymentAwardPercentageOfAwardShallVestOnHurdleAchievementDateSubjectToAchievementOfPerformanceCondition>
    <vani:ShareBasedPaymentAwardPercentageOfAwardShallVestFirstAnniversaryAfterHurdleAchievementDateSubjectToAchievementOfPerformanceCondition
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag13"
      unitRef="Pure">0.33</vani:ShareBasedPaymentAwardPercentageOfAwardShallVestFirstAnniversaryAfterHurdleAchievementDateSubjectToAchievementOfPerformanceCondition>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="D20251231" id="Tag20">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="I20251231"
      id="Tag21"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="I20241231"
      id="Tag22"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration contextRef="D20251231_DomesticCountryMember" id="Tag25">http://xbrl.sec.gov/country/2025#CA</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="D20251231" id="Tag26">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="D20251231" id="Tag27">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="D20251231" id="Tag28">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="D20251231" id="Tag29">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="D20251231" id="Tag30">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="D20251231" id="Tag31">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="D20251231" id="Tag32">In addition to the services provided by our MSP, we  have also formed an IT Steering Committee, whose members include representatives from our management team as well as our MSP, to review our cybersecurity program initiatives and related program metrics.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <vani:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodIncludingSubsequentPeriodToPerformancePeriodEndDate
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag51">P6Y</vani:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodIncludingSubsequentPeriodToPerformancePeriodEndDate>
    <vani:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodSubsequentToPerformancePeriodEndDate
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag52">P2Y</vani:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodSubsequentToPerformancePeriodEndDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="D20251231_43" id="Tag222">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="D20251231_43" id="Tag223">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="D20251231_43" id="Tag224">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="D20251231_43" id="Tag225">false</ecd:Rule10b51ArrTrmntdFlag>
    <vani:MediumTermNotesTerm
      contextRef="D20250917_CortigentIncMember_PromissoryNoteMember"
      id="Tag263">P5Y</vani:MediumTermNotesTerm>
    <dei:DocumentType contextRef="D20251231" id="Tag781">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="D20251231" id="Tag769">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="D20251231" id="Tag788">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D20251231" id="Tag768">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D20251231" id="Tag770">001-36747</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D20251231" id="Tag779">Vivani Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D20251231" id="Tag776">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D20251231" id="Tag764">02-0692322</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D20251231" id="Tag767">1350     S. Loop Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D20251231" id="Tag763">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="D20251231" id="Tag766">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D20251231" id="Tag790">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D20251231" id="Tag773">506-8462</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D20251231" id="Tag775">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D20251231" id="Tag780">VANI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D20251231" id="Tag777">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="D20251231" id="Tag782">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="D20251231" id="Tag783">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="D20251231" id="Tag784">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="D20251231" id="Tag785">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D20251231" id="Tag771">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D20251231" id="Tag772">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D20251231" id="Tag774">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="D20251231" id="Tag778">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="D20251231" id="Tag786">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="I20250630"
      decimals="-5"
      id="Tag787"
      unitRef="USD">45900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I20260325"
      decimals="0"
      id="Tag789"
      unitRef="Shares">84647803</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="D20251231" id="Tag765">Portions
of the registrant&#x2019;s Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders (the &#x201c;2026 Proxy Statement&#x201d;)
are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The registrant intends
to file a Proxy Statement pursuant to Regulation 14A with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;)
within 120 days after the end of registrant&#x2019;s fiscal year end of December 31, 2025.

</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="D20251231" id="Tag880">
&lt;div style="margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;a href="#TOC" id="BDJ5_25102024134849680" style="text-decoration: none; color: #000000; cursor: default; outline: none; pointer-events: none;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;&lt;b&gt;Item &lt;span id="fs_E33EPVXJUO00000000000000000000fs" style="display: inline; line-height: inherit;"&gt;1&lt;/span&gt;C. Cybersecurity Risk Management.&lt;/b&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit; font-weight: bold;"&gt;Overview&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit; text-indent: 0.25in; margin: 0px;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;We recognize the critical importance of m&lt;/span&gt;aintaining the safety and security of our information technology systems and data and maintain a cybersecurity risk management program as a part of our overall risk management strategy that is focused on identifying, assessing and managing cybersecurity risks. &lt;span style="-sec-ix-hidden:Tag28;line-height: inherit;;"&gt;&lt;span style="-sec-ix-hidden:Tag27"&gt;We engage a Managed Services Provider (&#x201c;MSP&#x201d;),&lt;/span&gt; with a highly experienced and responsive staff including a virtual Chief Information Officer (&#x201c;vCIO&#x201d;), to assist us with the identification, monitoring and management of risks from cybersecurity threats. They assist us with our technology, infrastructure and risk management through the deployment of a number of security controls and tools. We also take steps to limit third-party vendors&#x2019; access to our systems, and we are in the process of developing additional vendor risk management procedures.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fs_O0JCRDFN8000000000000000000000B"&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Board Oversight of Cyber Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit; margin: 0px; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;The Audit Committee of our Board of Di&lt;/span&gt;rectors oversees our policies and procedures with respect to risk management, including our management of risks from cybersecurity threats. &lt;span id="fs_7SSNRXQLZ400000000000000000000FM" style="line-height: inherit;"&gt;&lt;span style="-sec-ix-hidden:Tag29;line-height: inherit;;"&gt;The Audit Committee administers this cybersecurity risk oversight function through the receipt and review of reports from the management team and the vCIO on the Company&#x2019;s information technology systems and the status of the cybersecurity risk management tools.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;b&gt;Cybersecurity Risk Management and Strategy &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-indent: 18pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;We rely on information technology systems and data processing so that we and our service providers, collaborators, consultants, contractors or partners can operate to collect, process, transmit and store electronic information in our day-to-day operations. Our internal computer systems and data processing along with those of our third-party vendors, consultants, collaborators, contractors or partners may be vulnerable to risks from cybersecurity threats. &lt;span id="fs_OCHFGX599C00000000000000000000FM"&gt;&lt;span style="-sec-ix-hidden:Tag26"&gt;To help manage these risks, we convene a monthly IT Steering Committee and engage and rely on external experts, including an Information Technology MSP.&lt;/span&gt;&#160;In &lt;span id="fs_IY5TA0I21S00000000000000000000fs"&gt;2025&lt;/span&gt;, we adopted an IT Business Continuity and Disaster Recovery Plan, and we are currently in the process of developing additional cybersecurity policies and procedures as we continually work to enhance and evolve our program in light of the constantly evolving threats to our environment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;Our MSP assists us with our technology, infrastructure and risk management through the deployment of a number of security controls and tools, including, but not limited to, endpoint protection tools, phishing protection and access controls. We also take steps to limit third-party vendors&#x2019; access to our systems, and we are in the process of developing additional vendor risk management procedures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;Program highlights include:&lt;/span&gt;&lt;/p&gt;
&lt;ul style="list-style-type: disc; margin-left: 18px; margin-bottom: 0px;"&gt;
&lt;li class="mylistitemclass" style="font: 10pt / 1.2 'Times New Roman', Times, serif;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt; Aligning with various government and industry standards such as the National Institute of Standards and Technology (&#x201c;NIST&#x201d;) Cybersecurity Framework and others,&lt;/span&gt;&lt;/li&gt;
&lt;li class="mylistitemclass" style="font: 10pt / 1.2 'Times New Roman', Times, serif;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;Conducting ongoing security awareness training to keep employees informed of threats and how to spot them,&lt;/span&gt;&lt;/li&gt;
&lt;li class="mylistitemclass" style="font: 10pt / 1.2 'Times New Roman', Times, serif;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;Evaluating the cybersecurity policies of third-party vendors and service providers,&lt;/span&gt;&lt;/li&gt;
&lt;li class="mylistitemclass" style="font: 10pt / 1.2 'Times New Roman', Times, serif;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;Implementing redundant systems for mission critical operations,&lt;/span&gt;&lt;/li&gt;
&lt;li class="mylistitemclass" style="font: 10pt / 1.2 'Times New Roman', Times, serif;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;Developing and implementing Business Continuity/Disaster Recovery plans and procedures, and&lt;/span&gt;&lt;/li&gt;
&lt;li class="mylistitemclass" style="font: 10pt / 1.2 'Times New Roman', Times, serif;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;Incorporating robust protective and mitigating security measures &lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="border-right: none; border-left: none; line-height: inherit;"&gt;&lt;span id="fs_GBQ6MYNMZK00000000000000000000FM" style="line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;&lt;span style="-sec-ix-hidden:Tag30;line-height: inherit;;"&gt;To date, we have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;However, like other companies in our industry,&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt; &lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;we and our third-party vendors&lt;/span&gt; may, from time to time, experience threats and security incidents that could affect our information or systems.&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;b&gt;Governance Related to Cybersecurity Risks&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fs_1YIURWS74W00000000000000000000"&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0.25in; z-index: 40;"&gt;&lt;span style="border-right: none; border-left: none; font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="-sec-ix-hidden:Tag32;line-height: inherit;;"&gt;In addition to the services provided by our MSP, &lt;/span&gt;&lt;span id="fs_64JF1L9O8000000000000000000000FM" style="line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;we have also formed an IT Steering Committee, whose members include employees with relevant experience, representatives from our management team and MSP, as well as our&#160;vCIO, to review our cybersecurity program initiatives and related program metrics.&lt;/span&gt;&lt;span id="fs_UIPZAADLCG00000000000000000000FM" style="line-height: inherit;"&gt; &lt;span id="fs_FU6BW5SL8W00000000000000000000FM"&gt;Our IT Steering Committee provides cybersecurity updates and reports to our Audit Committee at each quarterly meeting or more frequently as needed.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;
</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="D20251231" id="Tag878">
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Board Oversight of Cyber Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit; margin: 0px; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;The Audit Committee of our Board of Di&lt;/span&gt;rectors oversees our policies and procedures with respect to risk management, including our management of risks from cybersecurity threats. &lt;span id="fs_7SSNRXQLZ400000000000000000000FM" style="line-height: inherit;"&gt;&lt;span style="-sec-ix-hidden:Tag29;line-height: inherit;;"&gt;The Audit Committee administers this cybersecurity risk oversight function through the receipt and review of reports from the management team and the vCIO on the Company&#x2019;s information technology systems and the status of the cybersecurity risk management tools.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="D20251231" id="Tag879">&lt;span style="-sec-ix-hidden:Tag29;line-height: inherit;;"&gt;The Audit Committee administers this cybersecurity risk oversight function through the receipt and review of reports from the management team and the vCIO on the Company&#x2019;s information technology systems and the status of the cybersecurity risk management tools.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="D20251231" id="Tag877">&lt;span style="-sec-ix-hidden:Tag26"&gt;To help manage these risks, we convene a monthly IT Steering Committee and engage and rely on external experts, including an Information Technology MSP.&lt;/span&gt;&#160;In &lt;span id="fs_IY5TA0I21S00000000000000000000fs"&gt;2025&lt;/span&gt;, we adopted an IT Business Continuity and Disaster Recovery Plan, and we are currently in the process of developing additional cybersecurity policies and procedures as we continually work to enhance and evolve our program in light of the constantly evolving threats to our environment.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="D20251231" id="Tag881">&lt;span style="line-height: inherit;"&gt;&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;&lt;span style="-sec-ix-hidden:Tag30;line-height: inherit;;"&gt;To date, we have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;However, like other companies in our industry,&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt; &lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;we and our third-party vendors&lt;/span&gt; may, from time to time, experience threats and security incidents that could affect our information or systems.&lt;/span&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="D20251231" id="Tag882">
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0.25in; z-index: 40;"&gt;&lt;span style="border-right: none; border-left: none; font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="-sec-ix-hidden:Tag32;line-height: inherit;;"&gt;In addition to the services provided by our MSP, &lt;/span&gt;&lt;span id="fs_64JF1L9O8000000000000000000000FM" style="line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;we have also formed an IT Steering Committee, whose members include employees with relevant experience, representatives from our management team and MSP, as well as our&#160;vCIO, to review our cybersecurity program initiatives and related program metrics.&lt;/span&gt;&lt;span id="fs_UIPZAADLCG00000000000000000000FM" style="line-height: inherit;"&gt; &lt;span id="fs_FU6BW5SL8W00000000000000000000FM"&gt;Our IT Steering Committee provides cybersecurity updates and reports to our Audit Committee at each quarterly meeting or more frequently as needed.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="D20251231" id="Tag883">&lt;span style="line-height: inherit;"&gt;we have also formed an IT Steering Committee, whose members include employees with relevant experience, representatives from our management team and MSP, as well as our&#160;vCIO, to review our cybersecurity program initiatives and related program metrics.&lt;/span&gt;&lt;span id="fs_UIPZAADLCG00000000000000000000FM" style="line-height: inherit;"&gt; &lt;span id="fs_FU6BW5SL8W00000000000000000000FM"&gt;Our IT Steering Committee provides cybersecurity updates and reports to our Audit Committee at each quarterly meeting or more frequently as needed.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="D20251231" id="Tag884">Our IT Steering Committee provides cybersecurity updates and reports to our Audit Committee at each quarterly meeting or more frequently as needed.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <dei:AuditorFirmId contextRef="D20251231" id="Tag54">207</dei:AuditorFirmId>
    <dei:AuditorName contextRef="D20251231" id="Tag55">BPM LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="D20251231" id="Tag56">Walnut Creek, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I20251231"
      decimals="-3"
      id="Tag422"
      unitRef="USD">16232000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I20241231"
      decimals="-3"
      id="Tag395"
      unitRef="USD">18352000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vani:ResearchAndDevelopmentTaxIncentiveReceivableCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag433"
      unitRef="USD">654000</vani:ResearchAndDevelopmentTaxIncentiveReceivableCurrent>
    <vani:ResearchAndDevelopmentTaxIncentiveReceivableCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag410"
      unitRef="USD">253000</vani:ResearchAndDevelopmentTaxIncentiveReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag423"
      unitRef="USD">1012000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag396"
      unitRef="USD">1837000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag424"
      unitRef="USD">17898000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag397"
      unitRef="USD">20442000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20251231"
      decimals="-3"
      id="Tag420"
      unitRef="USD">2879000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20241231"
      decimals="-3"
      id="Tag398"
      unitRef="USD">1693000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I20251231"
      decimals="-3"
      id="Tag419"
      unitRef="USD">17230000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I20241231"
      decimals="-3"
      id="Tag399"
      unitRef="USD">17957000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag439"
      unitRef="USD">1338000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag440"
      unitRef="USD">1338000</us-gaap:RestrictedCashNoncurrent>
    <vani:DepositsAndOtherAssets
      contextRef="I20251231"
      decimals="-3"
      id="Tag425"
      unitRef="USD">48000</vani:DepositsAndOtherAssets>
    <vani:DepositsAndOtherAssets
      contextRef="I20241231"
      decimals="-3"
      id="Tag400"
      unitRef="USD">131000</vani:DepositsAndOtherAssets>
    <us-gaap:Assets
      contextRef="I20251231"
      decimals="-3"
      id="Tag432"
      unitRef="USD">39393000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="I20241231"
      decimals="-3"
      id="Tag401"
      unitRef="USD">41561000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag426"
      unitRef="USD">1032000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag402"
      unitRef="USD">817000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag427"
      unitRef="USD">1736000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag403"
      unitRef="USD">1803000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag428"
      unitRef="USD">1675000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag389"
      unitRef="USD">1675000</us-gaap:LitigationReserveCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag429"
      unitRef="USD">365000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag404"
      unitRef="USD">343000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag417"
      unitRef="USD">1794000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag405"
      unitRef="USD">1348000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag430"
      unitRef="USD">6602000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag406"
      unitRef="USD">5986000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag418"
      unitRef="USD">17061000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag390"
      unitRef="USD">17965000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="I20251231"
      decimals="-3"
      id="Tag431"
      unitRef="USD">23663000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="I20241231"
      decimals="-3"
      id="Tag407"
      unitRef="USD">23951000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="I20241231"
      decimals="INF"
      id="Tag1"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="I20251231"
      decimals="4"
      id="Tag391"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="I20241231"
      decimals="INF"
      id="Tag15"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="I20251231"
      decimals="-3"
      id="Tag394"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="I20241231"
      decimals="INF"
      id="Tag16"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="I20251231"
      decimals="-3"
      id="Tag386"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="I20251231"
      id="Tag388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="I20241231"
      id="Tag387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="I20241231"
      decimals="INF"
      id="Tag2"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="I20251231"
      decimals="4"
      id="Tag392"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I20241231"
      decimals="INF"
      id="Tag17"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I20251231"
      decimals="-3"
      id="Tag393"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20251231"
      decimals="INF"
      id="Tag19"
      unitRef="Shares">76428000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20251231"
      decimals="-3"
      id="Tag408"
      unitRef="Shares">76428000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20241231"
      decimals="INF"
      id="Tag18"
      unitRef="Shares">59235000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20241231"
      decimals="-3"
      id="Tag409"
      unitRef="Shares">59235000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="I20251231"
      decimals="-3"
      id="Tag435"
      unitRef="USD">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="I20241231"
      decimals="-3"
      id="Tag411"
      unitRef="USD">6000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="I20251231"
      decimals="-3"
      id="Tag436"
      unitRef="USD">164225000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="I20241231"
      decimals="-3"
      id="Tag412"
      unitRef="USD">139480000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I20251231"
      decimals="-3"
      id="Tag434"
      unitRef="USD">30000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I20241231"
      decimals="-3"
      id="Tag413"
      unitRef="USD">48000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I20251231"
      decimals="-3"
      id="Tag421"
      unitRef="USD">-148533000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I20241231"
      decimals="-3"
      id="Tag414"
      unitRef="USD">-121924000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="I20251231"
      decimals="-3"
      id="Tag437"
      unitRef="USD">15730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231"
      decimals="-3"
      id="Tag415"
      unitRef="USD">17610000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="I20251231"
      decimals="-3"
      id="Tag438"
      unitRef="USD">39393000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="I20241231"
      decimals="-3"
      id="Tag416"
      unitRef="USD">41561000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag61"
      unitRef="USD">18126000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag68"
      unitRef="USD">15745000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag62"
      unitRef="USD">9430000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag69"
      unitRef="USD">8932000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="D20251231"
      decimals="-3"
      id="Tag63"
      unitRef="USD">27556000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D20241231"
      decimals="-3"
      id="Tag70"
      unitRef="USD">24677000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="D20251231"
      decimals="-3"
      id="Tag64"
      unitRef="USD">-27556000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D20241231"
      decimals="-3"
      id="Tag71"
      unitRef="USD">-24677000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag65"
      unitRef="USD">947000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag72"
      unitRef="USD">1191000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231"
      decimals="-3"
      id="Tag66"
      unitRef="USD">-26609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231"
      decimals="-3"
      id="Tag73"
      unitRef="USD">-23486000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D20251231"
      decimals="2"
      id="Tag57"
      unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="D20251231"
      decimals="2"
      id="Tag67"
      unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D20241231"
      decimals="2"
      id="Tag58"
      unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="D20241231"
      decimals="2"
      id="Tag74"
      unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D20251231"
      decimals="-3"
      id="Tag59"
      unitRef="Shares">62389000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D20251231"
      decimals="-3"
      id="Tag75"
      unitRef="Shares">62389000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D20241231"
      decimals="-3"
      id="Tag60"
      unitRef="Shares">54981000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D20241231"
      decimals="-3"
      id="Tag76"
      unitRef="Shares">54981000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231"
      decimals="-3"
      id="Tag383"
      unitRef="USD">-26609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231"
      decimals="-3"
      id="Tag381"
      unitRef="USD">-23486000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="D20251231"
      decimals="-3"
      id="Tag385"
      unitRef="USD">-18000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="D20241231"
      decimals="-3"
      id="Tag380"
      unitRef="USD">-92000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D20251231"
      decimals="-3"
      id="Tag384"
      unitRef="USD">-26627000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D20241231"
      decimals="-3"
      id="Tag382"
      unitRef="USD">-23578000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20231231_CommonStockMember"
      decimals="-3"
      id="Tag275"
      unitRef="Shares">51031000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="I20231231_CommonStockMember"
      decimals="-3"
      id="Tag272"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20231231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag270"
      unitRef="USD">119054000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20231231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Tag274"
      unitRef="USD">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20231231_RetainedEarningsMember"
      decimals="-3"
      id="Tag271"
      unitRef="USD">-98438000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20231231"
      decimals="-3"
      id="Tag273"
      unitRef="USD">20761000</us-gaap:StockholdersEquity>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithSecuritiesPurchaseAgreementIssuanceCosts
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag268"
      unitRef="USD">1300000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithSecuritiesPurchaseAgreementIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231_CommonStockMember"
      decimals="-3"
      id="Tag292"
      unitRef="Shares">3947000</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231_CommonStockMember"
      id="Tag297"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag298"
      unitRef="USD">13687000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag303"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231_RetainedEarningsMember"
      id="Tag306"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231"
      decimals="-3"
      id="Tag307"
      unitRef="USD">13687000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithAtMarketOfferingIssuanceCosts
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag265"
      unitRef="USD">344000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithAtMarketOfferingIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231_CommonStockMember"
      decimals="-3"
      id="Tag293"
      unitRef="Shares">288000</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231_CommonStockMember"
      decimals="-3"
      id="Tag295"
      unitRef="USD">1000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag299"
      unitRef="USD">159000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag302"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231_RetainedEarningsMember"
      id="Tag305"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231"
      decimals="-3"
      id="Tag308"
      unitRef="USD">160000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivatePurchaseIssuanceCosts
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag266"
      unitRef="USD">30000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivatePurchaseIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts
      contextRef="D20241231_CommonStockMember"
      decimals="-3"
      id="Tag294"
      unitRef="Shares">3969000</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts
      contextRef="D20241231_CommonStockMember"
      id="Tag296"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag300"
      unitRef="USD">4970000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts
      contextRef="D20241231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag301"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts
      contextRef="D20241231_RetainedEarningsMember"
      id="Tag304"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts
      contextRef="D20241231"
      decimals="-3"
      id="Tag309"
      unitRef="USD">4970000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePurchaseNetOfIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20251231_CommonStockMember"
      id="Tag280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag276"
      unitRef="USD">1610000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20241231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20241231_RetainedEarningsMember"
      id="Tag278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20241231"
      decimals="-3"
      id="Tag279"
      unitRef="USD">1610000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20241231_CommonStockMember"
      id="Tag361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      id="Tag362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20241231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Tag363"
      unitRef="USD">-92000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20241231_RetainedEarningsMember"
      id="Tag364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20241231"
      decimals="-3"
      id="Tag365"
      unitRef="USD">-92000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231_CommonStockMember"
      id="Tag281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      id="Tag282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231_RetainedEarningsMember"
      decimals="-3"
      id="Tag284"
      unitRef="USD">-23486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231"
      decimals="-3"
      id="Tag285"
      unitRef="USD">-23486000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20241231_CommonStockMember"
      decimals="-3"
      id="Tag291"
      unitRef="Shares">59235000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_CommonStockMember"
      decimals="-3"
      id="Tag290"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag287"
      unitRef="USD">139480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Tag286"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_RetainedEarningsMember"
      decimals="-3"
      id="Tag289"
      unitRef="USD">-121924000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231"
      decimals="-3"
      id="Tag288"
      unitRef="USD">17610000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20241231_CommonStockMember"
      decimals="-3"
      id="Tag310"
      unitRef="Shares">59235000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_CommonStockMember"
      decimals="-3"
      id="Tag311"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag312"
      unitRef="USD">139480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Tag313"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231_RetainedEarningsMember"
      decimals="-3"
      id="Tag314"
      unitRef="USD">-121924000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231"
      decimals="-3"
      id="Tag315"
      unitRef="USD">17610000</us-gaap:StockholdersEquity>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithAtMarketOfferingIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag264"
      unitRef="USD">37000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithAtMarketOfferingIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231_CommonStockMember"
      decimals="-3"
      id="Tag316"
      unitRef="Shares">9000</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231_CommonStockMember"
      id="Tag327"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag317"
      unitRef="USD">-28000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag328"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231_RetainedEarningsMember"
      id="Tag329"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231"
      decimals="-3"
      id="Tag318"
      unitRef="USD">-28000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivateSalesTransactionIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag269"
      unitRef="USD">57000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivateSalesTransactionIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20251231_CommonStockMember"
      decimals="-3"
      id="Tag358"
      unitRef="Shares">7480000</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20251231_CommonStockMember"
      decimals="-3"
      id="Tag353"
      unitRef="USD">1000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag354"
      unitRef="USD">8542000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag355"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20251231_RetainedEarningsMember"
      id="Tag356"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20251231"
      decimals="-3"
      id="Tag357"
      unitRef="USD">8543000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithRegisteredDirectOfferingIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag267"
      unitRef="USD">972000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithRegisteredDirectOfferingIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20251231_CommonStockMember"
      decimals="-3"
      id="Tag346"
      unitRef="Shares">6000000</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20251231_CommonStockMember"
      decimals="-3"
      id="Tag341"
      unitRef="USD">1000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag342"
      unitRef="USD">8747000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag344"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20251231_RetainedEarningsMember"
      id="Tag345"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20251231"
      decimals="-3"
      id="Tag343"
      unitRef="USD">8748000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPrivatePlacement
      contextRef="D20251231_CommonStockMember"
      decimals="-3"
      id="Tag352"
      unitRef="Shares">3704000</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithPrivatePlacement>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement
      contextRef="D20251231_CommonStockMember"
      id="Tag351"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag347"
      unitRef="USD">6000000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag349"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement
      contextRef="D20251231_RetainedEarningsMember"
      id="Tag350"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement
      contextRef="D20251231"
      decimals="-3"
      id="Tag348"
      unitRef="USD">6000000</vani:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithPrivatePlacement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20251231_CommonStockMember"
      id="Tag332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag319"
      unitRef="USD">1484000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20251231_RetainedEarningsMember"
      id="Tag331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D20251231"
      decimals="-3"
      id="Tag320"
      unitRef="USD">1484000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="D20251231_CommonStockMember"
      id="Tag338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      id="Tag337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Tag336"
      unitRef="USD">-117000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="D20251231_RetainedEarningsMember"
      id="Tag339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="D20251231"
      decimals="-3"
      id="Tag360"
      unitRef="USD">-117000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="D20251231_CommonStockMember"
      id="Tag366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      id="Tag367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Tag368"
      unitRef="USD">99000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="D20251231_RetainedEarningsMember"
      id="Tag369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="D20251231"
      decimals="-3"
      id="Tag370"
      unitRef="USD">99000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_CommonStockMember"
      id="Tag333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      id="Tag334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_AccumulatedOtherComprehensiveIncomeMember"
      id="Tag335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_RetainedEarningsMember"
      decimals="-3"
      id="Tag321"
      unitRef="USD">-26609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231"
      decimals="-3"
      id="Tag322"
      unitRef="USD">-26609000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20251231_CommonStockMember"
      decimals="-3"
      id="Tag323"
      unitRef="Shares">76428000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="I20251231_CommonStockMember"
      decimals="-3"
      id="Tag324"
      unitRef="USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag325"
      unitRef="USD">164225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20251231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Tag359"
      unitRef="USD">30000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20251231_RetainedEarningsMember"
      decimals="-3"
      id="Tag326"
      unitRef="USD">-148533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20251231"
      decimals="-3"
      id="Tag340"
      unitRef="USD">15730000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231"
      decimals="-3"
      id="Tag484"
      unitRef="USD">-26609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231"
      decimals="-3"
      id="Tag454"
      unitRef="USD">-23486000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D20251231"
      decimals="-3"
      id="Tag461"
      unitRef="USD">424000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D20241231"
      decimals="-3"
      id="Tag445"
      unitRef="USD">400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="D20251231"
      decimals="-3"
      id="Tag460"
      unitRef="USD">1484000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D20241231"
      decimals="-3"
      id="Tag446"
      unitRef="USD">1610000</us-gaap:ShareBasedCompensation>
    <vani:AdjustmentsForReclassificationOfForeignCurrencyTranslationAdjustments
      contextRef="D20251231"
      decimals="-3"
      id="Tag496"
      unitRef="USD">117000</vani:AdjustmentsForReclassificationOfForeignCurrencyTranslationAdjustments>
    <vani:AdjustmentsForReclassificationOfForeignCurrencyTranslationAdjustments
      contextRef="D20241231"
      id="Tag495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="D20251231"
      id="Tag497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="D20241231"
      decimals="-3"
      id="Tag443"
      unitRef="USD">-60000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag462"
      unitRef="USD">269000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag447"
      unitRef="USD">276000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <vani:IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="D20251231"
      decimals="-3"
      id="Tag488"
      unitRef="USD">401000</vani:IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable>
    <vani:IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="D20241231"
      decimals="-3"
      id="Tag489"
      unitRef="USD">253000</vani:IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D20251231"
      decimals="-3"
      id="Tag490"
      unitRef="USD">-908000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D20241231"
      decimals="-3"
      id="Tag448"
      unitRef="USD">-491000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D20251231"
      decimals="-3"
      id="Tag463"
      unitRef="USD">-222000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D20241231"
      decimals="-3"
      id="Tag449"
      unitRef="USD">248000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="D20251231"
      decimals="-3"
      id="Tag464"
      unitRef="USD">22000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="D20241231"
      decimals="-3"
      id="Tag450"
      unitRef="USD">-53000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D20251231"
      decimals="-3"
      id="Tag476"
      unitRef="USD">-78000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="D20241231"
      decimals="-3"
      id="Tag451"
      unitRef="USD">-79000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D20251231"
      decimals="-3"
      id="Tag485"
      unitRef="USD">-24320000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D20241231"
      decimals="-3"
      id="Tag455"
      unitRef="USD">-20786000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D20251231"
      decimals="-3"
      id="Tag478"
      unitRef="USD">1173000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D20241231"
      decimals="-3"
      id="Tag452"
      unitRef="USD">556000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D20251231"
      decimals="-3"
      id="Tag465"
      unitRef="USD">-1173000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D20241231"
      decimals="-3"
      id="Tag453"
      unitRef="USD">-556000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithSecuritiesPurchaseAgreementIssuanceCosts
      contextRef="D20241231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag502"
      unitRef="USD">1300000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedInConnectionWithSecuritiesPurchaseAgreementIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20251231"
      id="Tag498"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231"
      decimals="-3"
      id="Tag459"
      unitRef="USD">13687000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231"
      decimals="-3"
      id="Tag483"
      unitRef="USD">-28000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231"
      decimals="-3"
      id="Tag458"
      unitRef="USD">160000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectorPrivateSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20251231"
      id="Tag499"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectorPrivateSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20241231"
      decimals="-3"
      id="Tag456"
      unitRef="USD">4970000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectorPrivateSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivateSalesTransactionIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag503"
      unitRef="USD">57000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivateSalesTransactionIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20251231"
      decimals="-3"
      id="Tag479"
      unitRef="USD">8543000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivateSalesTransactionNetOfIssuanceCosts
      contextRef="D20241231"
      id="Tag493"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithRegisteredDirectOfferingIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag501"
      unitRef="USD">972000</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithRegisteredDirectOfferingIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20251231"
      decimals="-3"
      id="Tag480"
      unitRef="USD">8748000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithRegisteredDirectOfferingNetOfIssuanceCosts
      contextRef="D20241231"
      id="Tag494"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivatePlacementIssuanceCosts
      contextRef="D20251231_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Tag504"
      unitRef="USD">0</vani:AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConnectionWithPrivatePlacementIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfIssuanceCosts
      contextRef="D20251231"
      decimals="-3"
      id="Tag481"
      unitRef="USD">6000000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithPrivatePlacementNetOfIssuanceCosts
      contextRef="D20241231"
      id="Tag482"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:ProceedsFromInsurancePremiumLoanGross
      contextRef="D20251231"
      decimals="-3"
      id="Tag466"
      unitRef="USD">355000</vani:ProceedsFromInsurancePremiumLoanGross>
    <vani:ProceedsFromInsurancePremiumLoanGross
      contextRef="D20241231"
      decimals="-3"
      id="Tag457"
      unitRef="USD">426000</vani:ProceedsFromInsurancePremiumLoanGross>
    <vani:RepaymentsOfPrincipalForInsurancePremiumLoanClassifiedAsFinancingActivities
      contextRef="D20251231"
      decimals="-3"
      id="Tag492"
      unitRef="USD">-344000</vani:RepaymentsOfPrincipalForInsurancePremiumLoanClassifiedAsFinancingActivities>
    <vani:RepaymentsOfPrincipalForInsurancePremiumLoanClassifiedAsFinancingActivities
      contextRef="D20241231"
      decimals="-3"
      id="Tag491"
      unitRef="USD">-189000</vani:RepaymentsOfPrincipalForInsurancePremiumLoanClassifiedAsFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D20251231"
      decimals="-3"
      id="Tag477"
      unitRef="USD">23274000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D20241231"
      decimals="-3"
      id="Tag470"
      unitRef="USD">19054000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="D20251231"
      decimals="-3"
      id="Tag475"
      unitRef="USD">99000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="D20241231"
      decimals="-3"
      id="Tag467"
      unitRef="USD">-14000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D20251231"
      decimals="-3"
      id="Tag486"
      unitRef="USD">-2120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D20241231"
      decimals="-3"
      id="Tag471"
      unitRef="USD">-2302000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="I20241231"
      decimals="-3"
      id="Tag472"
      unitRef="USD">19690000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="I20231231"
      decimals="-3"
      id="Tag468"
      unitRef="USD">21992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="I20251231"
      decimals="-3"
      id="Tag487"
      unitRef="USD">17570000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="I20241231"
      decimals="-3"
      id="Tag473"
      unitRef="USD">19690000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="D20251231"
      id="Tag500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="D20241231"
      decimals="-3"
      id="Tag444"
      unitRef="USD">2000</us-gaap:IncomeTaxesPaidNet>
    <vani:EstablishmentOfOperatingRightofuseAssetsThroughOperatingLeaseObligations
      contextRef="D20251231"
      decimals="-3"
      id="Tag469"
      unitRef="USD">839000</vani:EstablishmentOfOperatingRightofuseAssetsThroughOperatingLeaseObligations>
    <vani:EstablishmentOfOperatingRightofuseAssetsThroughOperatingLeaseObligations
      contextRef="D20241231"
      id="Tag441"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:PurchaseOfPropertyAndEquipmentInAccruedExpenses
      contextRef="D20251231"
      decimals="-3"
      id="Tag474"
      unitRef="USD">437000</vani:PurchaseOfPropertyAndEquipmentInAccruedExpenses>
    <vani:PurchaseOfPropertyAndEquipmentInAccruedExpenses
      contextRef="D20241231"
      id="Tag442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NatureOfOperations contextRef="D20251231" id="Tag848">
&lt;p id="xdx_803_eus-gaap--NatureOfOperations_zZJoej2Vp2K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;1. &lt;span id="xdx_825_zHMQ1xCxDFR5" style="line-height: inherit;"&gt;Organization and Business Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px 10pt; font: 10pt / 1.2 'Times New Roman', Times, serif; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="line-height: inherit; font-size: 10pt; margin-bottom: 10pt;"&gt;Vivani&#160;&lt;/span&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;Medical, Inc.&lt;span&gt;&#160;&lt;/span&gt;&lt;span style="color: #000000; line-height: inherit;"&gt;(&#x201c;Vivani,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; or similar terms) is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal&#x2122; technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address leading causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain&#160;patients.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt; color: #000000; line-height: inherit;"&gt;According to the U.S. Centers for Disease Control and Prevention, adherence is defined as the extent to which an individual&#x2019;s behavior, including taking medications, corresponds to recommendations from a health care provider. An alarmingly high proportion of patients, approximately&lt;/span&gt;&lt;span&gt;&#160;&lt;span&gt;50&lt;/span&gt;%, do not, or cannot, take their medicine as prescribed in the real world, a statistic that applies to both daily oral as well as weekly injectable medicines. For example, a recent study has shown that&#160;&lt;span&gt;64&lt;/span&gt;% of patients taking Wegovy&#xae; (&lt;span style="color: #000000; line-height: inherit;"&gt;semaglutide injection&lt;/span&gt;) discontinue treatment within the first year, a number that increases to&#160;&lt;span&gt;76&lt;/span&gt;% by the second year. Unfortunately, GLP-&lt;span&gt;&lt;span id="fs_KKT57FNSZ400000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;discontinuation may result in failure to achieve target outcomes and a quick reversal of the health benefits in the majority of patients.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;At Vivani, we are developing a portfolio of miniature, ultra long-acting&#160;subdermal drug implant candidates based on our NanoPortal technology that, unlike most oral and injectable medicines, are designed with the goal of guaranteeing medication adherence by delivering therapeutic drug levels for up to&#160;&lt;span&gt;six months&lt;/span&gt;&#160;or longer. Our&#160;NanoPortal implant technology has the potential to &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;enable patients to maintain continuous and therapeutic drug exposure levels with convenient once or twice yearly administration and the ability to stop receiving therapy at any time, if necessary, by removing the implant&lt;/span&gt;. In addition, we aim to minimize fluctuations in patients&#x2019; drug levels&lt;span style="color: #000000; line-height: inherit;"&gt;&#160;which may improve the tolerability of medicines, including&lt;/span&gt;&#160;GLP-&lt;span&gt;&lt;span id="fs_8S2PCMK1CW00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;receptor agonists which produce side effects that are associated with fluctuating drug levels in the blood.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;Our emerging portfolio of miniature, ultra long-acting drug implant candidates have the potential to revolutionize the treatment of chronic diseases by directly addressing poor medication adherence and improving drug tolerability in patients, both of which may translate into better health outcomes for patients in the real-world setting. Vivani's lead program, NPM-&lt;span&gt;&lt;span id="fs_UQS92JM1MO00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;, is a miniature,&#160;&lt;span&gt;&lt;span id="fs_F4ZNZNQLZ400000000000000000000fs" style="display: inline;"&gt;six&lt;/span&gt;&lt;/span&gt;-month, GLP-&lt;span&gt;&lt;span id="fs_2E31GYN46800000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;(semaglutide) implant currently in development for chronic weight management in obese and overweight patients. NPM-&lt;span&gt;&lt;span id="fs_7T28M77YC000000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;&#160;achieved encouraging preclinical data in rats&#160;showing approximately&#160;&lt;span&gt;20&lt;/span&gt;% weight loss, as compared to a control group receiving sham implants, which was&#160;maintained for a full year after a single administration. We are also developing NPM-&lt;span&gt;&lt;span id="fs_6XYHS2SE5S00000000000000000000fs" style="display: inline;"&gt;133&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;, a miniature, &lt;span id="fs_KNU3UJH9BK00000000000000000000fs"&gt;six&lt;/span&gt;-month, GLP-&lt;span id="fs_O85K2GP1O000000000000000000000fs"&gt;1&lt;/span&gt; (semaglutide) implant&lt;/span&gt;&#160;for the treatment of type-&lt;span&gt;&lt;span id="fs_MGFX5MFH6O00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;&lt;/span&gt;&#160;diabetes. Preliminary feasibility data support the additional potential benefit of once yearly dosing for both semaglutide implant programs, NPM-&lt;span&gt;&lt;span id="fs_Y0R9CO01HS00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;&#160;and NPM-&lt;span&gt;&lt;span id="fs_PVEB6E34WG00000000000000000000fs" style="display: inline;"&gt;133&lt;/span&gt;&lt;/span&gt;. In addition, we are also developing NPM-&lt;span id="fs_S33OJNKKA800000000000000000000fs" style="display: inline;"&gt;115&lt;/span&gt; (exenatide implant) for the treatment of chronic weight management,&#160;and OKV-&lt;span&gt;&lt;span id="fs_1RKZ7TJPK000000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;&lt;/span&gt;, a GLP-&lt;span&gt;&lt;span id="fs_BQPA3EM00G00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;-based implant in development for chronic weight management and related conditions in companion&#160;cats and dogs. OKV-&lt;span&gt;&lt;span id="fs_LYFMUR035S00000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;&lt;/span&gt;&#160;is being developed in collaboration with animal health partner Okava Pharmaceuticals, Inc. (&lt;span style="color: #000000; line-height: inherit;"&gt;&#x201c;&lt;/span&gt;Okava&lt;span style="color: #000000; line-height: inherit;"&gt;&#x201d;&lt;/span&gt;).&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;Vivani resulted from the business combination of Second Sight Medical Products, Inc. (&#x201c;Second Sight&#x201d;) and Nano Precision Medical, Inc. (&#x201c;NPM&#x201d;). On August 30, 2022, Second Sight and NPM completed their merger pursuant to which NPM became a wholly owned subsidiary of Second Sight and the combined company of NPM and Second Sight was renamed Vivani Medical, Inc. Vivani&#x2019;s main priority is the further development of its miniature, ultra long-acting drug implant candidate programs. In parallel, Vivani&#x2019;s management team remains committed to identifying and exploring strategic options that will enable further development of its pioneering neurostimulation systems from legacy company Second Sight which are aimed at helping patients recover critical body functions.&#160;As noted below,&lt;span&gt;&#160;&lt;/span&gt;&lt;span style="color: #000000; line-height: inherit;"&gt;we subsequently contributed our Second Sight assets and certain liabilities to Cortigent, Inc. (&#x201c;Cortigent&#x201d;), our wholly owned subsidiary to advance our pioneering neurostimulation technology.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0px; color: #000000; font: 10pt / 1.2 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;i&gt;&lt;span style="font-size: 10pt; color: #000000; line-height: inherit;"&gt;Preclinical and &lt;i style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: #000000; line-height: inherit;"&gt;NanoPortal&#x2122;&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;Platform Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;In February 2024, Vivani announced positive preclinical weight loss data with its exenatide implant, NPM-&lt;span&gt;&lt;span id="fs_44H2PYTWGG00000000000000000000fs" style="display: inline;"&gt;115&lt;/span&gt;&lt;/span&gt;, that was comparable to semaglutide, the active ingredient in Ozempic&#xae; and&#160;Wegovy&#xae;, and a strategic shift to prioritize the Company's obesity portfolio. In a study of high-fat diet-induced obese mice, the exenatide implant generated weight loss of approximately&#160;&lt;span&gt;20&lt;/span&gt;% compared to a sham implant control after a&#160;&lt;span&gt;28&lt;/span&gt;-day treatment duration, comparable to the extent of weight loss observed in mice treated with semaglutide injections in the same study.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: black; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;In February 2024, the Company also disclosed that&#160;semaglutide, the active ingredient in&#160;Ozempic&#xae;,&#160;Wegovy&#xae;&#160;and&#160;Rybelsus&#xae;,&#160;is the active pharmaceutical ingredient in NPM-&lt;span&gt;&lt;span id="fs_8R74TB698G00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;, another miniature, ultra long-acting subdermal GLP-&lt;span&gt;&lt;span id="fs_VBQGJMB0CW00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;implant in development for chronic weight management, further prioritizing our obesity treatment portfolio. NPM-&lt;span&gt;&lt;span id="fs_KX4O22UBKW00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;&#160;has the added potential benefit of once-yearly administration.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;On May 28, 2024, Vivani announced the publication of positive weight loss data supporting the potential veterinary use of OKV-&lt;span&gt;&lt;span id="fs_Q8KS9HMKG000000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;&lt;/span&gt;, the Company's miniature, ultra long-acting GLP-&lt;span&gt;&lt;span id="fs_587W0FJAJK00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;implant under development with partner Okava for the treatment of pre-diabetes, diabetes and obesity in companion felines. The device is intended to be conveniently inserted under the skin during routine veterinary visits and is being designed to deliver&#160;&lt;span&gt;six months&lt;/span&gt;&#160;of GLP-&lt;span&gt;&lt;span id="fs_I2IU1UQMK000000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;therapy with a single administration.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;On September 4, 2024, Vivani announced positive preclinical liver fat results with its miniature, ultra long-acting GLP-&lt;span&gt;&lt;span id="fs_MPUCFM5JJ400000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;(exenatide) implant, NPM-&lt;span id="fs_DDS2CR8L9S00000000000000000000fs" style="display: inline;"&gt;115&lt;/span&gt;, under development for chronic weight management in obese and overweight individuals. The&#160;implant produced sham-implant adjusted liver fat reduction of&#160;&lt;span&gt;82&lt;/span&gt;% at Week &lt;span id="fs_N2TW6PEC5C00000000000000000000fs" style="display: inline;"&gt;12&lt;/span&gt; in an obese mouse model from a single administration with expected twice-yearly dosing. These liver fat data are consistent with published results from similar investigations with semaglutide.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;On August 5, 2025,&#160;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times; line-height: 1.2; text-indent: 0.25in; margin: 0in;"&gt;Vivani&#160;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;announced&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; color: #000000; line-height: 1.2; text-indent: 0.25in; margin: 0in;"&gt;positive weight&#160;loss data from an ongoing&#160;preclinic&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;al study&#160;of NPM-&lt;span id="fs_0XF9A6XEC000000000000000000000fs"&gt;139&lt;/span&gt;, an&#160;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;ultra long-acting subdermal GLP-&lt;/span&gt;&lt;span style="cursor: default;"&gt;&lt;span id="fs_N36TIY555C00000000000000000000fs"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&#160;(semaglutide) implant in development for chronic weight management,&lt;/span&gt;&#160;in rats, which&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times;"&gt;&#160;showed approximately 20% sham-controlled weight loss, maintained for longer than &lt;span id="fs_AKZ3EEJHVK00000000000000000000fs"&gt;6&lt;/span&gt; months after administration of a single implant.&#160;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company also announced the successful completion of LIBERATE-&lt;span id="fs_LBCGYKZUW000000000000000000000fs"&gt;1&lt;/span&gt;, the first-in-human application of&lt;span&gt;&#160;&lt;/span&gt;Vivani&#x2019;s&lt;span&gt;&#160;&lt;/span&gt;NanoPortalTM&#160;implant technology, which showed a positive safety and tolerability profile, along with encouraging performance data. Based on the promising preclinical feasibility of the&lt;span&gt;&#160;&lt;/span&gt;semaglutide&lt;span&gt;&#160;&lt;/span&gt;implant and the successful completion of LIBERATE-&lt;span id="fs_2LOYQLYVLC00000000000000000000fs"&gt;1&lt;/span&gt;,&lt;span&gt;&#160;&lt;/span&gt;Vivani&#160;announced its intention to focus our resources and prioritize efforts to accelerate NPM-&lt;span id="fs_E05GL7GK0000000000000000000000fs"&gt;139&lt;/span&gt; into clinical-stage development.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;i&gt;&lt;span style="font-size: 10pt; color: #000000; line-height: inherit;"&gt;Clinical Development&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; color: #000000; line-height: inherit;"&gt;On July 14, 2023, we filed a&lt;/span&gt;&lt;span&gt;n Investigational New Drug Application (&#x201c;IND&#x201d;) for NPM-&lt;span&gt;&lt;span id="fs_SGT5HQNSJK00000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;&lt;/span&gt;&#160;(exenatide implant) with the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) to support the initiation of a first-in-human study of our&#160;GLP-&lt;span&gt;&lt;span id="fs_CL74H5HIEO00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;implant in patients with type&#160;&lt;span&gt;&lt;span id="fs_H7ZAVAS8Y800000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;&lt;/span&gt;&#160;diabetes. On August 18, 2023, FDA provided written notification that the study was on full clinical hold, primarily due to insufficient Chemistry, Manufacturing, and Controls (&#x201c;CMC&#x201d;) information to assess the risk to human subjects.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; line-height: 1.2; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span&gt;On June 13, 2024, Vivani announced that the FDA cleared the IND and lifted the clinical hold for NPM-&lt;span&gt;&lt;span id="fs_5FV58QIB2O00000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;&lt;/span&gt;, the Company's miniature,&#160;&lt;span&gt;&lt;span id="fs_6OCCEQLL3400000000000000000000fs" style="display: inline;"&gt;six&lt;/span&gt;&lt;/span&gt;-month GLP-&lt;span&gt;&lt;span id="fs_5IQQIB4ZPC00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;implant proposed for development for the treatment of patients with type&#160;&lt;span&gt;&lt;span id="fs_I24QB8E68000000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;&lt;/span&gt;&#160;diabetes.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; color: black; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span&gt;On July 11, 2024, the Company provided an update of the clinical development plans for NPM-&lt;span&gt;&lt;span id="fs_IKZXVRBEN400000000000000000000fs" style="display: inline;"&gt;115&lt;/span&gt;&lt;/span&gt;, the clinical program associated with the miniature, ultra long-acting GLP-&lt;span&gt;&lt;span id="fs_28JGX85Y6O00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;(high-dose exenatide) implant for chronic weight management in obese and overweight individuals. The Company redesigned the first-in-human study, LIBERATE-&lt;span&gt;&lt;span id="fs_PKX9FMIM5S00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#x2122;, initially intended to explore the safety, tolerability and pharmacokinetics of NPM-&lt;span id="fs_3AJQZ3H6GW00000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;, its low-dose&#160;exenatide implant in patients with type&#160;&lt;span&gt;&lt;span id="fs_14AO2TQJEO00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;&lt;/span&gt;&#160;diabetes, to instead evaluate NPM-&lt;span id="fs_9NST3F1E2800000000000000000000fs" style="display: inline;"&gt;115&lt;/span&gt;, its high dose exenatide implant in obese and overweight individuals.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; color: black; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span&gt;On September 26, 2024, the Company reported receiving regulatory approval to initiate its first-in-human clinical trial with NPM-&lt;span&gt;&lt;span id="fs_FGZ6N0PXKW00000000000000000000fs" style="display: inline;"&gt;115&lt;/span&gt;&lt;/span&gt;, a miniature, ultra long-acting GLP-&lt;span&gt;&lt;span id="fs_R5SXTD5WPS00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;(exenatide) implant in obese and overweight individuals in Australia. This clinical trial, known as LIBERATE-&lt;span&gt;&lt;span id="fs_H3WIXULPDC00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;, investigated the safety, tolerability and full pharmacokinetic profile of our exenatide implant. The trial also represented the first clinical application of the Company&#x2019;s proprietary NanoPortal drug implant technology. LIBERATE-&lt;span&gt;&lt;span id="fs_VNG8WHEU4G00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;was redesigned to enroll participants who were titrated on weekly semaglutide injections for&#160;&lt;span&gt;8&lt;/span&gt;&#160;weeks (&lt;span&gt;&lt;span id="fs_6D7VSNRYG000000000000000000000fs" style="display: inline;"&gt;0.25&lt;/span&gt;&lt;/span&gt;&#160;mg/week for&#160;&lt;span&gt;&lt;span id="fs_XFFLPMOCTC00000000000000000000fs" style="display: inline;"&gt;4&lt;/span&gt;&lt;/span&gt;&#160;weeks followed by&#160;&lt;span&gt;&lt;span id="fs_7TZT01E78G00000000000000000000fs" style="display: inline;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&#160;mg/week for&#160;&lt;span&gt;&lt;span id="fs_8GGK446K6O00000000000000000000fs" style="display: inline;"&gt;4&lt;/span&gt;&lt;/span&gt;&#160;weeks) before being randomized to receive a single administration of Vivani&#x2019;s exenatide implant (n=&lt;span&gt;&lt;span id="fs_NFDL8CX24G00000000000000000000fs" style="display: inline;"&gt;8&lt;/span&gt;&lt;/span&gt;), weekly exenatide injections (n=&lt;span&gt;&lt;span id="fs_YGT1T2JJHS00000000000000000000fs" style="display: inline;"&gt;8&lt;/span&gt;&lt;/span&gt;), or weekly&#160;&lt;span&gt;&lt;span id="fs_UTBMOBXUSG00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;mg semaglutide injections (n=&lt;span&gt;&lt;span id="fs_PM2P7ON5W000000000000000000000fs" style="display: inline;"&gt;8&lt;/span&gt;&lt;/span&gt;) for a&#160;&lt;span&gt;9&lt;/span&gt;-week treatment duration. The trial was initiated at the end of&#160;&lt;span&gt;&lt;span id="fs_VK0M45SVCW00000000000000000000fs" style="display: inline;"&gt;2024&lt;/span&gt;&lt;/span&gt;&#160;and top-line data was released in August 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0px; text-align: left;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;







 &lt;/div&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt;On December 19, 2024,&#160;&lt;/span&gt;Vivani&lt;span&gt;&#160;announced that screening and enrollment of LIBERATE-&lt;span&gt;&lt;span id="fs_7UL47971MO00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;, the first-in-human clinical trial with a GLP-&lt;span&gt;&lt;span id="fs_P8DODV7YC000000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;implant in obese and overweight patients, was initiated at&#160;&lt;span&gt;two&lt;/span&gt;&#160;study centers in Australia. The primary objective of the study was to investigate the safety, tolerability and full pharmacokinetic profile of an&#160;&lt;/span&gt;exenatide&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt;&#160;implant in obese or overweight individuals.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; color: black; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span&gt;On March 13, 2025, the Company announced the successful administration of its first GLP-&lt;span&gt;&lt;span id="fs_BEJANA9CVK00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;(exenatide) implant in the LIBERATE-&lt;span&gt;&lt;span id="fs_U4DO59Q7LS00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;clinical trial. This milestone marked a critical step toward potentially addressing&#160;&lt;span&gt;&lt;span id="fs_FW446YLL8000000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt;&lt;/span&gt;&#160;of&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;healthcare&#x2019;s&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;most pressing challenges: medication adherence in metabolic diseases including chronic weight management and type&#160;&lt;span&gt;&lt;span id="fs_SUUC838HPS00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;&lt;/span&gt;&#160;diabetes. The Company also announced full enrollment in the LIBERATE-&lt;span&gt;&lt;span id="fs_S6RTDM8R0G00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;study, which was achieved in just&#160;&lt;span&gt;&lt;span id="fs_OF8R7IR7U800000000000000000000fs" style="display: inline;"&gt;four&lt;/span&gt;&lt;/span&gt;&#160;weeks after enrollment of the first subject, signaling early potential interest for this&#160;&lt;span&gt;&lt;span id="fs_OLTAKRMOG000000000000000000000fs" style="display: inline;"&gt;six&lt;/span&gt;&lt;/span&gt;-month, subdermal GLP-&lt;span&gt;&lt;span id="fs_JIQ0NUIB3K00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;implant.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; font-family: 'times new roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div style="color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0pt; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times; font-size: 10pt; line-height: 1.1; margin: 0pt;"&gt;
&lt;p style="margin: 0in; color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span&gt;On August 5, 2025,&#160;Vivani&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;announced plans to support the rapid advancement of NPM-&lt;span&gt;&lt;span id="fs_BJUXB4U4U800000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;, a novel&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;semaglutide&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;implant, based on promising results from the LIBERATE-&lt;span&gt;&lt;span id="fs_3T5MGTGQ0W00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;clinical study and additional positive data from a preclinical study with a&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;semaglutide&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;implant. LIBERATE-&lt;span&gt;&lt;span id="fs_EDK9DDT8K000000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;, the first-in-human application of&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;Vivani's&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;proprietary&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;NanoPortal&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;implant technology, demonstrated a positive safety and tolerability profile and encouraging performance data, thus meeting the study's primary objectives. This study provided information on the GLP-&lt;span&gt;&lt;span id="fs_DON0CDFSAO00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;exposure levels obtained with an&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;exenatide&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;configuration, thereby paving the road for future clinical development of the technology, not only for&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;exenatide&#160;implants (NPM-&lt;span&gt;&lt;span id="fs_DEVFLTBPWG00000000000000000000fs" style="display: inline;"&gt;115&lt;/span&gt;&lt;/span&gt;&#160;and OKV-&lt;span&gt;&lt;span id="fs_Z6APADH2IO00000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;&lt;/span&gt;), but also for&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;semaglutide&#160;implants (NPM-&lt;span&gt;&lt;span id="fs_VRT3NDZ96O00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;&#160;and NPM-&lt;span&gt;&lt;span id="fs_IGBB0ZR9Q800000000000000000000fs" style="display: inline;"&gt;133&lt;/span&gt;&lt;/span&gt;) and other applications of&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;NanoPortal&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;technology that the Company may pursue in the future.&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;Vivani&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;also announced new NPM-&lt;span&gt;&lt;span id="fs_ZN2TUAU0EO00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;&#160;(semaglutide&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;implant) preclinical feasibility data that demonstrated approximately&#160;&lt;span&gt;20&lt;/span&gt;% sham-adjusted weight loss with a single implant,&#160;which had been maintained for more than&#160;&lt;span&gt;&lt;span id="fs_024GVQE1GW00000000000000000000fs" style="display: inline;"&gt;six&lt;/span&gt;&lt;/span&gt;&#160;months at the time of the announcement. These semaglutide&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;data also support the potential for a&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;semaglutide&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;implant with annual dosing. Based on the LIBERATE-&lt;span&gt;&lt;span id="fs_K3TBRSZETC00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;data supporting the clinical application of the&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;NanoPortal&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;platform technology, and the preclinical weight loss data with a&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;semaglutide&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;implant configuration,&#160;Vivani&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;announced plans to prioritize advancement of NPM-&lt;span&gt;&lt;span id="fs_KYGVYICFLS00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;, with clinical development expected to begin in&#160;&lt;span&gt;&lt;span id="fs_6RUECUM56800000000000000000000fs" style="display: inline;"&gt;2026&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in; color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 0.25in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;br/&gt;&lt;/p&gt;






 &lt;/div&gt;
&lt;div style="color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times; font-size: 10pt; line-height: 1.2; margin: 0px;"&gt;
&lt;p style="margin: 0pt; text-indent: 18pt; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.1;"&gt;&lt;span&gt;On September 4, 2025, Vivani&#160;announced plans to initiate a Phase&#160;&lt;span&gt;&lt;span id="fs_7VZTT7JXVK00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;clinical study for the NPM-&lt;span&gt;&lt;span id="fs_90LGCJLN3400000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;&#160;semaglutide implant program in the first half of&#160;&lt;span&gt;&lt;span id="fs_OIEMK1H5Q800000000000000000000fs" style="display: inline;"&gt;2026&lt;/span&gt;&lt;/span&gt;, pending regulatory clearance, along with high-level details of the anticipated&#160;study design. The Company also announced parallel preparations to initiate a Phase&#160;&lt;span&gt;&lt;span id="fs_DZ9IN34WC000000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;&lt;/span&gt;&#160;clinical study of NPM-&lt;span&gt;&lt;span id="fs_NGXWDUF5CW00000000000000000000fs" style="display: inline;"&gt;139&lt;/span&gt;&lt;/span&gt;&#160;pending enabling results from the Phase&#160;&lt;span&gt;&lt;span id="fs_60DYDP14IO00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;study and regulatory feedback.&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000;"&gt;The Company currently expects the Phase 1 study to initiate in mid-&lt;span id="fs_LW7JMCAI5S00000000000000000000fs"&gt;2026&lt;/span&gt;.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;






 &lt;/div&gt;
&lt;div style="border-top: none; border-right: none; border-bottom: none; border-image: initial; border-left: 1pt none windowtext; padding: 0in 0in 0in 22pt; margin-left: 22.5pt; margin-right: 0in;"&gt;
&lt;p style="line-height: 6pt; border: none; padding: 0in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 5pt; color: #000000; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;






 &lt;/div&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;i&gt;&lt;span style="font-size: 10pt; color: #000000; line-height: inherit;"&gt;Cortigent, Inc.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-indent: 18pt; line-height: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times; font-size: 13.3333px; float: none; display: inline !important;"&gt;In December 2022, we contributed our neurostimulation assets and certain liabilities from legacy company Second Sight to Cortigent, our wholly owned subsidiary, to advance our pioneering neurostimulation technology. Cortigent had&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;5,000,000&lt;/span&gt;&lt;span style="color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times; font-size: 13.3333px; float: none; display: inline !important;"&gt;&lt;span&gt;&#160;&lt;/span&gt;shares of common stock outstanding, all owned by Vivani&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;.&lt;span&gt;&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;On March 21, 2023, Vivani announced a proposed initial public offering ("IPO") to be registered on a Form S-&lt;span id="fs_5I4YSOBBKG00000000000000000000fs"&gt;1&lt;/span&gt; registration statement for Cortigent to fund its operations separately from Vivani&#x2019;s.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-indent: 18pt; line-height: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt; line-height: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;On August 25, 2023, the Company and Cortigent entered into an Amendment No.&#160;&lt;span&gt;&lt;span id="fs_4PVCUMEBTC00000000000000000000fs"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;(the &#x201c;Amendment&#x201d;) to the Transition Funding, Support and Services Agreement dated March 19, 2023 (the &#x201c;TFSSA&#x201d;). Pursuant to the TFSSA, Vivani&#160;agreed to advance funds and provide or cause to be provided to Cortigent the services and funding intended to cover salaries and related costs, rent and other overhead in order to permit Cortigent to operate in substantially the same manner&#160;as Second Sight prior to the formation of Cortigent.&#160;Efforts to support a successful IPO of Cortigent were paused in March 2025 and efforts were focused at that time on a potential spin-off transaction with the filing of a Form&#160;&lt;span&gt;&lt;span id="fs_W9X5MZA4LC00000000000000000000fs"&gt;10&lt;/span&gt;&lt;/span&gt;&#160;registration statement.&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000;"&gt;On March 12, 2025, the Company announced the proposed spin-off of&#160;Cortigent&#160;into a fully independent, publicly traded company,&#160;subject to the satisfaction of certain conditions, including, among others, final approval of&#160;Vivani&#x2019;s&#160;board of directors, receipt of a favorable opinion that the transaction will qualify for non-recognition of gain or loss as a result of receipt of&#160;Cortigent&#160;shares for U.S. Federal Income Tax purposes, and SEC and&#160;Nasdaq&#160;approval.&#160;&lt;/span&gt;The TFSSA terminated effective December 31, 2024.&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #231f20;"&gt;Vivani continues to pursue a path forward to unlock stockholder value associated with this asset&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000;"&gt;. If Cortigent is spun off through a Form &lt;span id="fs_4T38JK2V7400000000000000000000fs"&gt;10&lt;/span&gt; registration statement, the loan payable from Cortigent to Vivani will be forgiven&lt;/span&gt;.&#160;&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000;"&gt;A&#160;Form &lt;span id="fs_DNER3LWLLC00000000000000000000fs"&gt;10&lt;/span&gt; registration statement was filed&#160;with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on May 29, 2025.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 18pt; line-height: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: medium; text-indent: 18pt; line-height: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="color: #000000; line-height: 12pt; margin: 0pt; font-family: 'times new roman', times; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt; margin: 0pt; text-indent: 18pt; line-height: 12pt;"&gt;On September 17, 202&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&lt;span id="fs_UZV80G6K5S00000000000000000000fs"&gt;5&lt;/span&gt;,&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;Vivani&lt;span&gt;&#160;announced that its board of directors had set a record date for the approved spin-off of&#160;&lt;/span&gt;Cortigent&lt;span&gt;.&#160;&lt;/span&gt;Vivani's&lt;span&gt;&#160;stockholders holding common stock as of that record date would receive&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: black; line-height: 12pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&lt;span&gt;common stock in&#160;&lt;/span&gt;Cortigent&lt;span&gt;. This record date was withdrawn on October 3, 2025, due to&#160;delays arising from the shutdown of the U.S. federal government. Thereafter,&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #231f20; line-height: 12pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&lt;span&gt;&#160;&lt;/span&gt;Cortigent&lt;span&gt;&#160;filed amendments to its registration statement on Form S-&lt;span id="fs_BNH1P5UBTC00000000000000000000fs"&gt;1&lt;/span&gt; on December 2, 2025 and January 9, 2026.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman', serif; color: #000000;"&gt;&lt;span style="margin: 0pt; text-indent: 18pt; line-height: 12pt;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;span&gt;If&#160;&lt;/span&gt;Cortigent&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;span style="font-size: 13.3333px; margin: 0pt; text-indent: 18pt; line-height: 12pt;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&#160;successf&lt;/span&gt;ully completes an IPO,&#160;it&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 13.3333px; color: #000000; font-family: 'Times New Roman', serif; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;will&lt;/span&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'Times New Roman', serif; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;repay to Vivani $1.5 million of transition funding from the proceeds of that offering and issue a &lt;span style="-sec-ix-hidden:Tag263"&gt;five-year&lt;/span&gt;&#160;promissory note requiring repayment of $2 million at five percent per year upon maturity of the promissory note&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: medium; text-indent: 18pt; line-height: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; color: #000000; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: medium; text-indent: 18pt; line-height: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="color: #000000; line-height: 12pt; margin: 0pt; font-family: 'times new roman', times; text-indent: 18pt;"&gt;&lt;span style="color: black; line-height: 12pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;span style="color: #231f20; line-height: 12pt; margin: 0pt; text-indent: 18pt;"&gt;&lt;span style="font-family: 'Times New Roman', serif; color: #000000;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;Currently, both a spin-off to be registered on a Form &lt;span id="fs_0W0I52UBOW00000000000000000000fs"&gt;10&lt;/span&gt; and an IPO to be registered on a Form S-&lt;span id="fs_023DUY7GCG00000000000000000000fs"&gt;1&lt;/span&gt; registration statement are approaches being considered&#160;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;to transition&#160;&lt;/span&gt;Cortigent&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&#160;to becoming a separate reporting company that may&lt;/span&gt;&#160;provide an opportunity for&#160;Vivani's&#160;stockholders to potentially realize value in&#160;Cortigent&#x2019;s&#160;assets. In the IPO scenario,&#160;Vivani&#160;would retain an ownership stake in&#160;Cortigent. In the Form &lt;span id="fs_TLWYJHSUN400000000000000000000fs"&gt;10&lt;/span&gt; spin-off scenario, shares of&#160;Cortigent&#x2019;s&#160;common stock would be distributed to the holders of&#160;Vivani's&#160;common stock.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&#160;The strategic goal of either&#160;transaction is to create&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span id="fs_O5SU7Q0GF400000000000000000000fs"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;span&gt;&#160;&lt;/span&gt;focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;







 &lt;/div&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;i&gt;&lt;span style="font-size: 10pt; color: #000000; line-height: inherit;"&gt;Okava&#160;Pharmaceuticals,&#160;Inc.&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0pt; text-indent: 18pt; line-height: 12pt; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span&gt;On April 12, 2025, Vivani entered into an amendment to its License and Supply Agreement with&#160;Okava&#160;which&#160;expanded Vivani's ongoing collaboration to include dogs in the development of OKV-&lt;span&gt;&lt;span id="fs_D1L1EM8NYO00000000000000000000fs" style="display: inline;"&gt;119&lt;/span&gt;&lt;/span&gt;, a long-acting GLP-&lt;span&gt;&lt;span id="fs_Z75KK8OPHC00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;&lt;/span&gt;&#160;therapy for weight management, type&#160;&lt;span&gt;&lt;span id="fs_2WUHLABFWW00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;&lt;/span&gt;&#160;diabetes, and other&#160;cardiometabolic&#160;conditions.&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;The amendment added $5M in regulatory milestone payments related to the development of products for the treatment of obesity in dogs.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;Liquidity and Capital Resources&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit; font-family: 'times new roman', times;"&gt;&lt;span style="line-height: inherit;"&gt;From inception,&#160;&lt;/span&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;our operations have been funded primarily through the sales of our common stock and warrants.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit; font-family: 'times new roman', times;"&gt;&lt;span style="line-height: inherit;"&gt;Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with no revenue that is developing novel medical devices, including limitations on our operating capital resources. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; color: black; line-height: inherit;"&gt;To support our future operations, the Company entered&#160;into three private equity purchase agreements in March 2025, May 2025 and August 2025. These agreements will bring an additional $12.6 million of committed capital into the Company between &lt;span id="fs_3HPGCSV9Z400000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and July 15, 2026. Additionally, o&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="color: #000000; line-height: inherit;"&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;n January 25, 2026,&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; line-height: inherit;"&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;the Company entered into a share purchase agreement with an entity affiliated with&#160;&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-right: none; border-left: none; line-height: inherit;"&gt;&lt;span style="cursor: default; line-height: inherit;"&gt;&lt;span id="fs_TXWP0PCNRK00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;of its&#160;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;independent&lt;/span&gt;&#160;directors for the purchase of an aggregate of 1,351,351&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;shares of common stock of the Company at a purchase price of $1.48&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;per share, the last reported sale price of the common stock on January 23, 2026. This private placement of common stock resulted in gross proceeds of approximately $2.0&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;million to the Company. Concurrent with the private placement, the Company also entered into a Placement Agency Agreement with&#160;&lt;/span&gt;ThinkEquity,&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;LLC relating to the sale by the Company of 1,689,200&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;shares of the Company&#x2019;s common stock in a registered direct offering, also at a purchase price of $1.48&#160;per share. The gross proceeds from the Registered Offering were approximately $2.5&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;million, before placement agent fees and other estimated offering expenses.&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;For additional information, refer to Note &lt;span id="fs_TRD592H7UO00000000000000000000fs" style="display: inline;"&gt;15&lt;/span&gt; Subsequent Event.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;We estimate that currently available cash will provide sufficient funds to enable the Company to meet its planned obligations&#160;for at least the next&#160;&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;&lt;span id="fs_MG462AN1EO00000000000000000000fs" style="display: inline;"&gt;twelve&lt;/span&gt;&lt;/span&gt;&#160;months. Our ability to continue as a going concern is dependent on our ability to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there can be no assurances that we will be able to do so&lt;/span&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0.25in; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit;"&gt;.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;






 </us-gaap:NatureOfOperations>
    <vani:PercentageOfPatientsDoNotTakeTheirMedicineAsPrescribedInRealWorld
      contextRef="D20251231"
      decimals="2"
      id="Tag852"
      unitRef="Pure">0.50</vani:PercentageOfPatientsDoNotTakeTheirMedicineAsPrescribedInRealWorld>
    <vani:PercentageOfPatientsTakingWegovySemaglutideInjectableDiscontinueTherapyWithinFirstYearOfTreatment
      contextRef="D20251231"
      decimals="2"
      id="Tag853"
      unitRef="Pure">0.64</vani:PercentageOfPatientsTakingWegovySemaglutideInjectableDiscontinueTherapyWithinFirstYearOfTreatment>
    <vani:PercentageOfPatientsTakingWegovySemaglutideInjectableDiscontinueTherapyWithinSecondYearOfTreatment
      contextRef="D20251231"
      decimals="2"
      id="Tag854"
      unitRef="Pure">0.76</vani:PercentageOfPatientsTakingWegovySemaglutideInjectableDiscontinueTherapyWithinSecondYearOfTreatment>
    <vani:PeriodForDeliveringTherapeuticDrugLevels contextRef="D20251231_MinimumMember" id="Tag870">P6M</vani:PeriodForDeliveringTherapeuticDrugLevels>
    <vani:PercentageOfWeightLossAchievedInPreclinicalData
      contextRef="D20251231"
      decimals="2"
      id="Tag855"
      unitRef="Pure">0.20</vani:PercentageOfWeightLossAchievedInPreclinicalData>
    <vani:PercentageOfWeightLossAfterExenatideImplantTherapyForPatientsWhomHasHighFatDietInducedObeseMice
      contextRef="D20240229"
      decimals="2"
      id="Tag856"
      unitRef="Pure">0.20</vani:PercentageOfWeightLossAfterExenatideImplantTherapyForPatientsWhomHasHighFatDietInducedObeseMice>
    <vani:PeriodOfShamImplantControlTherapy contextRef="D20240229" id="Tag857">P28D</vani:PeriodOfShamImplantControlTherapy>
    <vani:PeriodOfSpecificTherapyWithSingleAdministration contextRef="D20240528" id="Tag858">P6M</vani:PeriodOfSpecificTherapyWithSingleAdministration>
    <vani:PercentageOfLiverFatReductionAfterExenatideImplantTherapyForPatientsWhomHasHighFatDietInducedObeseMice
      contextRef="D20240904"
      decimals="2"
      id="Tag859"
      unitRef="Pure">0.82</vani:PercentageOfLiverFatReductionAfterExenatideImplantTherapyForPatientsWhomHasHighFatDietInducedObeseMice>
    <vani:PercentageOfWeightLossAchievedInPreclinicalData
      contextRef="D20250805"
      decimals="2"
      id="Tag869"
      unitRef="Pure">0.20</vani:PercentageOfWeightLossAchievedInPreclinicalData>
    <vani:NumberOfWeeksBeforeBeingRandomizedToReceiveTherapy
      contextRef="D20240926"
      decimals="0"
      id="Tag860"
      unitRef="Week">8</vani:NumberOfWeeksBeforeBeingRandomizedToReceiveTherapy>
    <vani:NumberOfWeeksForWeeklySemaglutideInjectionsTherapy
      contextRef="D20240926"
      decimals="0"
      id="Tag861"
      unitRef="Week">9</vani:NumberOfWeeksForWeeklySemaglutideInjectionsTherapy>
    <vani:NumberOfStudyCentre
      contextRef="I20241219_AU"
      decimals="0"
      id="Tag871"
      unitRef="N">2</vani:NumberOfStudyCentre>
    <vani:PercentageOfWeightLossAchievedInPreclinicalData
      contextRef="D20251231"
      decimals="2"
      id="Tag862"
      unitRef="Pure">0.20</vani:PercentageOfWeightLossAchievedInPreclinicalData>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20221231_CortigentIncMember"
      decimals="0"
      id="Tag873"
      unitRef="Shares">5000000</us-gaap:CommonStockSharesOutstanding>
    <vani:TransitionFundingLoan
      contextRef="D20250917_CortigentIncMember"
      decimals="-5"
      id="Tag874"
      unitRef="USD">1500000</vani:TransitionFundingLoan>
    <us-gaap:MediumTermNotes
      contextRef="I20250917_CortigentIncMember_PromissoryNoteMember"
      decimals="-6"
      id="Tag875"
      unitRef="USD">2000000</us-gaap:MediumTermNotes>
    <vani:MediumTermNotesInterestRate
      contextRef="D20250917_CortigentIncMember_PromissoryNoteMember"
      decimals="2"
      id="Tag876"
      unitRef="Pure">0.05</vani:MediumTermNotesInterestRate>
    <vani:RegulatoryMilestonePaymentsAdded
      contextRef="D20251231_LicenseAndSupplyAgreementMember_OkavaPharmaceuticalsIncMember"
      decimals="-6"
      id="Tag868"
      unitRef="USD">5000000</vani:RegulatoryMilestonePaymentsAdded>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="D20251231"
      decimals="-6"
      id="Tag849"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <vani:NumberOfEquityPurchaseAgreements contextRef="D20251231" decimals="0" id="Tag850" unitRef="N">3</vani:NumberOfEquityPurchaseAgreements>
    <vani:CommittedCapital
      contextRef="I20260715"
      decimals="-5"
      id="Tag851"
      unitRef="USD">12600000</vani:CommittedCapital>
    <us-gaap:SharesIssued
      contextRef="I20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="0"
      id="Tag863"
      unitRef="Shares">1351351</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="I20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="2"
      id="Tag872"
      unitRef="USDPerShare">1.48</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="-5"
      id="Tag865"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <vani:SaleOfCommonStockAtDirectOfferingAuthorizedShares
      contextRef="I20260125_SubsequentEventMember_ThinkEquityLlcMember_PlacementAgencyAgreementMember"
      decimals="0"
      id="Tag864"
      unitRef="Shares">1689200</vani:SaleOfCommonStockAtDirectOfferingAuthorizedShares>
    <vani:SaleOfCommonStockAtDirectOfferingPricePerShare
      contextRef="D20260125_SubsequentEventMember_PlacementAgencyAgreementMember_ThinkEquityLlcMember"
      decimals="2"
      id="Tag866"
      unitRef="USDPerShare">1.48</vani:SaleOfCommonStockAtDirectOfferingPricePerShare>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingGross
      contextRef="D20260125_SubsequentEventMember_PlacementAgencyAgreementMember_ThinkEquityLlcMember"
      decimals="-5"
      id="Tag867"
      unitRef="USD">2500000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingGross>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="D20251231" id="Tag144">
&lt;p id="xdx_803_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_z4T1PZ569DQ1" style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 0pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;2.&#160;&lt;span id="xdx_82B_zHYfMWdyuW42"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fof168c30a0024470294b4947ddc73299d"&gt;
&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_ztFKkamq8NW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_864_zyJCA7t2ML15"&gt;Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include&#160;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;the accounts of the Company and its wholly owned subsidiaries.&#160;&lt;/span&gt;Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p id="xdx_85E_zdTUIn8Npxwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo5b409162670645cf9db3b280235a55bd"&gt;
&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zR3x5G0Rjrne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_868_zvGEg3p4kIz8"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities &lt;span style="font-size: 10pt; line-height: inherit;"&gt;and disclosure of contingent assets and liabilities &lt;/span&gt; at the date of the financial statements and the reported amounts of expenses during the reporting period. We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those&#160;estimates are adjusted accordingly. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred tax assets. Actual results could differ &lt;span style="font-size: 10pt; line-height: inherit;"&gt;materially&lt;/span&gt; from those estimates.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;








&lt;p id="xdx_235_zcpRoaEpCVN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;








&lt;div id="fo578e8200016f4aaeaae9a647085c428b"&gt;
&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQ1T8uaKVR16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86C_zVDcsQCWb189"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We consider all highly liquid investments with a maturity of &lt;span id="fs_DQIPSJIZ5C00000000000000000000fs" style="display: inline;"&gt;three&lt;/span&gt; months or less at the date of purchase to be cash equivalents. Cash is carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds that are in excess of current needs in high credit quality instruments such as money market funds. As of &lt;span id="fs_B7M4E8X9AO00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_0089CRTQF400000000000000000000FM"&gt;2024&lt;/span&gt; restricted cash of $&lt;span id="xdx_90B_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_dm_c20231231_zT3Y7IIeZ2y5" title="Restricted cash and cash equivalents"&gt;1.3 million&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_dm_c20221231_zGilnyU8bTj1" title="Restricted cash and cash equivalents"&gt;1.3 million&lt;/span&gt;, respectively, relates to a letter of credit as a condition of our facilities lease guarantee requirements and is classified as long-term restricted cash on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo8c918b6879ca4de39f26bbcc014006a0"&gt;
&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zM8kwbhbIzYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;P&lt;span id="xdx_86B_z2DK0bujMP7e"&gt;roperty and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Property and equipment are recorded at historical cost less accumulated depreciation.&#160;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheets and any resulting gains or losses are reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Depreciation &lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;is computed using the straight-line method over the estimated useful lives of the respective assets&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fof19f85a99d6040bab63f68afbb18f47b"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%; border-collapse: collapse; height: 42px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; width: 46%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_z6yysO2BLdMd" title="Estimated useful lives::XDX::P5Y"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 16px; width: 53%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z3nrI9Zh3cI" title="Estimated useful lives::XDX::P7Y"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zIjGtBoXivjg" title="Estimated useful lives::XDX::P3Y"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;







 &lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBjhQKCsXxrg" title="Estimated useful lives::XDX::P7Y"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB4nKNFg2C65" title="Estimated useful lives::XDX::P5Y"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zOODIjnIpk01" title="Estimated useful lives::XDX::P10Y"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 &lt;/div&gt;
&lt;p id="xdx_8A0_zlwIDVbQDEug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;We&#160;&lt;/span&gt;review our property and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Depreciation of property and equipment amounted to $&lt;span id="xdx_900_eus-gaap--DepreciationAndAmortization_dm_c20230101__20231231_zmYUfALdL6pc" style="line-height: inherit;" title="Depreciation and amortization of property and equipment"&gt;0.4 million&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DepreciationAndAmortization_dm_c20220101__20221231_zjPjSfBpTRUd" style="line-height: inherit;" title="Depreciation and amortization of property and equipment"&gt;0.4 million&lt;/span&gt; for the years ended &lt;span id="fs_RTDKL7BZ0G00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_H3M879P5B400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p id="xdx_854_znm200hzR9ek" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="foe160d0f8bf4e40238c7d70e9f14c823a" style="line-height: 1.2;"&gt;
&lt;p id="xdx_847_eus-gaap--LessorLeasesPolicyTextBlock_z6odnS7ykyZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86B_zGaR8qQrJIXe" style="line-height: inherit;"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Leases are accounted for under the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;span id="fs_95KX2NY1YO00000000000000000000fs"&gt;842&lt;/span&gt;, Leases (&#x201c;ASC &lt;span id="fs_QB3LR849GG00000000000000000000fs"&gt;842&lt;/span&gt;&#x201d;). Under ASC &lt;span id="fs_IUTT1WV9LC00000000000000000000fs" style="line-height: inherit; display: inline;"&gt;842&lt;/span&gt;, the Company determines if an arrangement contains a lease at inception. Right of use assets (&#x201c;ROU assets&#x201d;) represent the right to use an underlying asset for the lease term while lease liabilities represent the obligation to make lease payments for the lease term. Leases are then classified as either finance or operating, with classification affecting the pattern of expense recognition in the statements of operations and comprehensive loss.&#160;All leases greater than &lt;span id="fs_6BXRV0WR1C00000000000000000000fs" style="line-height: inherit; display: inline;"&gt;12&lt;/span&gt; months result in the recognition of a ROU asset and liability at the lease commencement date based on the present value of the lease payments over the lease term. The present value of the lease payments is calculated using the applicable weighted-average discount rate. The weighted-average discount rate is based on the discount rate implicit in the lease, or if the implicit rate is not readily determinable from the lease, the applicable incremental borrowing rate is estimated. The incremental borrowing rate is estimated using the currency denomination of the lease, the contractual lease term and the Company&#x2019;s applicable borrowing rate. To determine the incremental borrowing rate, reference is made to interest rates that would be available to finance assets similar to the assets under lease in their related geographical location. The Company does not have finance leases.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit; font-family: 'times new roman', times;"&gt;The Company has elected not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with a lease as a single lease component. It also elected to be exempt from balance sheet recognition of all leases with an initial term of &lt;/span&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_520JD3IUDC00000000000000000000fs" style="font-size: 10pt; text-indent: 0.25in; line-height: inherit; display: inline;"&gt;12&lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt; months or less.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Certain leases include &lt;span id="fs_L5GHDLL6K000000000000000000000fs" style="line-height: inherit; display: inline;"&gt;one&lt;/span&gt; or more options to renew with renewal terms that can extend the lease term. The exercise of the lease renewal options is at the Company&#x2019;s discretion and are included in the determination of the ROU asset and lease liability when the option is reasonably certain of being exercised.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo26a65fd2833e48ce951a2c82e6e750fb" style="line-height: 1.2;"&gt;
&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z75F4FaHF1N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_866_zcBJGLHjqxZe" style="line-height: inherit;"&gt;Research and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Research and development costs are charged to operations in the period incurred and amounted to $&lt;span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20230101__20231231_zPF51ehp4RZ4" style="line-height: inherit;" title="Research and development costs"&gt;18.1 million&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20220101__20221231_zvq200PZSZd1" style="line-height: inherit;" title="Research and development costs"&gt;15.7 million&lt;/span&gt;, net of grant income, for the years ended &lt;span id="fs_MM6BHN6VLC00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_GY42C6E8VK00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo7cd45dcdcf13430ab1486843942146b0" style="line-height: 1.2;"&gt;
&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zOhd3QPYxrE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_869_zihbwubcwik9" style="line-height: inherit;"&gt;Patent Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Due to the uncertainty associated with the successful development of &lt;span id="fs_Y1FG55AZB400000000000000000000fs" style="line-height: inherit; display: inline;"&gt;one&lt;/span&gt; or more commercially viable products based on our research efforts and any related patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated costs, are expensed as incurred. Patent costs were $&lt;span id="xdx_902_eus-gaap--OtherGeneralExpense_dm_c20230101__20231231_z6azpdZxuss4" style="line-height: inherit;" title="Patent costs"&gt;0.3 million&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--OtherGeneralExpense_dm_c20220101__20221231_zB2LYgrHaZci" style="line-height: inherit;" title="Patent costs"&gt;0.3 million&lt;/span&gt; for the years ended &lt;span id="fs_0N7CDEHHOG00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_5GCH6IXLGG00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively, and are included in general and administrative expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p id="xdx_850_zpKWnFwpuSjf" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo80ae1a9e2b43444cb46c0b7f363d4e22" style="line-height: 1.2;"&gt;
&lt;p id="xdx_841_ecustom--NhGrantPolicyTextBlock_z4meUJqqqt5k" style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_860_z9zcX7a2T6xd" style="line-height: inherit;"&gt;NIH Grant&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;From time to time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset against the related operating expenses as the costs are incurred.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;During the year ended December 31, 2025, grants offset against operating expenses were $35,000, all of which were offset against research and developments. During the year ended December 31, 2024, grants offset against operating expenses were $0.2 million, all of which were offset against research and development expenses.&lt;/span&gt; &lt;/p&gt;







 &lt;/div&gt;
&lt;p id="xdx_851_zzquOmnvtti1" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="focd3388ce337b47f6a0e6dc53c5ce511c"&gt;
&lt;p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zSWhJCXUjdrj" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_861_z0ZNUfCQabR5" style="line-height: inherit;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Financial instruments that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and SIPC insurance limits of $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zbeL7yqt1faf" style="line-height: inherit;" title="FDIC insured amount"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--CashSPICInsuredAmount_iI_c20231231_zcsPyykkDpac" style="line-height: inherit;" title="SPIC insured amount"&gt;500,000&lt;/span&gt; (including cash of $&lt;span id="xdx_90C_ecustom--SPICCashLimitCoverage_iI_c20231231_zYrmE7G0mVQf" style="line-height: inherit;" title="SPIC cash limit coverage"&gt;250,000&lt;/span&gt;), respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We also maintain cash at a bank in Switzerland &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;and a bank in Australia.&lt;/span&gt;&#160;Accounts at said bank are insured up to an amount specified by the deposit insurance agency&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;of their respective countries.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;

&lt;p id="xdx_85C_znKFVvYBSMCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fof1b1d314af55423cb7f7768d772fb144"&gt;
&lt;p id="xdx_84A_ecustom--ForeignOperationsPolicyTextBlock_z3TeHtMOcWbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_860_zKeNbeJq4q2e"&gt;Foreign Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;The accompanying consolidated financial statements as of &lt;span id="fs_8QPBXZS9FK00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_9FG10WWKIO00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; include assets amounting to approximately $&lt;span id="xdx_90B_eus-gaap--Assets_iI_c20231231__srt--StatementGeographicalAxis__custom--CountryMember_zySyZkl5dAOd" style="line-height: inherit;"&gt;0&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Assets_iI_c20221231__srt--StatementGeographicalAxis__custom--CountryMember_zbftWWCh17td" style="line-height: inherit;"&gt;26,000&lt;/span&gt;, respectively, relating to our operations in Switzerland. &lt;span style="font-size: 10pt; line-height: inherit;"&gt;In the fourth quarter of &lt;span id="fs_FI9OJ4K3C000000000000000000000fs" style="line-height: inherit;"&gt;2023&lt;/span&gt;, Vivani Medical Australia Pty Ltd., a wholly owned subsidiary in Australia was established to support studies of our product candidates.&lt;/span&gt; &lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;The accompanying consolidated financial statements as of &lt;/span&gt;&lt;span id="fs_UK7JS4J62800000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt; and &lt;span style="font-size: 10pt; line-height: inherit;"&gt;&lt;span id="fs_R8DS5R9PKW00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;include assets amounting&lt;/span&gt; to approximately $700,000 and $446,000, respectively, relating to our operations in Australia. &lt;/span&gt;Unanticipated events in foreign countries could disrupt our operations and impair the value of these assets.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo36efd011b07449b4a954c0abe23dc9c3"&gt;
&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zOfRdV7senyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;F&lt;span id="xdx_867_zCjTTpFs98ff"&gt;air Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into &lt;span id="fs_WTF6I7NLTS00000000000000000000fs" style="display: inline;"&gt;three&lt;/span&gt; levels and requires that assets and liabilities carried at fair value be classified and disclosed in &lt;span id="fs_FCRY644E5S00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt; of &lt;span id="fs_DM56XLUWPS00000000000000000000fs" style="display: inline;"&gt;three&lt;/span&gt; categories, as presented below. Disclosure as to transfers in and out of Levels &lt;span id="fs_REJC0J8G4W00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt; and &lt;span id="fs_5PFPTCXQV400000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;, and activity in Level &lt;span id="fs_9LR138J3R400000000000000000000fs" style="display: inline;"&gt;3&lt;/span&gt; fair value measurements, is also required.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Level &lt;span id="fs_BC43FKT1CW00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level &lt;span id="fs_CZLY16CEE800000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt; inputs include active-exchange traded securities and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Level &lt;span id="fs_94OSABB81C00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;. Inputs, other than quoted prices included within Level &lt;span id="fs_WPZQEHMKZ400000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level &lt;span id="fs_8VETQ3268W00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt; inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Level &lt;span id="fs_TZWBO8KG4W00000000000000000000fs" style="display: inline;"&gt;3&lt;/span&gt;. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level &lt;span id="fs_LM3NFUWTFK00000000000000000000fs" style="display: inline;"&gt;3&lt;/span&gt; inputs include infrequently traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We determine the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Cash equivalents, which include &lt;span style="font-size: 10pt;"&gt;certificates of deposit and &lt;/span&gt; money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our consolidated balance sheet, and they are valued using Level &lt;span id="fs_P7RK07FHUO00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt; inputs.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p id="xdx_854_zOTmV9zigZC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fodebc0766021d4c5394d63a697795f125"&gt;
&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zI3zgzL8s03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_863_zeDgHJg4PxHa"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC &lt;span id="fs_5W0YZYMLGG00000000000000000000fs"&gt;718&lt;/span&gt;, &lt;i&gt;Shares-Based Payments. &lt;/i&gt;The Company&#x2019;s stock-based awards consist of stock options and restricted stock units granted to employees and directors. Stock-based compensation cost is measured at the grant-date fair value of the award and is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award for equity awards with service conditions, and derived service period for equity awards with market and service conditions. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;The fair value of stock option awards with service conditions is estimated using the Black-Scholes option pricing model. The assumptions used in the Black-Scholes option pricing model are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The grant price of the issuances is determined based on the fair value of the shares at the date of grant.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The risk-free interest rate for periods within the contractual life of the option is based on the U.S. treasury yield in effect at the time of grant.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;We calculate the expected term of options using a weighted average of option vesting periods and an estimate of &lt;span id="fs_4PU9MF4BLC00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt;-half of the period between vesting and expiration of the option.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Volatility is determined based on our average historical volatilities since our trading history, supplemented with average historical volatilities of comparable companies in our similar industry.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-right: 1pt; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 &lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;The fair value and derived service period of equity awards with market and service conditions are estimated on the grant date using a Monte Carlo simulation model. A Monte Carlo simulation model requires inputs such as the risk-free interest rate, expected term, expected dividend yield, and expected volatility.&lt;/span&gt; &lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo226d13eff1784b91a1f29b3ae5532ecd"&gt;
&lt;p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zDsxsjig9zPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86B_zlfaEinHIKe7"&gt;Comprehensive Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We comply with provisions of FASB ASC &lt;span id="fs_LDMPXH7CAO00000000000000000000fs" style="display: inline;"&gt;220&lt;/span&gt;, &lt;i&gt;Comprehensive Income&lt;/i&gt;, which requires companies to report all changes in equity during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner sources.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Comprehensive loss is reported on the face of the financial statements. For the year ended &lt;span id="fs_0X9QDPARA800000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_E2FCI4BK3400000000000000000000FM"&gt;2024&lt;/span&gt;, comprehensive loss is the total of net loss and other comprehensive income, which consists entirely of foreign currency translation adjustments.&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;During the year ended &lt;span id="fs_LQDPFBLVTC00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, the Company recorded a $0.1 million reclassification from accumulated other comprehensive income to net loss related to the liquidation of its wholly owned Swiss subsidiary. The reclassification represents the release of cumulative foreign currency translation adjustments in accordance with ASC &lt;span id="fs_5TVHEJTMEO00000000000000000000fs"&gt;830&lt;/span&gt;,&#160;&lt;span style="font-style: italic;"&gt;Foreign Currency Matters&#160;&lt;/span&gt;and is included within other income, net in the condensed consolidated statements of operations. There were no material reclassifications from other comprehensive loss to net loss during the year ended December 31, 2024.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p id="xdx_858_zc21seT2LXmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo1f419db810c54d87825d9e6a2481df9f"&gt;
&lt;p id="xdx_849_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVVJbtE8l115" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_869_zNLidJnPdQl5"&gt;Foreign Currency Translation and Transaction Gains and Losses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The financial statements and transactions of the subsidiary&#x2019;s operations are reported in the local (functional) currency of Swiss francs (CHF) and of Australian dollars (AUD) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency financial statements are recorded as other comprehensive income. Revenues and expenses are translated at the average exchange rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions denominated in a currency other than the foreign operations&#x2019; functional currencies are included in other income, net in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fofd9fe28290a74cd6bc2bb48fcdcd67e7"&gt;
&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zZRZnzTqsLp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;I&lt;span id="xdx_861_zyNrV0aFai8b"&gt;ncome Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We &lt;span style="font-size: 10pt;"&gt;account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We &lt;span style="font-size: 10pt; line-height: inherit;"&gt;record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for tax purposes since inception and have significant tax losses and tax credit carry-forwards&lt;/span&gt;.&#160;&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;div id="fo173765796a934754af0cd6f6d776810c"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;div id="fod3997abb415848f488702ab3f0e48c2b"&gt;
&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_z4B1penBPEl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_864_zQ2uLaQh9m1e"&gt;Net Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;We compute earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC &lt;span id="fs_4QCE250MZ400000000000000000000fs"&gt;260&lt;/span&gt;, &lt;i&gt;Earnings Per Share&lt;/i&gt;. Basic EPS is calculated as net income (loss) available to common stockholders divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock, calculated using the treasury stock or if&#x2011;converted methods, as applicable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;For periods in which we incurred a net loss, basic and diluted net loss per common share are the same, as the inclusion of potential common shares would be anti&#x2011;dilutive. Accordingly, outstanding securities that could potentially dilute EPS, including warrants, stock options, and restricted stock units were excluded from the calculation of diluted EPS for the periods presented. As of December 31, 2025 and &lt;span id="fs_3FCZYAU6WG00000000000000000000fs"&gt;2024&lt;/span&gt;, the anti&#x2011;dilutive securities excluded from diluted EPS are summarized below (in thousands).&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo6176497830784e039e1ccc49c8524cbc"&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; display: none; text-indent: 0.25in; visibility: hidden;"&gt;&lt;span id="xdx_8BB_zrDxom1aeEW8" style="font-family: 'times new roman', times;"&gt;Schedule of net loss per share&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 103px; width: 90%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_491_20231231_ztcKWc3wuUv" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_495_20221231_ztpvZwvVJH2f" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_GFALX0X8F400000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_DBWYDJYSBK00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_V2THASS5Q800000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_uShares_zOzfmDZAhKul" style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;7,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_zvK5mVnRAUob" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 74%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying stock options outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;8,366&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,809&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--SharesUnderlyingRestrictedStockUnitOutstanding_iI_pid_uShares_zmX44ZaNYmU1" style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;800&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;695&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--SharesUnderlyingRsus_iI_pid_uShares_zvHU14qF657f" style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;16,785&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;16,844&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 &lt;/div&gt;







 &lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo2de79316779544a78829f9050d601df0"&gt;
&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z19a8g366Nhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86C_zY6uG2tuaNG7"&gt;Operating Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Operating &lt;span style="font-size: 10pt;"&gt;segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented for each of our segments. We have two reporting segments, specifically the Biopharm Division and Neurostimulation Division. Neither division is revenue producing. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd. The Neurostimulation Division includes activities from Cortigent and our subsidiary in Switzerland&lt;/span&gt;.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman', times;"&gt;The Company&#x2019;s long-term assets are located in the United States.&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo62c1aea7a12c4a5896f9f170556d0090"&gt;
&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ96aoq7t0t6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_867_zjxC35KM4J9"&gt;Recently &lt;/span&gt;&lt;/b&gt;&lt;span style="font-weight: bold;"&gt;Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0pt 0px; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit; font-family: 'times new roman', times; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit;"&gt;In&#160;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;November 2024, the FASB issued Accounting Standards Update ("ASU") No. &lt;span id="fs_D4WD55PSYO00000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_WJWG6SGUV400000000000000000000fs"&gt;03&lt;/span&gt;&#160;&lt;i&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic &lt;span id="fs_OVDZTZR64000000000000000000000fs"&gt;220&lt;/span&gt;-&lt;span id="fs_MJMZ7K3LN400000000000000000000fs"&gt;40&lt;/span&gt;): Disaggregation of Income Statement Expenses&#160;&lt;/i&gt;(ASU No. &lt;span id="fs_8KNV7WRAUO00000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_JARQ68W18W00000000000000000000fs"&gt;03&lt;/span&gt;&#x201d;), which&#160;will improve the disclosures about a public business entity&#x2019;s expenses and&#160;requires detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions&#160;such as cost of sales, selling, general and administrative, and research and development&#160;on the face of the income statement. ASU &lt;span id="fs_7X6EWRFUN400000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_YZ7OV7MFJ400000000000000000000fs"&gt;03&lt;/span&gt; is effective for the Company or fiscal years beginning on January 1, 2027, and for interim periods within fiscal years beginning on January 1, 2028. Early adoption is permitted. The guidance may be applied either (&lt;span id="fs_63VP7E0XLS00000000000000000000fs"&gt;1&lt;/span&gt;) prospectively to financial statements issued for reporting periods after the effective date of ASU &lt;span id="fs_1KIG3IHYUO00000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_A2YO8ZJF6800000000000000000000fs"&gt;03&lt;/span&gt; or (&lt;span id="fs_7BLVJ7QH4W00000000000000000000fs"&gt;2&lt;/span&gt;) retrospectively to all prior periods presented in the financial statements. The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial statements and continues to evaluate disclosure presentation alternatives.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0pt 0px; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;In December 2025, the FASB issued&#160;ASU No. &lt;span id="fs_JLDDU1O9C000000000000000000000fs"&gt;2025&lt;/span&gt;-&lt;span id="fs_P1NFFJOIB400000000000000000000fs"&gt;10&lt;/span&gt;, &lt;i&gt;Government Grants (Topic &lt;span id="fs_PT8OZZU82800000000000000000000fs"&gt;832&lt;/span&gt;): Accounting for Government Grants Received by Business Entities.&lt;/i&gt; This ASU provides authoritative guidance for the recognition, measurement and presentation of government grants received by a business entity. This ASU is effective for annual reporting periods beginning after December 15, 2028 and interim periods within those annual periods. The guidance can be applied on a modified prospective, modified retrospective, or retrospective approach; early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0pt 0px; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit; font-family: 'times new roman', times; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;In December 2025, the FASB issued ASU &lt;span id="fs_KZ4IEQUBU800000000000000000000fs"&gt;2025&lt;/span&gt;-&lt;span id="fs_ZA0TCQPX4000000000000000000000fs"&gt;11&lt;/span&gt;, &lt;i&gt;Interim Reporting (Topic &lt;span id="fs_7Q7A14Q3MO00000000000000000000fs"&gt;270&lt;/span&gt;) - Narrow-Scope Improvements.&lt;/i&gt; This ASU clarifies interim disclosure requirements; it does not attempt to expand or reduce disclosures. ASU &lt;span id="fs_PODAFFGP9C00000000000000000000fs"&gt;2025&lt;/span&gt;-&lt;span id="fs_4E5XWGONU800000000000000000000fs"&gt;11&lt;/span&gt; also includes a disclosure principle to help entities determine which events since the end of the last annual reporting period are material for disclosure. This ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The guidance can be applied on a prospective basis, or a retrospective basis for all or any prior periods, and early adoption is permitted. The Company is currently evaluating the impact of this ASU; however, it is not anticipated to have a material impact on its consolidated financial statements&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;b&gt;&lt;/b&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;b&gt;&lt;span style="font-size: 10.0pt;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;b&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;In&#160;December 2023, the FASB issued ASU No. &lt;span id="fs_0N1Y2XRJSG00000000000000000000fs"&gt;2023&lt;/span&gt;-&lt;span id="fs_OM63TTJYG000000000000000000000fs"&gt;09&lt;/span&gt;, &lt;i&gt;Improvements to Income Tax Disclosures (Topic &lt;span id="fs_FJHHY1Z8BK00000000000000000000fs"&gt;740&lt;/span&gt;)&lt;/i&gt;. The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid.&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;The Company adopted this ASU on a prospective basis effective January 1, 2025. Tax disclosures in Note &lt;span id="fs_1IMCCFWZ7K00000000000000000000fs"&gt;11&lt;/span&gt; of the financial statements reflect the impacts of the adoption.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;







 &lt;/div&gt;







 </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="D20251231" id="Tag132">
&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_ztFKkamq8NW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_864_zyJCA7t2ML15"&gt;Principles of Consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include&#160;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;the accounts of the Company and its wholly owned subsidiaries.&#160;&lt;/span&gt;Intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="D20251231" id="Tag130">
&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zR3x5G0Rjrne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_868_zvGEg3p4kIz8"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities &lt;span style="font-size: 10pt; line-height: inherit;"&gt;and disclosure of contingent assets and liabilities &lt;/span&gt; at the date of the financial statements and the reported amounts of expenses during the reporting period. We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those&#160;estimates are adjusted accordingly. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred tax assets. Actual results could differ &lt;span style="font-size: 10pt; line-height: inherit;"&gt;materially&lt;/span&gt; from those estimates.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="D20251231" id="Tag129">
&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQ1T8uaKVR16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86C_zVDcsQCWb189"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We consider all highly liquid investments with a maturity of &lt;span id="fs_DQIPSJIZ5C00000000000000000000fs" style="display: inline;"&gt;three&lt;/span&gt; months or less at the date of purchase to be cash equivalents. Cash is carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds that are in excess of current needs in high credit quality instruments such as money market funds. As of &lt;span id="fs_B7M4E8X9AO00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_0089CRTQF400000000000000000000FM"&gt;2024&lt;/span&gt; restricted cash of $&lt;span id="xdx_90B_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_dm_c20231231_zT3Y7IIeZ2y5" title="Restricted cash and cash equivalents"&gt;1.3 million&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_dm_c20221231_zGilnyU8bTj1" title="Restricted cash and cash equivalents"&gt;1.3 million&lt;/span&gt;, respectively, relates to a letter of credit as a condition of our facilities lease guarantee requirements and is classified as long-term restricted cash on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="I20251231"
      decimals="-5"
      id="Tag141"
      unitRef="USD">1300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="I20241231"
      decimals="-5"
      id="Tag140"
      unitRef="USD">1300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="D20251231" id="Tag143">
&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zM8kwbhbIzYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;P&lt;span id="xdx_86B_z2DK0bujMP7e"&gt;roperty and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Property and equipment are recorded at historical cost less accumulated depreciation.&#160;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the balance sheets and any resulting gains or losses are reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Depreciation &lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;is computed using the straight-line method over the estimated useful lives of the respective assets&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fof19f85a99d6040bab63f68afbb18f47b"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%; border-collapse: collapse; height: 42px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; width: 46%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_z6yysO2BLdMd" title="Estimated useful lives::XDX::P5Y"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 16px; width: 53%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z3nrI9Zh3cI" title="Estimated useful lives::XDX::P7Y"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zIjGtBoXivjg" title="Estimated useful lives::XDX::P3Y"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;







 &lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBjhQKCsXxrg" title="Estimated useful lives::XDX::P7Y"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB4nKNFg2C65" title="Estimated useful lives::XDX::P5Y"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zOODIjnIpk01" title="Estimated useful lives::XDX::P10Y"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 &lt;/div&gt;
&lt;p id="xdx_8A0_zlwIDVbQDEug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;We&#160;&lt;/span&gt;review our property and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Depreciation of property and equipment amounted to $&lt;span id="xdx_900_eus-gaap--DepreciationAndAmortization_dm_c20230101__20231231_zmYUfALdL6pc" style="line-height: inherit;" title="Depreciation and amortization of property and equipment"&gt;0.4 million&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DepreciationAndAmortization_dm_c20220101__20221231_zjPjSfBpTRUd" style="line-height: inherit;" title="Depreciation and amortization of property and equipment"&gt;0.4 million&lt;/span&gt; for the years ended &lt;span id="fs_RTDKL7BZ0G00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_H3M879P5B400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <vani:ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock contextRef="D20251231" id="Tag131">
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%; border-collapse: collapse; height: 42px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; width: 46%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_z6yysO2BLdMd" title="Estimated useful lives::XDX::P5Y"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 16px; width: 53%; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_z3nrI9Zh3cI" title="Estimated useful lives::XDX::P7Y"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zIjGtBoXivjg" title="Estimated useful lives::XDX::P3Y"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;







 &lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zBjhQKCsXxrg" title="Estimated useful lives::XDX::P7Y"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Furniture, fixtures and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB4nKNFg2C65" title="Estimated useful lives::XDX::P5Y"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-left: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x2013; &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtxL_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zOODIjnIpk01" title="Estimated useful lives::XDX::P10Y"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 </vani:ScheduleOfEstimatedUsefulLifeOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="I20251231_EquipmentMember_MinimumMember"
      id="Tag153">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="I20251231_EquipmentMember_MaximumMember"
      id="Tag156">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="I20251231_ComputerEquipmentMember_MinimumMember"
      id="Tag152">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="I20251231_ComputerEquipmentMember_MaximumMember"
      id="Tag155">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="I20251231_FurnitureAndFixturesMember_MinimumMember"
      id="Tag151">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="I20251231_FurnitureAndFixturesMember_MaximumMember"
      id="Tag154">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="D20251231"
      decimals="-5"
      id="Tag157"
      unitRef="USD">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D20241231"
      decimals="-5"
      id="Tag158"
      unitRef="USD">400000</us-gaap:Depreciation>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="D20251231" id="Tag150">
&lt;p id="xdx_847_eus-gaap--LessorLeasesPolicyTextBlock_z6odnS7ykyZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86B_zGaR8qQrJIXe" style="line-height: inherit;"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Leases are accounted for under the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;span id="fs_95KX2NY1YO00000000000000000000fs"&gt;842&lt;/span&gt;, Leases (&#x201c;ASC &lt;span id="fs_QB3LR849GG00000000000000000000fs"&gt;842&lt;/span&gt;&#x201d;). Under ASC &lt;span id="fs_IUTT1WV9LC00000000000000000000fs" style="line-height: inherit; display: inline;"&gt;842&lt;/span&gt;, the Company determines if an arrangement contains a lease at inception. Right of use assets (&#x201c;ROU assets&#x201d;) represent the right to use an underlying asset for the lease term while lease liabilities represent the obligation to make lease payments for the lease term. Leases are then classified as either finance or operating, with classification affecting the pattern of expense recognition in the statements of operations and comprehensive loss.&#160;All leases greater than &lt;span id="fs_6BXRV0WR1C00000000000000000000fs" style="line-height: inherit; display: inline;"&gt;12&lt;/span&gt; months result in the recognition of a ROU asset and liability at the lease commencement date based on the present value of the lease payments over the lease term. The present value of the lease payments is calculated using the applicable weighted-average discount rate. The weighted-average discount rate is based on the discount rate implicit in the lease, or if the implicit rate is not readily determinable from the lease, the applicable incremental borrowing rate is estimated. The incremental borrowing rate is estimated using the currency denomination of the lease, the contractual lease term and the Company&#x2019;s applicable borrowing rate. To determine the incremental borrowing rate, reference is made to interest rates that would be available to finance assets similar to the assets under lease in their related geographical location. The Company does not have finance leases.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit; font-family: 'times new roman', times;"&gt;The Company has elected not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with a lease as a single lease component. It also elected to be exempt from balance sheet recognition of all leases with an initial term of &lt;/span&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_520JD3IUDC00000000000000000000fs" style="font-size: 10pt; text-indent: 0.25in; line-height: inherit; display: inline;"&gt;12&lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt; months or less.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Certain leases include &lt;span id="fs_L5GHDLL6K000000000000000000000fs" style="line-height: inherit; display: inline;"&gt;one&lt;/span&gt; or more options to renew with renewal terms that can extend the lease term. The exercise of the lease renewal options is at the Company&#x2019;s discretion and are included in the determination of the ROU asset and lease liability when the option is reasonably certain of being exercised.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="D20251231" id="Tag127">
&lt;p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_z75F4FaHF1N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_866_zcBJGLHjqxZe" style="line-height: inherit;"&gt;Research and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Research and development costs are charged to operations in the period incurred and amounted to $&lt;span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20230101__20231231_zPF51ehp4RZ4" style="line-height: inherit;" title="Research and development costs"&gt;18.1 million&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OtherResearchAndDevelopmentExpense_dm_c20220101__20221231_zvq200PZSZd1" style="line-height: inherit;" title="Research and development costs"&gt;15.7 million&lt;/span&gt;, net of grant income, for the years ended &lt;span id="fs_MM6BHN6VLC00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_GY42C6E8VK00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="D20251231"
      decimals="-5"
      id="Tag139"
      unitRef="USD">18100000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="D20241231"
      decimals="-5"
      id="Tag138"
      unitRef="USD">15700000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="D20251231" id="Tag126">
&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zOhd3QPYxrE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_869_zihbwubcwik9" style="line-height: inherit;"&gt;Patent Costs&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Due to the uncertainty associated with the successful development of &lt;span id="fs_Y1FG55AZB400000000000000000000fs" style="line-height: inherit; display: inline;"&gt;one&lt;/span&gt; or more commercially viable products based on our research efforts and any related patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated costs, are expensed as incurred. Patent costs were $&lt;span id="xdx_902_eus-gaap--OtherGeneralExpense_dm_c20230101__20231231_z6azpdZxuss4" style="line-height: inherit;" title="Patent costs"&gt;0.3 million&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--OtherGeneralExpense_dm_c20220101__20221231_zB2LYgrHaZci" style="line-height: inherit;" title="Patent costs"&gt;0.3 million&lt;/span&gt; for the years ended &lt;span id="fs_0N7CDEHHOG00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_5GCH6IXLGG00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively, and are included in general and administrative expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:OtherGeneralExpense
      contextRef="D20251231"
      decimals="-5"
      id="Tag137"
      unitRef="USD">300000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="D20241231"
      decimals="-5"
      id="Tag136"
      unitRef="USD">300000</us-gaap:OtherGeneralExpense>
    <vani:NhGrantPolicyTextBlock contextRef="D20251231" id="Tag128">
&lt;p id="xdx_841_ecustom--NhGrantPolicyTextBlock_z4meUJqqqt5k" style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_860_z9zcX7a2T6xd" style="line-height: inherit;"&gt;NIH Grant&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;From time to time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset against the related operating expenses as the costs are incurred.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;During the year ended December 31, 2025, grants offset against operating expenses were $35,000, all of which were offset against research and developments. During the year ended December 31, 2024, grants offset against operating expenses were $0.2 million, all of which were offset against research and development expenses.&lt;/span&gt; &lt;/p&gt;







 </vani:NhGrantPolicyTextBlock>
    <vani:GrantsAgainstOperatingExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag164"
      unitRef="USD">35000000</vani:GrantsAgainstOperatingExpense>
    <vani:GrantsAgainstOperatingExpense
      contextRef="D20241231"
      decimals="-5"
      id="Tag165"
      unitRef="USD">200000</vani:GrantsAgainstOperatingExpense>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="D20251231" id="Tag125">
&lt;p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zSWhJCXUjdrj" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_861_z0ZNUfCQabR5" style="line-height: inherit;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Financial instruments that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and SIPC insurance limits of $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zbeL7yqt1faf" style="line-height: inherit;" title="FDIC insured amount"&gt;250,000&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--CashSPICInsuredAmount_iI_c20231231_zcsPyykkDpac" style="line-height: inherit;" title="SPIC insured amount"&gt;500,000&lt;/span&gt; (including cash of $&lt;span id="xdx_90C_ecustom--SPICCashLimitCoverage_iI_c20231231_zYrmE7G0mVQf" style="line-height: inherit;" title="SPIC cash limit coverage"&gt;250,000&lt;/span&gt;), respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We also maintain cash at a bank in Switzerland &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;and a bank in Australia.&lt;/span&gt;&#160;Accounts at said bank are insured up to an amount specified by the deposit insurance agency&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;of their respective countries.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;







 </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="I20251231"
      decimals="0"
      id="Tag135"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <vani:CashSPICInsuredAmount
      contextRef="I20251231"
      decimals="0"
      id="Tag134"
      unitRef="USD">500000</vani:CashSPICInsuredAmount>
    <vani:SPICCashLimitCoverage
      contextRef="I20251231"
      decimals="0"
      id="Tag133"
      unitRef="USD">250000</vani:SPICCashLimitCoverage>
    <vani:ForeignOperationsPolicyTextBlock contextRef="D20251231" id="Tag120">
&lt;p id="xdx_84A_ecustom--ForeignOperationsPolicyTextBlock_z3TeHtMOcWbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_860_zKeNbeJq4q2e"&gt;Foreign Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;The accompanying consolidated financial statements as of &lt;span id="fs_8QPBXZS9FK00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_9FG10WWKIO00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; include assets amounting to approximately $&lt;span id="xdx_90B_eus-gaap--Assets_iI_c20231231__srt--StatementGeographicalAxis__custom--CountryMember_zySyZkl5dAOd" style="line-height: inherit;"&gt;0&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Assets_iI_c20221231__srt--StatementGeographicalAxis__custom--CountryMember_zbftWWCh17td" style="line-height: inherit;"&gt;26,000&lt;/span&gt;, respectively, relating to our operations in Switzerland. &lt;span style="font-size: 10pt; line-height: inherit;"&gt;In the fourth quarter of &lt;span id="fs_FI9OJ4K3C000000000000000000000fs" style="line-height: inherit;"&gt;2023&lt;/span&gt;, Vivani Medical Australia Pty Ltd., a wholly owned subsidiary in Australia was established to support studies of our product candidates.&lt;/span&gt; &lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;The accompanying consolidated financial statements as of &lt;/span&gt;&lt;span id="fs_UK7JS4J62800000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt; and &lt;span style="font-size: 10pt; line-height: inherit;"&gt;&lt;span id="fs_R8DS5R9PKW00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&#160;&lt;/span&gt;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;include assets amounting&lt;/span&gt; to approximately $700,000 and $446,000, respectively, relating to our operations in Australia. &lt;/span&gt;Unanticipated events in foreign countries could disrupt our operations and impair the value of these assets.&lt;/span&gt;&lt;/p&gt;







 </vani:ForeignOperationsPolicyTextBlock>
    <us-gaap:Assets
      contextRef="I20251231_CH"
      decimals="0"
      id="Tag145"
      unitRef="USD">0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="I20241231_CH"
      decimals="0"
      id="Tag146"
      unitRef="USD">26000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="I20251231_AU"
      decimals="0"
      id="Tag147"
      unitRef="USD">700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="I20241231_AU"
      decimals="0"
      id="Tag148"
      unitRef="USD">446000</us-gaap:Assets>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="D20251231" id="Tag124">
&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zOfRdV7senyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;F&lt;span id="xdx_867_zCjTTpFs98ff"&gt;air Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into &lt;span id="fs_WTF6I7NLTS00000000000000000000fs" style="display: inline;"&gt;three&lt;/span&gt; levels and requires that assets and liabilities carried at fair value be classified and disclosed in &lt;span id="fs_FCRY644E5S00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt; of &lt;span id="fs_DM56XLUWPS00000000000000000000fs" style="display: inline;"&gt;three&lt;/span&gt; categories, as presented below. Disclosure as to transfers in and out of Levels &lt;span id="fs_REJC0J8G4W00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt; and &lt;span id="fs_5PFPTCXQV400000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;, and activity in Level &lt;span id="fs_9LR138J3R400000000000000000000fs" style="display: inline;"&gt;3&lt;/span&gt; fair value measurements, is also required.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Level &lt;span id="fs_BC43FKT1CW00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level &lt;span id="fs_CZLY16CEE800000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt; inputs include active-exchange traded securities and exchange-based derivatives.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Level &lt;span id="fs_94OSABB81C00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt;. Inputs, other than quoted prices included within Level &lt;span id="fs_WPZQEHMKZ400000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt;, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level &lt;span id="fs_8VETQ3268W00000000000000000000fs" style="display: inline;"&gt;2&lt;/span&gt; inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-value hedges.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Level &lt;span id="fs_TZWBO8KG4W00000000000000000000fs" style="display: inline;"&gt;3&lt;/span&gt;. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level &lt;span id="fs_LM3NFUWTFK00000000000000000000fs" style="display: inline;"&gt;3&lt;/span&gt; inputs include infrequently traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We determine the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of the assets and liabilities at each reporting period end.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Cash equivalents, which include &lt;span style="font-size: 10pt;"&gt;certificates of deposit and &lt;/span&gt; money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our consolidated balance sheet, and they are valued using Level &lt;span id="fs_P7RK07FHUO00000000000000000000fs" style="display: inline;"&gt;1&lt;/span&gt; inputs.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="D20251231" id="Tag122">
&lt;p id="xdx_848_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zI3zgzL8s03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_863_zeDgHJg4PxHa"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;The Company accounts for stock-based compensation in accordance with FASB ASC &lt;span id="fs_5W0YZYMLGG00000000000000000000fs"&gt;718&lt;/span&gt;, &lt;i&gt;Shares-Based Payments. &lt;/i&gt;The Company&#x2019;s stock-based awards consist of stock options and restricted stock units granted to employees and directors. Stock-based compensation cost is measured at the grant-date fair value of the award and is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award for equity awards with service conditions, and derived service period for equity awards with market and service conditions. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;The fair value of stock option awards with service conditions is estimated using the Black-Scholes option pricing model. The assumptions used in the Black-Scholes option pricing model are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The grant price of the issuances is determined based on the fair value of the shares at the date of grant.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The risk-free interest rate for periods within the contractual life of the option is based on the U.S. treasury yield in effect at the time of grant.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;We calculate the expected term of options using a weighted average of option vesting periods and an estimate of &lt;span id="fs_4PU9MF4BLC00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt;-half of the period between vesting and expiration of the option.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Volatility is determined based on our average historical volatilities since our trading history, supplemented with average historical volatilities of comparable companies in our similar industry.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 29px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-right: 1pt; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 </us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="D20251231" id="Tag119">
&lt;p id="xdx_845_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zDsxsjig9zPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86B_zlfaEinHIKe7"&gt;Comprehensive Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We comply with provisions of FASB ASC &lt;span id="fs_LDMPXH7CAO00000000000000000000fs" style="display: inline;"&gt;220&lt;/span&gt;, &lt;i&gt;Comprehensive Income&lt;/i&gt;, which requires companies to report all changes in equity during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner sources.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Comprehensive loss is reported on the face of the financial statements. For the year ended &lt;span id="fs_0X9QDPARA800000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_E2FCI4BK3400000000000000000000FM"&gt;2024&lt;/span&gt;, comprehensive loss is the total of net loss and other comprehensive income, which consists entirely of foreign currency translation adjustments.&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;During the year ended &lt;span id="fs_LQDPFBLVTC00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, the Company recorded a $0.1 million reclassification from accumulated other comprehensive income to net loss related to the liquidation of its wholly owned Swiss subsidiary. The reclassification represents the release of cumulative foreign currency translation adjustments in accordance with ASC &lt;span id="fs_5TVHEJTMEO00000000000000000000fs"&gt;830&lt;/span&gt;,&#160;&lt;span style="font-style: italic;"&gt;Foreign Currency Matters&#160;&lt;/span&gt;and is included within other income, net in the condensed consolidated statements of operations. There were no material reclassifications from other comprehensive loss to net loss during the year ended December 31, 2024.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;







 </us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="D20251231_CH"
      decimals="-5"
      id="Tag171"
      unitRef="USD">100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="D20241231_CH"
      decimals="-3"
      id="Tag170"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="D20251231" id="Tag118">
&lt;p id="xdx_849_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVVJbtE8l115" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_869_zNLidJnPdQl5"&gt;Foreign Currency Translation and Transaction Gains and Losses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The financial statements and transactions of the subsidiary&#x2019;s operations are reported in the local (functional) currency of Swiss francs (CHF) and of Australian dollars (AUD) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency financial statements are recorded as other comprehensive income. Revenues and expenses are translated at the average exchange rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions denominated in a currency other than the foreign operations&#x2019; functional currencies are included in other income, net in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="D20251231" id="Tag117">
&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zZRZnzTqsLp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;I&lt;span id="xdx_861_zyNrV0aFai8b"&gt;ncome Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We &lt;span style="font-size: 10pt;"&gt;account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We &lt;span style="font-size: 10pt; line-height: inherit;"&gt;record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for tax purposes since inception and have significant tax losses and tax credit carry-forwards&lt;/span&gt;.&#160;&lt;/span&gt;&lt;/p&gt;







 </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="D20251231" id="Tag123">
&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_z4B1penBPEl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_864_zQ2uLaQh9m1e"&gt;Net Loss per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;We compute earnings per share (&#x201c;EPS&#x201d;) in accordance with ASC &lt;span id="fs_4QCE250MZ400000000000000000000fs"&gt;260&lt;/span&gt;, &lt;i&gt;Earnings Per Share&lt;/i&gt;. Basic EPS is calculated as net income (loss) available to common stockholders divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock, calculated using the treasury stock or if&#x2011;converted methods, as applicable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;For periods in which we incurred a net loss, basic and diluted net loss per common share are the same, as the inclusion of potential common shares would be anti&#x2011;dilutive. Accordingly, outstanding securities that could potentially dilute EPS, including warrants, stock options, and restricted stock units were excluded from the calculation of diluted EPS for the periods presented. As of December 31, 2025 and &lt;span id="fs_3FCZYAU6WG00000000000000000000fs"&gt;2024&lt;/span&gt;, the anti&#x2011;dilutive securities excluded from diluted EPS are summarized below (in thousands).&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo6176497830784e039e1ccc49c8524cbc"&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; display: none; text-indent: 0.25in; visibility: hidden;"&gt;&lt;span id="xdx_8BB_zrDxom1aeEW8" style="font-family: 'times new roman', times;"&gt;Schedule of net loss per share&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 103px; width: 90%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_491_20231231_ztcKWc3wuUv" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_495_20221231_ztpvZwvVJH2f" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_GFALX0X8F400000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_DBWYDJYSBK00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_V2THASS5Q800000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_uShares_zOzfmDZAhKul" style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;7,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_zvK5mVnRAUob" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 74%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying stock options outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;8,366&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,809&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--SharesUnderlyingRestrictedStockUnitOutstanding_iI_pid_uShares_zmX44ZaNYmU1" style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;800&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;695&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--SharesUnderlyingRsus_iI_pid_uShares_zvHU14qF657f" style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;16,785&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;16,844&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 &lt;/div&gt;







 </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="D20251231" id="Tag159">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; display: none; text-indent: 0.25in; visibility: hidden;"&gt;&lt;span id="xdx_8BB_zrDxom1aeEW8" style="font-family: 'times new roman', times;"&gt;Schedule of net loss per share&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 103px; width: 90%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_491_20231231_ztcKWc3wuUv" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_495_20221231_ztpvZwvVJH2f" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_GFALX0X8F400000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_DBWYDJYSBK00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_V2THASS5Q800000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_uShares_zOzfmDZAhKul" style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying warrants outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;7,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_uShares_zvK5mVnRAUob" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 74%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying stock options outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;8,366&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,809&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--SharesUnderlyingRestrictedStockUnitOutstanding_iI_pid_uShares_zmX44ZaNYmU1" style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares underlying restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;800&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;695&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--SharesUnderlyingRsus_iI_pid_uShares_zvHU14qF657f" style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;16,785&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;16,844&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20251231_WarrantMember_3"
      decimals="-3"
      id="Tag168"
      unitRef="Shares">7619000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20241231_WarrantMember_1"
      decimals="-3"
      id="Tag166"
      unitRef="Shares">9340000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20251231_EmployeeStockOptionMember_3"
      decimals="-3"
      id="Tag160"
      unitRef="Shares">8366000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20241231_EmployeeStockOptionMember_3"
      decimals="-3"
      id="Tag162"
      unitRef="Shares">6809000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20251231_RestrictedStockUnitsRSUMember_1"
      decimals="-3"
      id="Tag161"
      unitRef="Shares">800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20241231_RestrictedStockUnitsRSUMember_1"
      decimals="-3"
      id="Tag163"
      unitRef="Shares">695000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20251231"
      decimals="-3"
      id="Tag169"
      unitRef="Shares">16785000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D20241231"
      decimals="-3"
      id="Tag167"
      unitRef="Shares">16844000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="D20251231" id="Tag121">
&lt;p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z19a8g366Nhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_86C_zY6uG2tuaNG7"&gt;Operating Segments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Operating &lt;span style="font-size: 10pt;"&gt;segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented for each of our segments. We have two reporting segments, specifically the Biopharm Division and Neurostimulation Division. Neither division is revenue producing. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd. The Neurostimulation Division includes activities from Cortigent and our subsidiary in Switzerland&lt;/span&gt;.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman', times;"&gt;The Company&#x2019;s long-term assets are located in the United States.&lt;/span&gt;&lt;/p&gt;







 </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="D20251231"
      decimals="0"
      id="Tag149"
      unitRef="SEGMENT">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D20251231" id="Tag142">
&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ96aoq7t0t6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span id="xdx_867_zjxC35KM4J9"&gt;Recently &lt;/span&gt;&lt;/b&gt;&lt;span style="font-weight: bold;"&gt;Issued Accounting Pronouncements Not Yet Adopted as of December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0pt 0px; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit; font-family: 'times new roman', times; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit;"&gt;In&#160;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;November 2024, the FASB issued Accounting Standards Update ("ASU") No. &lt;span id="fs_D4WD55PSYO00000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_WJWG6SGUV400000000000000000000fs"&gt;03&lt;/span&gt;&#160;&lt;i&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic &lt;span id="fs_OVDZTZR64000000000000000000000fs"&gt;220&lt;/span&gt;-&lt;span id="fs_MJMZ7K3LN400000000000000000000fs"&gt;40&lt;/span&gt;): Disaggregation of Income Statement Expenses&#160;&lt;/i&gt;(ASU No. &lt;span id="fs_8KNV7WRAUO00000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_JARQ68W18W00000000000000000000fs"&gt;03&lt;/span&gt;&#x201d;), which&#160;will improve the disclosures about a public business entity&#x2019;s expenses and&#160;requires detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions&#160;such as cost of sales, selling, general and administrative, and research and development&#160;on the face of the income statement. ASU &lt;span id="fs_7X6EWRFUN400000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_YZ7OV7MFJ400000000000000000000fs"&gt;03&lt;/span&gt; is effective for the Company or fiscal years beginning on January 1, 2027, and for interim periods within fiscal years beginning on January 1, 2028. Early adoption is permitted. The guidance may be applied either (&lt;span id="fs_63VP7E0XLS00000000000000000000fs"&gt;1&lt;/span&gt;) prospectively to financial statements issued for reporting periods after the effective date of ASU &lt;span id="fs_1KIG3IHYUO00000000000000000000fs"&gt;2024&lt;/span&gt;-&lt;span id="fs_A2YO8ZJF6800000000000000000000fs"&gt;03&lt;/span&gt; or (&lt;span id="fs_7BLVJ7QH4W00000000000000000000fs"&gt;2&lt;/span&gt;) retrospectively to all prior periods presented in the financial statements. The Company does not expect the adoption of this guidance to have a material effect on its consolidated financial statements and continues to evaluate disclosure presentation alternatives.&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0pt 0px; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;In December 2025, the FASB issued&#160;ASU No. &lt;span id="fs_JLDDU1O9C000000000000000000000fs"&gt;2025&lt;/span&gt;-&lt;span id="fs_P1NFFJOIB400000000000000000000fs"&gt;10&lt;/span&gt;, &lt;i&gt;Government Grants (Topic &lt;span id="fs_PT8OZZU82800000000000000000000fs"&gt;832&lt;/span&gt;): Accounting for Government Grants Received by Business Entities.&lt;/i&gt; This ASU provides authoritative guidance for the recognition, measurement and presentation of government grants received by a business entity. This ASU is effective for annual reporting periods beginning after December 15, 2028 and interim periods within those annual periods. The guidance can be applied on a modified prospective, modified retrospective, or retrospective approach; early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0pt 0px; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit; font-family: 'times new roman', times; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-size-adjust: none; font-language-override: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;In December 2025, the FASB issued ASU &lt;span id="fs_KZ4IEQUBU800000000000000000000fs"&gt;2025&lt;/span&gt;-&lt;span id="fs_ZA0TCQPX4000000000000000000000fs"&gt;11&lt;/span&gt;, &lt;i&gt;Interim Reporting (Topic &lt;span id="fs_7Q7A14Q3MO00000000000000000000fs"&gt;270&lt;/span&gt;) - Narrow-Scope Improvements.&lt;/i&gt; This ASU clarifies interim disclosure requirements; it does not attempt to expand or reduce disclosures. ASU &lt;span id="fs_PODAFFGP9C00000000000000000000fs"&gt;2025&lt;/span&gt;-&lt;span id="fs_4E5XWGONU800000000000000000000fs"&gt;11&lt;/span&gt; also includes a disclosure principle to help entities determine which events since the end of the last annual reporting period are material for disclosure. This ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. The guidance can be applied on a prospective basis, or a retrospective basis for all or any prior periods, and early adoption is permitted. The Company is currently evaluating the impact of this ASU; however, it is not anticipated to have a material impact on its consolidated financial statements&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;b&gt;&lt;/b&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;b&gt;&lt;span style="font-size: 10.0pt;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;b&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;In&#160;December 2023, the FASB issued ASU No. &lt;span id="fs_0N1Y2XRJSG00000000000000000000fs"&gt;2023&lt;/span&gt;-&lt;span id="fs_OM63TTJYG000000000000000000000fs"&gt;09&lt;/span&gt;, &lt;i&gt;Improvements to Income Tax Disclosures (Topic &lt;span id="fs_FJHHY1Z8BK00000000000000000000fs"&gt;740&lt;/span&gt;)&lt;/i&gt;. The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid.&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;The Company adopted this ASU on a prospective basis effective January 1, 2025. Tax disclosures in Note &lt;span id="fs_1IMCCFWZ7K00000000000000000000fs"&gt;11&lt;/span&gt; of the financial statements reflect the impacts of the adoption.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;







 </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="D20251231" id="Tag78">
&lt;p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zthrZemlMx5d" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 1pt;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3&lt;/span&gt;.&#160;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span id="xdx_82C_zO26qu93Tj32" style="line-height: inherit;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 1pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;Cash equivalents, &lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;which include certificates of deposit and money market funds, are the only financial instruments measured and recorded at fair value on our consolidated balance sheet, and are valued using Level 1 inputs. As of&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit;"&gt;&lt;span id="fs_H93GE1RC6O00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;and&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit;"&gt;&lt;span id="fs_311UHOTRQO00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;, the Company did not have any Level 1 and Level 2 financial liabilities or Level 3 financial assets or liabilities measured at fair value on a recurring basis. No transfers between Level 1 and Level 2 or transfers in or out of Level 3 occurred during the twelve months ended&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit;"&gt;&lt;span id="fs_YN0NTVGD5C00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;and&lt;span style="line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit;"&gt;&lt;span id="fs_YUFA1BQ20G00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;div id="fs_J3UU8LD78G00000000000000000000B"&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;The following table presents certificates of deposit and money market
          funds at their level within the fair value hierarchy as of &lt;span id="fs_SVBLCJXNIO00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_Q6Z2HYNZZ400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; (in thousands).&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 1pt;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 88px; width: 100%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;/td&gt;
&lt;td colspan="14" style="padding-bottom: 1pt; text-align: center; border-bottom: 1pt solid #000000; height: 17px; box-shadow: none;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;&lt;span id="fs_4H4CA0ZQTS00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Level 1&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Level 2&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Level 3&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 48%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160; Money market funds&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span id="fo1e2c2d9301364a5a8b04f41b842e02a7" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span id="focc2d48fbc25f4cdab9194e8ab5049717" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_IRGZ8EBXKW00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_ZCS3QIXKDS00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;








           &lt;/tr&gt;








          &lt;/tbody&gt;














































         &lt;/table&gt;
















































        &lt;/div&gt;
















































       &lt;/div&gt;
&lt;div style="border-left: none; border-right: none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 110px; width: 100%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none; width: 47.9934%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center; height: 17px; box-shadow: none; width: 0.982801%;"&gt;&lt;/td&gt;
&lt;td colspan="14" style="padding-bottom: 1pt; text-align: center; border-bottom: 1pt solid #000000; height: 17px; box-shadow: none; width: 49.7952%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;&lt;span id="fs_OAXRM5U44W00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none; width: 47.9934%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Level 1&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Level 2&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Level 3&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 47.9934%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 47.9934%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 1px; width: 47.9934%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&#160; Certificates of deposit&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;9,996&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;9,996&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_4G0M12L9AO00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_PYYL2WGSGW00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; width: 47.9934%; box-shadow: none;"&gt;&#160; Money market funds&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;7,441&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;7,441&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;&lt;span id="fs_GUU3LT972800000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;&lt;span id="fs_SO3GYLWZ4W00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 47.9934%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;17,437&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;17,437&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;&lt;span id="fs_8HM1PPE1KG00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;&lt;span id="fs_K8MFGA4JSW00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;/td&gt;











         &lt;/tr&gt;











        &lt;/tbody&gt;

































       &lt;/table&gt;

































      &lt;/div&gt;

































     &lt;/div&gt;
































    </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="D20251231" id="Tag77">
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;The following table presents certificates of deposit and money market
          funds at their level within the fair value hierarchy as of &lt;span id="fs_SVBLCJXNIO00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_Q6Z2HYNZZ400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; (in thousands).&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 1pt;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 88px; width: 100%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;/td&gt;
&lt;td colspan="14" style="padding-bottom: 1pt; text-align: center; border-bottom: 1pt solid #000000; height: 17px; box-shadow: none;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;&lt;span id="fs_4H4CA0ZQTS00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Level 1&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Level 2&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Level 3&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 48%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&#160;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160; Money market funds&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span id="fo1e2c2d9301364a5a8b04f41b842e02a7" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span id="focc2d48fbc25f4cdab9194e8ab5049717" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&#160;&lt;/td&gt;








           &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;15,423&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_IRGZ8EBXKW00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-width: 2.8pt; border-bottom-style: double; height: 15px; box-shadow: none; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_ZCS3QIXKDS00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;








           &lt;/tr&gt;








          &lt;/tbody&gt;














































         &lt;/table&gt;
















































        &lt;/div&gt;
















































       &lt;/div&gt;
&lt;div style="border-left: none; border-right: none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 110px; width: 100%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none; width: 47.9934%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center; height: 17px; box-shadow: none; width: 0.982801%;"&gt;&lt;/td&gt;
&lt;td colspan="14" style="padding-bottom: 1pt; text-align: center; border-bottom: 1pt solid #000000; height: 17px; box-shadow: none; width: 49.7952%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;&lt;span id="fs_OAXRM5U44W00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none; width: 47.9934%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Level 1&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Level 2&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; border-bottom: 1pt solid #000000; box-shadow: none; width: 10.9746%;"&gt;Level 3&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 47.9934%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none; width: 9.99181%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&#160;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; box-shadow: none; width: 47.9934%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 9.99181%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 1px; width: 47.9934%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&#160; Certificates of deposit&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;9,996&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;9,996&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_4G0M12L9AO00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 9.99181%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_PYYL2WGSGW00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; width: 0.982801%; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; width: 47.9934%; box-shadow: none;"&gt;&#160; Money market funds&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;7,441&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;7,441&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;&lt;span id="fs_GUU3LT972800000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; width: 9.99181%; box-shadow: none;"&gt;&lt;span id="fs_SO3GYLWZ4W00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; width: 0.982801%; box-shadow: none;"&gt;&#160;&lt;/td&gt;











         &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 47.9934%;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;17,437&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;17,437&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;&lt;span id="fs_8HM1PPE1KG00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 0.982801%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; border-top: 1pt solid #000000; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; box-shadow: none; border-bottom-color: #000000 !important; width: 9.99181%;"&gt;&lt;span id="fs_K8MFGA4JSW00000000000000000000FM" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none; width: 0.982801%;"&gt;&lt;/td&gt;











         &lt;/tr&gt;











        &lt;/tbody&gt;

































       &lt;/table&gt;

































      </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231_MoneyMarketFundsMember"
      decimals="-3"
      id="Tag82"
      unitRef="USD">15423000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231_MoneyMarketFundsMember_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Tag90"
      unitRef="USD">15423000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember"
      id="Tag96"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231_MoneyMarketFundsMember_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember"
      id="Tag98"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231"
      decimals="-3"
      id="Tag89"
      unitRef="USD">15423000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Tag86"
      unitRef="USD">15423000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember"
      id="Tag95"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20251231_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember"
      id="Tag97"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_CertificatesOfDepositMember"
      decimals="-3"
      id="Tag91"
      unitRef="USD">9996000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_CertificatesOfDepositMember_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Tag92"
      unitRef="USD">9996000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_CertificatesOfDepositMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember"
      id="Tag93"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_CertificatesOfDepositMember_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember"
      id="Tag94"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_MoneyMarketFundsMember"
      decimals="-3"
      id="Tag85"
      unitRef="USD">7441000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_MoneyMarketFundsMember_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Tag84"
      unitRef="USD">7441000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember"
      id="Tag79"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_MoneyMarketFundsMember_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember"
      id="Tag87"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231"
      decimals="-3"
      id="Tag83"
      unitRef="USD">17437000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Tag81"
      unitRef="USD">17437000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember"
      id="Tag88"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="I20241231_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember"
      id="Tag80"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermDebtTextBlock contextRef="D20251231" id="Tag750">
&lt;div style="font-family: 'times new roman', times; font-size: 10pt;"&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;div style="font-family: 'times new roman', times; font-size: 10pt;"&gt;
&lt;p style="line-height: 1.2;"&gt;&lt;span style="border-right: none; border-left: none;"&gt;&lt;span style="font-weight: bold; line-height: inherit;"&gt;&lt;span id="fs_860SPW3JKW00000000000000000000fs"&gt;4&lt;/span&gt;. Insurance Premium Financing&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 1.2; margin: 10pt 0pt; text-indent: 0pt;"&gt;&lt;span style="border-right: none; border-left: none;"&gt;&lt;b style="color: #000000; font-family: 'times new roman', times; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 13.3333px; text-indent: -0.666667px;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="line-height: inherit; margin: 0in 0in 8pt; color: #000000;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit; display: inline !important;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&#160; &#160; &#160; &#160;&lt;/span&gt;In September&lt;span&gt; 2025, we entered into a finance agreement with First&#160;Insurance Funding in order to fund a portion of our insurance premiums for our professional liability policies. The amount financed is approximately $355,000&#160;and incurs interest at a rate of&#160;7.2%. The Company is required to make&#160;nine&#160;monthly&#160;payments of approximately&#160;$39,000&#160;through&#160;&lt;span id="fs_8KIC0XF7R400000000000000000000FM"&gt;May 2026&lt;/span&gt;. There was an outstanding balance of $249,000&#160;as of&#160;&lt;span id="fs_9F98Z1Q4DS00000000000000000000FM"&gt;&lt;span id="fs_Y3CKW3YV6800000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 1.2;"&gt;&lt;span style="border-right: none; border-left: none;"&gt;&#160; &#160; &#160; &#160;In September 2024, we entered into a finance agreement with First Insurance Funding in order to fund a portion of our insurance premiums for our professional liability policies. The amount financed is approximately $426,000 and incurs interest at a rate of 7.2%. The Company is required to make nine monthly payments of approximately $47,000 through May 2025. There was an outstanding balance of approximately $237,000 as of December 31, 2024, included in accrued expenses.&#160;&lt;b style="color: #000000; font-family: 'times new roman', times; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 13.3333px; text-indent: -0.666667px;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;span style="line-height: inherit; margin: 0in 0in 8pt; color: #000000;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;The amount has been fully repaid as of &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span id="fs_PER0V032V400000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; line-height: inherit;"&gt;&lt;span style="line-height: inherit; margin: 0in 0in 0pt; color: #000000;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: black; line-height: inherit;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;






 &lt;/div&gt;






 &lt;/div&gt;






 &lt;/div&gt;






 </us-gaap:ShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I20250930_LoansPayableMember"
      decimals="0"
      id="Tag757"
      unitRef="USD">355000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="I20250930_LoansPayableMember"
      decimals="3"
      id="Tag756"
      unitRef="Pure">0.072</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <vani:NumberOfPeriodicPayments
      contextRef="I20250930_LoansPayableMember"
      decimals="0"
      id="Tag754"
      unitRef="N">9</vani:NumberOfPeriodicPayments>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="D20250930_LoansPayableMember" id="Tag755">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="D20250930_LoansPayableMember"
      decimals="0"
      id="Tag758"
      unitRef="USD">39000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermBorrowings
      contextRef="I20251231_LoansPayableMember"
      decimals="0"
      id="Tag759"
      unitRef="USD">249000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I20240930_LoansPayableMember"
      decimals="0"
      id="Tag760"
      unitRef="USD">426000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="I20240930_LoansPayableMember"
      decimals="3"
      id="Tag751"
      unitRef="Pure">0.072</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <vani:NumberOfPeriodicPayments
      contextRef="I20240930_LoansPayableMember"
      decimals="0"
      id="Tag752"
      unitRef="N">9</vani:NumberOfPeriodicPayments>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="D20240930_LoansPayableMember" id="Tag753">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="D20240930_LoansPayableMember"
      decimals="0"
      id="Tag761"
      unitRef="USD">47000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermBorrowings
      contextRef="I20241231_LoansPayableMember"
      decimals="0"
      id="Tag762"
      unitRef="USD">237000</us-gaap:ShortTermBorrowings>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="D20251231" id="Tag36">
&lt;p id="xdx_801_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zQWdjM3pvUr7" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 1.25pt;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;5. &lt;span id="xdx_829_zuyxaW9utfmj" style="line-height: inherit;"&gt;Selected Balance Sheet Detail &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 1.25pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;Property and equipment, net of accumulated depreciation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&#160;&lt;/p&gt;
&lt;div id="fodbf09618c50641e691c4b6f6caaffcae" style="line-height: 1.2;"&gt;
&lt;p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWewKyWJV90l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B1_zOOs5tpyUCtl" style="font-family: 'times new roman', times; line-height: inherit;"&gt;Property and equipment consisted of the following as of &lt;span id="fs_AV28VYAJ0G00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_JVPGX79WVK00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 146px; width: 90%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;span id="fs_IVFJ7TACOW00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;span id="fs_PGDEIF3GG000000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;span id="fs_UN2K22IB8W00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="background-color: #cceeff;"&gt;
&lt;td style="background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;Property and equipment at cost:&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; padding: 0px 0px 0px 9px; box-shadow: none;"&gt;Equipment&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z0tNUzbAXHW5" style="text-align: right; height: 16px; box-shadow: none;"&gt;4,161&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zoJ1Vi6BH5wk" style="text-align: right; height: 16px; box-shadow: none;"&gt;3,937&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; padding: 0px 0px 0px 9px; box-shadow: none;"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td style="height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5QxXAZ5qHda" style="text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;380&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSGPkRGAVDsa" style="text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;367&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 0px 9px; height: 16px; box-shadow: none; width: 74%;"&gt;Computer software&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z7zMkp9OVxt1" style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zMrVVO6GuFml" style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 0px 9px; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;Construction in progress&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z4ENroSV1jDg" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;1,362&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zrt84sI8mXx6" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;Total property and equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231_zCjAYpeIqbyd" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;5,933&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231_zy8soDMdKtIg" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;4,334&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;Accumulated depreciation&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20231231_zchVrxpRPvK7" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;(3,054&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="padding: 0px 0px 0.5px; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none; width: 1.01103%;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_z8gUyxHlX0ke" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;(2,641&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;)&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_pn3n3_c20231231_zHchoIZGiaM3" style="text-align: right; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;2,879&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20221231_zQbXFXOpxuTa" style="text-align: right; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;1,693&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 &lt;/div&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;Contract Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Contract liabilities amounted to $&lt;span id="xdx_907_ecustom--ContractLiabilitiesOther_iI_c20231231_zH6FB1lAHg8d" style="line-height: inherit;" title="Contract liabilities"&gt;335,000&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--ContractLiabilitiesOther_iI_c20221231_zHezvSUETMn4" style="line-height: inherit;" title="Contract liabilities"&gt;335,000&lt;/span&gt; as of &lt;span id="fs_DWU0CT6MSG00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_TQ2Q72SA1S00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively, and are included in accrued expenses on the balance sheet.&lt;/span&gt;&lt;/p&gt;



</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="D20251231" id="Tag33">
&lt;p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zWewKyWJV90l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B1_zOOs5tpyUCtl" style="font-family: 'times new roman', times; line-height: inherit;"&gt;Property and equipment consisted of the following as of &lt;span id="fs_AV28VYAJ0G00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_JVPGX79WVK00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 146px; width: 90%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.1px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;span id="fs_IVFJ7TACOW00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;span id="fs_PGDEIF3GG000000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 17px; box-shadow: none;"&gt;&lt;span id="fs_UN2K22IB8W00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="background-color: #cceeff;"&gt;
&lt;td style="background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;Property and equipment at cost:&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; padding: 0px 0px 0px 9px; box-shadow: none;"&gt;Equipment&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_z0tNUzbAXHW5" style="text-align: right; height: 16px; box-shadow: none;"&gt;4,161&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zoJ1Vi6BH5wk" style="text-align: right; height: 16px; box-shadow: none;"&gt;3,937&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; padding: 0px 0px 0px 9px; box-shadow: none;"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td style="height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z5QxXAZ5qHda" style="text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;380&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zSGPkRGAVDsa" style="text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;367&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 0px 9px; height: 16px; box-shadow: none; width: 74%;"&gt;Computer software&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z7zMkp9OVxt1" style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zMrVVO6GuFml" style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 0px 9px; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;Construction in progress&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_z4ENroSV1jDg" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;1,362&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zrt84sI8mXx6" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;Total property and equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20231231_zCjAYpeIqbyd" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;5,933&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_c20221231_zy8soDMdKtIg" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;4,334&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;Accumulated depreciation&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20231231_zchVrxpRPvK7" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;(3,054&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="padding: 0px 0px 0.5px; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none; width: 1.01103%;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_c20221231_z8gUyxHlX0ke" style="border-bottom: 1pt solid black; text-align: right; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;(2,641&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; text-align: left; height: 16px; background-color: #cceeff; box-shadow: none;"&gt;)&lt;/td&gt;







 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_pn3n3_c20231231_zHchoIZGiaM3" style="text-align: right; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;2,879&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_c20221231_zQbXFXOpxuTa" style="text-align: right; height: 16px; border-bottom-width: 2.8pt; border-bottom-style: double; box-shadow: none; border-bottom-color: black !important;"&gt;1,693&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;







 &lt;/tr&gt;







 &lt;/tbody&gt;







 &lt;/table&gt;







 </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20251231_EquipmentMember"
      decimals="-3"
      id="Tag45"
      unitRef="USD">4161000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_EquipmentMember"
      decimals="-3"
      id="Tag37"
      unitRef="USD">3937000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20251231_FurnitureAndFixturesMember"
      decimals="-3"
      id="Tag46"
      unitRef="USD">380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_FurnitureAndFixturesMember"
      decimals="-3"
      id="Tag38"
      unitRef="USD">367000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20251231_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="Tag47"
      unitRef="USD">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="Tag43"
      unitRef="USD">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20251231_ConstructionInProgressMember"
      decimals="-3"
      id="Tag44"
      unitRef="USD">1362000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_ConstructionInProgressMember"
      id="Tag42"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20251231"
      decimals="-3"
      id="Tag48"
      unitRef="USD">5933000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231"
      decimals="-3"
      id="Tag39"
      unitRef="USD">4334000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="I20251231"
      decimals="-3"
      id="Tag50"
      unitRef="USD">3054000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="I20241231"
      decimals="-3"
      id="Tag40"
      unitRef="USD">2641000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20251231"
      decimals="-3"
      id="Tag49"
      unitRef="USD">2879000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20241231"
      decimals="-3"
      id="Tag41"
      unitRef="USD">1693000</us-gaap:PropertyPlantAndEquipmentNet>
    <vani:ContractLiabilitiesOther
      contextRef="I20251231"
      decimals="0"
      id="Tag34"
      unitRef="USD">335000</vani:ContractLiabilitiesOther>
    <vani:ContractLiabilitiesOther
      contextRef="I20241231"
      decimals="0"
      id="Tag35"
      unitRef="USD">335000</vani:ContractLiabilitiesOther>
    <vani:GrantsTextBlock contextRef="D20251231" id="Tag373">
&lt;p id="xdx_803_ecustom--GrantsTextBlock_zKcTXWnXZ5Fi" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;6. &lt;span id="xdx_82D_zQyBVzGCmxY6" style="line-height: inherit;"&gt;Grants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 1pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;We received an award for $&lt;span id="xdx_902_ecustom--GrantReceivedToSupportClinicalDevelopment_dm_c20180101__20181231_z8GYRb500E2f" style="line-height: inherit;" title="Received grant"&gt;1.6 million&lt;/span&gt; grant (with the intent to fund $&lt;span id="xdx_90A_ecustom--GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears_dm_c20180101__20181231_zjb6FUnpZGJa" style="line-height: inherit;" title="Grant receivable with intent to fund early feasibility clinical trial for years"&gt;6.4 million&lt;/span&gt; over &lt;span id="xdx_907_ecustom--GrantReceivedFundingPeriod_dxL_c20180101__20181231_zYDEjkQYzFU2" style="line-height: inherit;" title="Grant received funding period::XDX::P5Y"&gt;five years&lt;/span&gt;&#160;subject to annual review and approval) from the National Institutes of Health (&#x201c;NIH&#x201d;) to fund the &#x201c;Early Feasibility Clinical Trial of a Visual Cortical Prosthesis&#x201d; that commenced in January 2018. The final year of the grant ended in March 2024&lt;span style="font-size: 10pt; line-height: inherit;"&gt;, however the NIH issued us a no-cost extension allowing us to utilize the unfunded amount through March 2025&lt;/span&gt;. The NIH grant funds ongoing and planned clinical activities and are being used to conduct and support clinical testing of &lt;span id="fs_HENE9U2OSG00000000000000000000fs" style="display: inline; line-height: inherit;"&gt;six&lt;/span&gt; subjects implanted with the Orion&#x2122; Cortical Visual Prosthesis (&#x201c;Orion&#x201d;), submit and obtain Investigational Device Exemption approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;). During the year ended &lt;span id="fs_NR85U98SZ400000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;&lt;span&gt;&lt;span style="mso-comment-continuation: 2;"&gt;, $35,000&#160;of grants were offset against research and development, and $0 were offset against general and administrative expenses.&lt;/span&gt;&lt;/span&gt;&#160;During the year ended &lt;span id="fs_WCGHD11P3400000000000000000000FM"&gt;December 31, 2024&lt;/span&gt;, $0.2 million of grants were offset against research and development expenses, and $0 were offset against general and administrative expenses.&#160;As of &lt;span id="fs_TWDJE1Q7TS00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, we expect $0 will be available to offset future operating expenses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;









 </vani:GrantsTextBlock>
    <vani:GrantReceivedToSupportClinicalDevelopment
      contextRef="D20181231"
      decimals="-5"
      id="Tag372"
      unitRef="USD">1600000</vani:GrantReceivedToSupportClinicalDevelopment>
    <vani:GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears
      contextRef="D20181231"
      decimals="-5"
      id="Tag371"
      unitRef="USD">6400000</vani:GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears>
    <vani:GrantReceivedFundingPeriod contextRef="D20181231" id="Tag374">P5Y</vani:GrantReceivedFundingPeriod>
    <vani:GrantsOffsetAgainstOperatingResearchAndDevelopmentExpense
      contextRef="D20251231"
      decimals="0"
      id="Tag376"
      unitRef="USD">35000</vani:GrantsOffsetAgainstOperatingResearchAndDevelopmentExpense>
    <vani:GrantsOffsetAgainstOperatingGeneralAndAdministrativeExpense
      contextRef="D20251231"
      decimals="0"
      id="Tag377"
      unitRef="USD">0</vani:GrantsOffsetAgainstOperatingGeneralAndAdministrativeExpense>
    <vani:GrantsOffsetAgainstOperatingResearchAndDevelopmentExpense
      contextRef="D20241231"
      decimals="-5"
      id="Tag375"
      unitRef="USD">200000</vani:GrantsOffsetAgainstOperatingResearchAndDevelopmentExpense>
    <vani:GrantsOffsetAgainstOperatingGeneralAndAdministrativeExpense
      contextRef="D20251231"
      decimals="0"
      id="Tag378"
      unitRef="USD">0</vani:GrantsOffsetAgainstOperatingGeneralAndAdministrativeExpense>
    <vani:GrantsAvailableToOffsetFutureOperatingExpenses
      contextRef="I20241231"
      decimals="0"
      id="Tag379"
      unitRef="USD">0</vani:GrantsAvailableToOffsetFutureOperatingExpenses>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D20251231" id="Tag174">
&lt;div style="font-family: 'times new roman', times; font-size: 10pt;"&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zdk6gZkqUqE1" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;&lt;span id="fs_9N2R84NB4000000000000000000000fs" style="display: inline;"&gt;7&lt;/span&gt;. &lt;span id="xdx_82B_zexHWkZ8vQY2" style="line-height: inherit;"&gt;Equity Securities&lt;/span&gt;&#160;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-align: justify;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;We are authorized to issue &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJZVO112em8f" style="line-height: inherit;" title="Common stock, shares authorized"&gt;300,000,000&lt;/span&gt; shares of common stock with &lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvuEVe8w0Wzl" style="line-height: inherit;" title="Common stock, shares issued"&gt;76,427,764&lt;/span&gt; issued as of &lt;span id="fs_W05G8QOKGG00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;. In addition, we are authorized to issue &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zgxK1RH2gY88" style="line-height: inherit;" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of preferred stock with &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_uShares_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zH5P9hPzsXT4" style="line-height: inherit;" title="Preferred stock, shares issued"&gt;none&lt;/span&gt; issued.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; text-indent: 1.25pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





















 &lt;/div&gt;





















 &lt;/div&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;i&gt;&lt;span style="font-size: 10.0pt;"&gt;Securities Purchase Agreement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 9.6pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 8pt; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in 0in 8pt; font-size: 12pt; font-family: Aptos, sans-serif;"&gt;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;"&gt;On March 1, 2024, the Company entered into a securities purchase agreement with an institutional investor to purchase 3,947,368 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 3,947,368 shares of common stock, at a purchase price of $3.80 per share and accompanying warrant, in a registered direct offering. The warrants have an exercise price of $3.80 per share, are exercisable immediately upon issuance, and will expire &lt;span id="fs_200KNUTLB400000000000000000000fs"&gt;three&lt;/span&gt; years following the date of issuance. Simultaneously, the Company also entered into a placement agency agreement with Maxim Group LLC, which acted as the sole placement agent for the Offering. The gross proceeds of $15.0 million from the Offering, before paying the placement agent fees and other offering costs, were received on March 5, 2024. In connection with the Securities Purchase Agreement, the Company paid issuance costs of $1.3 million, resulting in net proceeds of $13.7 million.&lt;/span&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;i&gt;&lt;span style="font-size: 10.0pt;"&gt;The Sales Agreement&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10.0pt;"&gt;On April 22, 2024,&#160;the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;sup&gt;SM&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size: 10.0pt;"&gt; (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), under which the Company may offer and sell, from time to time at its sole discretion, shares of common stock, having an aggregate offering price of up to $75.0 million through Jefferies as its sales agent. Also on April 22, 2024, the Company&#160;filed a Registration Statement on Form S-&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_P1D27Z0MEO00000000000000000000fs"&gt;3&lt;/span&gt;&lt;/span&gt;, which was declared effective on May 3, 2024, including a sales agreement prospectus relating to the offering of up to $75.0 million shares of its common stock in accordance with the Sales Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The Company may sell the common stock under the Sales Agreement (A) in privately negotiated transactions; (B) as block transactions; or (C) by any other method permitted by law deemed to be an &#x201c;at-the-market&#x201d; offering as defined in Rule &lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_7MERMJEDC000000000000000000000fs"&gt;415&lt;/span&gt;&lt;/span&gt;(a)(&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_BENVW59EI800000000000000000000fs"&gt;4&lt;/span&gt;&lt;/span&gt;) under the Securities Act of &lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_19PIUD2GG000000000000000000000fs"&gt;1933&lt;/span&gt;&lt;/span&gt;, as amended, including sales made directly on the Nasdaq Capital Market or sales made into any other existing trading market for the shares of common stock. Jefferies will use commercially reasonable efforts to place the shares of common stock from time to time, based upon the Company's instructions (including any price, time or size limits or other customary parameters or conditions we may impose). The Company will pay Jefferies a commission of up to &lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_P6Q1LWJ1EO00000000000000000000fs"&gt;three&lt;/span&gt;&lt;/span&gt; percent (3.0%) of the gross sales proceeds of any common stock sold through Jefferies under the Sales Agreement, and also has provided Jefferies with customary indemnification rights. In addition, the Company has agreed to reimburse certain legal expenses and fees incurred by Jefferies in connection with the offering.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;The Company is not obligated to make any sales of common stock under the Sales Agreement. The offering of shares of common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;During the twelve months ended &lt;span id="fs_BN90GJ9NPS00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, the Company issued 9,215 shares of common stock for gross proceeds of $10,000 as part of the Sales Agreement with Jefferies. The Company paid expenses of $37,000, resulting in negative net proceeds of $28,000.&#160;During the twelve months ended &lt;span id="fs_DZRTRGQBEO00000000000000000000FM"&gt;December 31, 2024&lt;/span&gt;, the Company issued 287,970&#160;shares of common stock for gross proceeds of $504,000&#160;pursuant to the Sales Agreement. The Company paid expenses of $344,000, resulting in net proceeds of $160,000. &lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: black; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;i&gt;&lt;span style="font-size: 10.0pt; color: black;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_C37FNZGE4W00000000000000000000fs"&gt;2024&lt;/span&gt;&lt;/span&gt; Private Sale Transaction&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: black; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt;On November 8, 2024, the Company entered into a private sale transaction with&#160;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_O8VTVN43G000000000000000000000fs"&gt;one&lt;/span&gt;&lt;/span&gt;&#160;of its independent directors whereby the Company sold an aggregate of&#160;&lt;span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"&gt;3,968,253&lt;/span&gt;&#160;shares of the Company&#x2019;s common stock to the director at a price of $&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;1.26&lt;/span&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt;&#160;per share, which was the lower of the closing price of the Company&#x2019;s common stock on Nasdaq&#160;or the &lt;span id="fs_CVDY6GKP5C00000000000000000000fs" style="display: inline;"&gt;5&lt;/span&gt;-day average closing price of the Company&#x2019;s common stock on Nasdaq, each immediately prior to the closing date, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the common stock that occur after the date of the private sale transaction. The gross proceeds from this private sale transaction were $&lt;span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"&gt;5.0&lt;/span&gt;&#160;million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: black; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;i&gt;&lt;span style="font-size: 10.0pt; color: black;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_8X818TYT2O00000000000000000000fs"&gt;2025&lt;/span&gt;&lt;/span&gt; Private Sale Transactions&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;During 2025, the Company entered into multiple share purchase agreements with an entity affiliated with one of its independent directors and one share purchase agreement with one of its investors (collectively, the &#x201c;2025 Private Sales Transactions&#x201d;) pursuant to which the Company agreed to sell shares of its common stock in multiple tranche closings at prices equal to the closing price of the Company&#x2019;s common stock on Nasdaq on the respective agreement dates, subject to customary adjustments for reverse and forward stock splits, stock dividends, stock combinations, and similar transactions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;On&#160;March 26, 2025, the Company entered into a share&#160;purchase agreement with an entity affiliated with&#160;&lt;span id="fs_97629IF1QO00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt;&#160;of its &lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;independent&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;directors to sell an aggregate of 7,366,071&#160;shares of common stock in five tranche closings at a price of $1.12&#160;per share, representing the closing price of the Company&#x2019;s common stock on Nasdaq&#160;on that date. Gross proceeds from this transaction are expected to be approximately $8.25&#160;million.&lt;/span&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;






















 &lt;/div&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;On May 12, 2025, the Company entered into an&#160;additional share purchase agreement with an entity affiliated with one of its &lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;independent&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;directors to sell an aggregate of&#160;2,912,621 shares of common stock in two tranche&#160;closings at a price of  $1.03 per share, representing the closing price of the Company&#x2019;s common stock on Nasdaq on that date. Gross proceeds from this transaction are expected to be approximately&#160;$3.0 million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;On August 11, 2025, the Company entered into a share purchase agreement with an entity affiliated with&#160;&lt;span id="fs_C9UVPVX2TS00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt;&#160;of its &lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;independent&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;directors, and with another investor, to sell an aggregate of&#160; 7,936,507&#160;shares of common stock in&#160;twelve&#160;tranche&#160;closings at a price of $1.26&#160;per share, representing the closing price of the Company&#x2019;s common stock on Nasdaq on that date. Gross proceeds from this transaction are expected to be approximately $10.0 million.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000; font-family: 'times new roman', times;"&gt;During the twelve months ended &lt;span id="fs_PFSBTQ3ZO000000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, the Company issued 7,480,158 shares of common stock&#160;pursuant to the 2025 Private Sales Transactions, generating gross proceeds of $8.6 million.&#160;The remaining shares issuable under these agreements are expected to be issued in 2026 upon completion of the applicable tranche closings, with expected gross proceeds of approximately $12.6 million.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;i&gt;&lt;span style="font-size: 10.0pt;"&gt;2025 Private Placement&#160;and 2025 Registered Direct Offering&lt;/span&gt;&lt;/i&gt;&lt;span style="font-size: 10.0pt;"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;On October 26, 2025, the Company entered into a share purchase agreement with an entity affiliated with one of its &lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;independent&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;directors for the issuance and sale of an aggregate&#160;3,703,703 &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;shares of the Company&#x2019;s common stock at a
purchase price of &lt;/span&gt;


 $1.62 per share,&#160;which represented the last reported sale price of the Company&#x2019;s common stock on October 24, 2025 (the &#x201c;2025 Private Placement&#x201d;). The 2025 Private Placement resulted in gross proceeds of $6.0 million. No warrants, discounts, placement agent fees, or investment banking fees were incurred in connection with the transaction. The shares were issued pursuant to an exemption from registration under Rule 506 of Regulation D of the Securities Act of 1933, as amended, in reliance, in part, on representations made by the purchaser.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;Concurrent with the 2025 Private Placement, the
Company also entered into a placement agency agreement, dated October 26, 2025
(the &#x201c;Placement Agency Agreement&#x201d;) with ThinkEquity LLC (the &#x201c;Agent&#x201d;) relating
to the sale by the Company of 6,000,000 shares of the Company&#x2019;s common stock in a registered direct offering (the &#x201c;2025 Registered Direct Offering&#x201d;). The gross proceeds from the 2025 Registered Direct Offering were approximately  $9.7 million, before placement agent fees and other estimated offering
expenses. In connection with the Placement Agency Agreement, the Company agreed
to pay the Agent a cash fee of 7.0% of the gross proceeds from the sale  of the shares. The Company also agreed to reimburse the Agent for legal fees and other reimbursable expenses up to  $125,000.&#160;&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;Net proceeds, after giving effect to Agent fees
and expenses, and after giving effect to other financing costs associated with
the transaction, were $8.7 million.&lt;/span&gt;


&lt;/span&gt;&lt;/p&gt;





















 </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I20251231_CommonStockMember"
      decimals="0"
      id="Tag173"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20251231_CommonStockMember"
      decimals="0"
      id="Tag172"
      unitRef="Shares">76427764</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="I20251231"
      decimals="0"
      id="Tag175"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="I20251231"
      decimals="0"
      id="Tag176"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20240301_SecuritiesPurchaseAgreementMember_CommonStockMember"
      decimals="0"
      id="Tag199"
      unitRef="Shares">3947368</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="I20240301_SecuritiesPurchaseAgreementMember_CommonStockMember"
      decimals="4"
      id="Tag200"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember_CommonStockMember"
      decimals="0"
      id="Tag201"
      unitRef="Shares">3947368</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember_CommonStockMember"
      decimals="2"
      id="Tag202"
      unitRef="USDPerShare">3.8</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember"
      decimals="2"
      id="Tag203"
      unitRef="USDPerShare">3.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross
      contextRef="D20240301_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Tag204"
      unitRef="USD">15000000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D20240301_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Tag205"
      unitRef="USD">1300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts
      contextRef="D20240301_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Tag206"
      unitRef="USD">13700000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementNetOfIssuanceCosts>
    <vani:SaleOfCommonStockAtMarketOfferingAuthorizedAmount
      contextRef="I20240422_SalesAgreementMember_JefferiesLlcMember"
      decimals="-5"
      id="Tag177"
      unitRef="USD">75000000</vani:SaleOfCommonStockAtMarketOfferingAuthorizedAmount>
    <vani:SaleOfCommonStockAtMarketOfferingAuthorizedAmount
      contextRef="I20240422_SecuritiesPurchaseAgreementMember_JefferiesLlcMember"
      decimals="-5"
      id="Tag178"
      unitRef="USD">75000000</vani:SaleOfCommonStockAtMarketOfferingAuthorizedAmount>
    <vani:PercentageOfAggregateProceedsRaisedFromSaleOfSecuritiesForCashFeePaymentToPlacementAgency
      contextRef="I20240422_SalesAgreementMember_JefferiesLlcMember"
      decimals="3"
      id="Tag179"
      unitRef="Pure">0.03</vani:PercentageOfAggregateProceedsRaisedFromSaleOfSecuritiesForCashFeePaymentToPlacementAgency>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231_CommonStockMember_SalesAgreementMember"
      decimals="0"
      id="Tag195"
      unitRef="Shares">9215</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingGross
      contextRef="D20251231_SalesAgreementMember"
      decimals="-3"
      id="Tag196"
      unitRef="USD">10000000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D20251231_SalesAgreementMember"
      decimals="-3"
      id="Tag197"
      unitRef="USD">37000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20251231_SalesAgreementMember"
      decimals="-3"
      id="Tag198"
      unitRef="USD">28000000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231_CommonStockMember_SalesAgreementMember"
      decimals="0"
      id="Tag209"
      unitRef="Shares">287970</vani:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingGross
      contextRef="D20241231_SalesAgreementMember"
      decimals="0"
      id="Tag210"
      unitRef="USD">504000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithAtMarketOfferingGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D20241231_SalesAgreementMember"
      decimals="0"
      id="Tag212"
      unitRef="USD">344000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithAtMarketOfferingNetOfIssuanceCosts
      contextRef="D20241231_SalesAgreementMember"
      decimals="0"
      id="Tag211"
      unitRef="USD">160000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithAtMarketOfferingNetOfIssuanceCosts>
    <vani:SalesOfCommonStockNumberOfSharesIssuedInConnectionWithPrivateSale
      contextRef="D20241108_DirectorMember"
      decimals="0"
      id="Tag180"
      unitRef="Shares">3968253</vani:SalesOfCommonStockNumberOfSharesIssuedInConnectionWithPrivateSale>
    <vani:SalesOfCommonStockInConnectionWithPrivateSalePricePerShare
      contextRef="I20241108_DirectorMember"
      decimals="2"
      id="Tag193"
      unitRef="USDPerShare">1.26</vani:SalesOfCommonStockInConnectionWithPrivateSalePricePerShare>
    <vani:ProceedsFromSalesOfCommonStockInConnectionWithPrivateSaleGross
      contextRef="D20241108_DirectorMember"
      decimals="-5"
      id="Tag181"
      unitRef="USD">5000000</vani:ProceedsFromSalesOfCommonStockInConnectionWithPrivateSaleGross>
    <us-gaap:SharesIssued
      contextRef="I20250326_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="0"
      id="Tag182"
      unitRef="Shares">7366071</us-gaap:SharesIssued>
    <vani:NumberOfTranche
      contextRef="I20250326_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="0"
      id="Tag183"
      unitRef="N">5</vani:NumberOfTranche>
    <us-gaap:SharePrice
      contextRef="I20250326_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="2"
      id="Tag184"
      unitRef="USDPerShare">1.12</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20250326_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="-4"
      id="Tag185"
      unitRef="USD">8250000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SharesIssued
      contextRef="I20250512_IndependentDirectorOneMember_PrivatePlacementMember"
      decimals="0"
      id="Tag186"
      unitRef="Shares">2912621</us-gaap:SharesIssued>
    <vani:NumberOfTranche
      contextRef="I20250512_PrivatePlacementMember_EntityAffiliatedWithDirectorMember"
      decimals="0"
      id="Tag187"
      unitRef="N">2</vani:NumberOfTranche>
    <us-gaap:SharePrice
      contextRef="I20250512_IndependentDirectorOneMember_PrivatePlacementMember"
      decimals="2"
      id="Tag188"
      unitRef="USDPerShare">1.03</us-gaap:SharePrice>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross
      contextRef="D20250512_IndependentDirectorOneMember_PrivatePlacementMember"
      decimals="-5"
      id="Tag189"
      unitRef="USD">3000000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross>
    <us-gaap:SharesIssued
      contextRef="I20250811_EntityAffiliatedWithDirectorAndInvestorMember_PrivatePlacementMember"
      decimals="0"
      id="Tag190"
      unitRef="Shares">7936507</us-gaap:SharesIssued>
    <vani:NumberOfTranche
      contextRef="I20250811_EntityAffiliatedWithDirectorAndInvestorMember_PrivatePlacementMember"
      decimals="0"
      id="Tag194"
      unitRef="N">12</vani:NumberOfTranche>
    <us-gaap:SharePrice
      contextRef="I20250811_IndependentDirectorOneMember_PrivatePlacementMember"
      decimals="2"
      id="Tag191"
      unitRef="USDPerShare">1.26</us-gaap:SharePrice>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross
      contextRef="D20250811_PrivatePlacementMember_IndependentDirectorOneMember"
      decimals="-5"
      id="Tag192"
      unitRef="USD">10000000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross>
    <vani:SalesOfCommonStockNumberOfSharesIssuedInConnectionWithPrivateSale
      contextRef="D20251231_EntityAffiliatedWithDirectorAndInvestorMember_PrivatePlacementMember"
      decimals="0"
      id="Tag207"
      unitRef="Shares">7480158</vani:SalesOfCommonStockNumberOfSharesIssuedInConnectionWithPrivateSale>
    <vani:ProceedsFromSalesOfCommonStockInConnectionWithPrivateSaleGross
      contextRef="D20251231_EntityAffiliatedWithDirectorAndInvestorMember_PrivatePlacementMember"
      decimals="-5"
      id="Tag208"
      unitRef="USD">8600000</vani:ProceedsFromSalesOfCommonStockInConnectionWithPrivateSaleGross>
    <vani:ExpectedProceedsFromSalesOfCommonStockInConnectionWithPrivateSaleGross
      contextRef="D20251231_PrivatePlacementMember"
      decimals="-5"
      id="Tag220"
      unitRef="USD">12600000</vani:ExpectedProceedsFromSalesOfCommonStockInConnectionWithPrivateSaleGross>
    <us-gaap:SharesIssued
      contextRef="I20251026_CommonStockMember_EntityAffiliatedWithDirectorMember"
      decimals="0"
      id="Tag213"
      unitRef="Shares">3703703</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="I20251026_CommonStockMember_EntityAffiliatedWithDirectorMember"
      decimals="2"
      id="Tag214"
      unitRef="USDPerShare">1.62</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20251026_CommonStockMember_EntityAffiliatedWithDirectorMember"
      decimals="-5"
      id="Tag219"
      unitRef="USD">6000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <vani:SaleOfCommonStockAtDirectOfferingAuthorizedShares
      contextRef="I20251026_ThinkEquityLlcMember_PlacementAgencyAgreementMember"
      decimals="0"
      id="Tag215"
      unitRef="Shares">6000000</vani:SaleOfCommonStockAtDirectOfferingAuthorizedShares>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingGross
      contextRef="D20251026_ThinkEquityLlcMember_PlacementAgencyAgreementMember"
      decimals="-5"
      id="Tag216"
      unitRef="USD">9700000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingGross>
    <vani:PercentageOfAggregateProceedsRaisedFromSaleOfSecuritiesForCashFeePaymentToPlacementAgency
      contextRef="I20251026_ThinkEquityLlcMember_PlacementAgencyAgreementMember"
      decimals="3"
      id="Tag217"
      unitRef="Pure">0.07</vani:PercentageOfAggregateProceedsRaisedFromSaleOfSecuritiesForCashFeePaymentToPlacementAgency>
    <us-gaap:LegalFees
      contextRef="D20251026_ThinkEquityLlcMember_PlacementAgencyAgreementMember_MaximumMember"
      decimals="0"
      id="Tag218"
      unitRef="USD">125000</us-gaap:LegalFees>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingNet
      contextRef="D20251231_ThinkEquityLlcMember_PlacementAgencyAgreementMember"
      decimals="-5"
      id="Tag221"
      unitRef="USD">8700000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingNet>
    <vani:WarrantDisclosureTextBlock contextRef="D20251231" id="Tag226">
&lt;p id="xdx_801_ecustom--WarrantDisclosureTextBlock_z8yQsUgOkhfh" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;b&gt;8. &lt;span id="xdx_829_zzcVIzAWN50j" style="line-height: inherit;"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-align: justify;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;NPM, prior to the Merger &lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; line-height: inherit;"&gt;with Second Sight&lt;/span&gt;, issued common stock and warrants (collectively, the &#x201c;unit&#x201d; or &#x201c;units&#x201d;) in &lt;span id="fs_WA3HEKVC8W00000000000000000000fs" style="display: inline; line-height: inherit;"&gt;2019&lt;/span&gt;, &lt;span id="fs_O1PCXHJKDC00000000000000000000fs" style="display: inline; line-height: inherit;"&gt;2020&lt;/span&gt; and &lt;span id="fs_EH08E5UDO000000000000000000000fs" style="display: inline; line-height: inherit;"&gt;2021&lt;/span&gt; for $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20191231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z2GHNSlR2EH6" style="line-height: inherit;" title="Share price (in dollars per share)"&gt;&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_z0FZrgsFPiH7" style="line-height: inherit;" title="Share price (in dollars per share)"&gt;&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_uUSDPShares_c20211231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zNi7NiHzoeFh" style="line-height: inherit;" title="Share price (in dollars per share)"&gt;3.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; per unit. Outstanding warrants to purchase common stock are shown in the table below and generally expire &lt;span id="xdx_902_ecustom--ClassOfWarrantsOrRightsTerm_dxL_c20230101__20231231__us-gaap--SubsidiarySaleOfStockAxis__custom--RightOfferingMember_zdNh9Q3iMxPg" style="line-height: inherit;" title="Term of warrants::XDX::P5Y"&gt;5&lt;/span&gt; years from the date of issuance at $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20231231_zdK85Np1lbIb" style="line-height: inherit;" title="Exercise price per share"&gt;3.15&lt;/span&gt; per share exercise price, split adjusted, are transferable into&#160;one share of common stock and may be exercised on a cashless basis. The remaining warrants outstanding that were issued at $3.15 per unit prior to the merger with Second Sight will expire in 2026, if not exercised sooner.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt;In connection with the Securities Purchase Agreement entered on March 1, 2024,&#160;&lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt;the Company issued Warrants to purchase &lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt;3,947,368&lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt;3.80&lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt; per share. These Warrants are exercisable immediately upon issuance and will expire &lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit;"&gt;three years&lt;/span&gt;&lt;span style="font-size: 10pt; text-indent: 0.25in; line-height: inherit; margin: 0pt 0px;"&gt; following the date of issuanc&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;e.&#160;&lt;span&gt;The Warrants are exercisable for cash at an exercise price of $3.80 per share and, if exercised in full, could result in aggregate proceeds to the Company of approximately $15.0 million. In the absence of an effective registration statement covering the issuance of the shares underlying the Warrants, the Warrants may be exercised on a cashless basis in accordance with their terms&lt;/span&gt;&lt;span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.25in; line-height: 1.2; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;The warrants outstanding as of &lt;span id="fs_7IJ5VXPH9S00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; have&#160;no intrinsic value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div style="border-left: none; border-right: none; line-height: 1.2;"&gt;
&lt;div id="fs_BYNXI1JSLS00000000000000000000B"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;A summary of warrant activity for the year ended &lt;span id="fs_6DK6MNWVOW00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_WF7DX1JWF400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; is presented below (in thousands, except per share and contractual life data).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_ZFKNLFA03K00000000000000000000b"&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 215px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin: 0px; text-indent: 0px; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Exercise&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Remaining&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Contractual&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Per Share&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 10px; padding: 0px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Life (in Years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 56.7718%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants outstanding as of &lt;span id="fs_X5GSZNA00G00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; width: 1%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zg1df8u0khma" style="text-align: right; height: 15px; background-color: #cceeff; width: 11%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;9,733&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 1.85529%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.0723562%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQcYXDXFL6Hk" style="text-align: right; height: 15px; background-color: #cceeff; width: 11%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;11.60&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; width: 1%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; width: 11%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.125in; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Issued&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3,947&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.80&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-left: 0.125in; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9IFeuqSS1cj" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span id="fodd76dfe622754570bb5acc5f1aa065e3"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightToBeExercised_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlAxsJGD8MZ" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span id="foee53ce838bfd4fc6aa3d6c719491f7d1" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.125in; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-bottom: 1pt solid rgb(0, 0, 0); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1NxkYT6TSYj" style="text-align: right; height: 15px; border-bottom: 1pt solid rgb(0, 0, 0); box-shadow: none; width: 11%;"&gt;&lt;span style="border-right: none; border-left: none; font-family: 'times new roman', times; line-height: inherit;"&gt;(4,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;22.10&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants outstanding as of &lt;span id="fs_97EMRANKPC00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; border-bottom: 1pt solid rgb(0, 0, 0); width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHVhypEfK9qf" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; white-space: normal; border-bottom: 1pt solid rgb(0, 0, 0); width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;9,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMXRKoRWDa1k" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights_dxL_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zCDJV5avbndl" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;1.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&#160;&#160;&#160;Issued&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_znuMYkjvjYMg" style="text-align: right; height: 10px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span id="fs_884NIE6MN400000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 11%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ziiL9JeBjwN3" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: right; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&lt;span id="fs_KC42Y2XJ4000000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&#160;&#160;&#160;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom: 1pt solid rgb(0, 0, 0); width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zCL5IxQ7Xtvd" style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); width: 11%;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;(1,721&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px; text-align: left; height: 15px; box-shadow: none; vertical-align: bottom; width: 0.927644%;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightToBeForfeitedOrExpired_pid_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBNVcelyPtw2" style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.15&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants outstanding as of &lt;span id="fs_RQWXPXRN5S00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zea3x23pN45" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;7,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zK0IocaFsa1k" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.49&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_dxL_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHcGV8FCOSRj" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;0.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants exercisable as of &lt;span id="fs_LW8AEDEFWG00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_iE_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjezMXbxlYO" style="text-align: right; height: 15px; border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;7,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_iE_pid_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ziHRbvGFW109" style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.49&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_dxL_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvohwc8KiYn4" style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;0.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;

















        &lt;/tbody&gt;

















       &lt;/table&gt;

















      &lt;/div&gt;

















     &lt;/div&gt;

















    &lt;/div&gt;

















   </vani:WarrantDisclosureTextBlock>
    <vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20201231_NanoPrecisionMedicalIncWarrantMember_1"
      decimals="INF"
      id="Tag24"
      unitRef="USDPerShare">3.15</vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice>
    <vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20191231_NanoPrecisionMedicalIncWarrantMember"
      decimals="INF"
      id="Tag23"
      unitRef="USDPerShare">3.15</vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice>
    <vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20211231_NanoPrecisionMedicalIncWarrantMember_1"
      decimals="2"
      id="Tag234"
      unitRef="USDPerShare">3.15</vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice>
    <vani:ClassOfWarrantsOrRightsTerm contextRef="D20251231_RightOfferingMember" id="Tag229">P5Y</vani:ClassOfWarrantsOrRightsTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20251231_NanoPrecisionMedicalIncWarrantMember"
      decimals="2"
      id="Tag235"
      unitRef="USDPerShare">3.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="I20251231_NanoPrecisionMedicalIncWarrantMember"
      decimals="0"
      id="Tag232"
      unitRef="Shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20251231_NanoPrecisionMedicalIncWarrantMember"
      decimals="2"
      id="Tag260"
      unitRef="USDPerShare">3.15</vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember_CommonStockMember"
      decimals="0"
      id="Tag227"
      unitRef="Shares">3947368</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember"
      decimals="2"
      id="Tag228"
      unitRef="USDPerShare">3.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember"
      id="Tag230">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20240301_WarrantMember_SecuritiesPurchaseAgreementMember"
      decimals="2"
      id="Tag262"
      unitRef="USDPerShare">3.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross
      contextRef="D20240301_WarrantMember_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Tag261"
      unitRef="USD">15000000</vani:ProceedsFromIssuanceOfCommonStockAndWarrantsInConnectionWithSecuritiesPurchaseAgreementGross>
    <vani:ClassOfWarrantOrRightOutstandingIntrinsicValue
      contextRef="D20251231_WarrantMember_SecuritiesPurchaseAgreementMember"
      decimals="-6"
      id="Tag233"
      unitRef="USD">0</vani:ClassOfWarrantOrRightOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="D20251231" id="Tag231">
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;A summary of warrant activity for the year ended &lt;span id="fs_6DK6MNWVOW00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_WF7DX1JWF400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; is presented below (in thousands, except per share and contractual life data).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_ZFKNLFA03K00000000000000000000b"&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 215px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin: 0px; text-indent: 0px; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Exercise&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Remaining&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 15px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Contractual&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 11.0724%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Per Share&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 10px; padding: 0px; box-shadow: none; width: 12%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Life (in Years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 56.7718%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants outstanding as of &lt;span id="fs_X5GSZNA00G00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; width: 1%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zg1df8u0khma" style="text-align: right; height: 15px; background-color: #cceeff; width: 11%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;9,733&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 1.85529%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.0723562%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zQcYXDXFL6Hk" style="text-align: right; height: 15px; background-color: #cceeff; width: 11%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;11.60&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; width: 1%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: #cceeff; width: 11%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); width: 0.927644%; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.125in; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Issued&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3,947&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.80&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-left: 0.125in; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9IFeuqSS1cj" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span id="fodd76dfe622754570bb5acc5f1aa065e3"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightToBeExercised_pid_uUSDPShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlAxsJGD8MZ" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span id="foee53ce838bfd4fc6aa3d6c719491f7d1" style="line-height: inherit;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.125in; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-bottom: 1pt solid rgb(0, 0, 0); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1NxkYT6TSYj" style="text-align: right; height: 15px; border-bottom: 1pt solid rgb(0, 0, 0); box-shadow: none; width: 11%;"&gt;&lt;span style="border-right: none; border-left: none; font-family: 'times new roman', times; line-height: inherit;"&gt;(4,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;22.10&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants outstanding as of &lt;span id="fs_97EMRANKPC00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; border-bottom: 1pt solid rgb(0, 0, 0); width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHVhypEfK9qf" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; white-space: normal; border-bottom: 1pt solid rgb(0, 0, 0); width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;9,340&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMXRKoRWDa1k" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.42&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights_dxL_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zCDJV5avbndl" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;1.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&#160;&#160;&#160;Issued&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_znuMYkjvjYMg" style="text-align: right; height: 10px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span id="fs_884NIE6MN400000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 11%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&#160;&#160;&#160;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightExercised_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ziiL9JeBjwN3" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: right; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;"&gt;&lt;span id="fs_KC42Y2XJ4000000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&#160;&#160;&#160;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom: 1pt solid rgb(0, 0, 0); width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightForfeitedOrExpired_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zCL5IxQ7Xtvd" style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); width: 11%;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;(1,721&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px; text-align: left; height: 15px; box-shadow: none; vertical-align: bottom; width: 0.927644%;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--ClassOfWarrantOrRightToBeForfeitedOrExpired_pid_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBNVcelyPtw2" style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.15&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants outstanding as of &lt;span id="fs_RQWXPXRN5S00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zea3x23pN45" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;7,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zK0IocaFsa1k" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.49&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRights2_dxL_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHcGV8FCOSRj" style="text-align: right; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;0.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; background-color: rgb(204, 238, 255); box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 56.7718%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;Warrants exercisable as of &lt;span id="fs_LW8AEDEFWG00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights_iE_pn3n3_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjezMXbxlYO" style="text-align: right; height: 15px; border-bottom: 2.8pt double rgb(0, 0, 0); box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;7,619&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 1.85529%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 0.0723562%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedExercisePriceExercisableOfWarrantsOrRights11_iE_pid_uShares_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ziHRbvGFW109" style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;3.49&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeOfWarrantsOrRightsExercise_dxL_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zvohwc8KiYn4" style="text-align: right; height: 15px; box-shadow: none; width: 11%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;0.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none; width: 0.927644%;"&gt;&lt;span style="font-family: 'times new roman', times; line-height: inherit;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;

















         &lt;/tr&gt;

















        &lt;/tbody&gt;

















       &lt;/table&gt;

















      &lt;/div&gt;

















     </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I20231231_WarrantMember"
      decimals="-3"
      id="Tag240"
      unitRef="Shares">9733000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20231231_WarrantMember"
      decimals="2"
      id="Tag244"
      unitRef="USDPerShare">11.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vani:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="D20231231_WarrantMember" id="Tag253">P1Y4M24D</vani:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <vani:ClassOfWarrantOrRightGrantsInPeriod
      contextRef="D20241231_WarrantMember"
      decimals="-3"
      id="Tag251"
      unitRef="Shares">3947000</vani:ClassOfWarrantOrRightGrantsInPeriod>
    <vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20241231_WarrantMember"
      decimals="2"
      id="Tag250"
      unitRef="USDPerShare">3.8</vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice>
    <vani:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="D20241231_WarrantMember"
      id="Tag252"
      unitRef="Shares"
      xsi:nil="true"/>
    <vani:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice
      contextRef="D20241231_WarrantMember"
      id="Tag236"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <vani:ClassOfWarrantOrRightForfeituresAndExpirationsInPeriod
      contextRef="D20241231_WarrantMember"
      decimals="-3"
      id="Tag248"
      unitRef="Shares">-4340000</vani:ClassOfWarrantOrRightForfeituresAndExpirationsInPeriod>
    <vani:ClassOfWarrantOrRightForfeituresAndExpirationsWeightedAverageExercisePrice
      contextRef="D20241231_WarrantMember"
      decimals="2"
      id="Tag249"
      unitRef="USDPerShare">22.1</vani:ClassOfWarrantOrRightForfeituresAndExpirationsWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I20241231_WarrantMember"
      decimals="-3"
      id="Tag258"
      unitRef="Shares">9340000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20241231_WarrantMember"
      decimals="2"
      id="Tag259"
      unitRef="USDPerShare">3.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vani:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="D20241231_WarrantMember" id="Tag237">P1Y7M6D</vani:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <vani:ClassOfWarrantOrRightGrantsInPeriod
      contextRef="D20251231_WarrantMember"
      id="Tag254"
      unitRef="Shares"
      xsi:nil="true"/>
    <vani:ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20251231_WarrantMember"
      id="Tag255"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <vani:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="D20251231_WarrantMember"
      id="Tag257"
      unitRef="Shares"
      xsi:nil="true"/>
    <vani:ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice
      contextRef="D20251231_WarrantMember"
      id="Tag256"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <vani:ClassOfWarrantOrRightForfeituresAndExpirationsInPeriod
      contextRef="D20251231_WarrantMember"
      decimals="-3"
      id="Tag241"
      unitRef="Shares">-1721000</vani:ClassOfWarrantOrRightForfeituresAndExpirationsInPeriod>
    <vani:ClassOfWarrantOrRightForfeituresAndExpirationsWeightedAverageExercisePrice
      contextRef="D20251231_WarrantMember"
      decimals="2"
      id="Tag245"
      unitRef="USDPerShare">3.15</vani:ClassOfWarrantOrRightForfeituresAndExpirationsWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I20251231_WarrantMember"
      decimals="-3"
      id="Tag242"
      unitRef="Shares">7619000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20251231_WarrantMember"
      decimals="2"
      id="Tag246"
      unitRef="USDPerShare">3.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <vani:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="D20251231_WarrantMember" id="Tag238">P0Y10M24D</vani:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <vani:ClassOfWarrantOrRightExercisableNumber
      contextRef="D20251231_WarrantMember"
      decimals="-3"
      id="Tag243"
      unitRef="Shares">7619000</vani:ClassOfWarrantOrRightExercisableNumber>
    <vani:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="D20251231_WarrantMember"
      decimals="2"
      id="Tag247"
      unitRef="USDPerShare">3.49</vani:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <vani:ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm contextRef="D20251231_WarrantMember" id="Tag239">P0Y10M24D</vani:ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="D20251231" id="Tag99">
&lt;p id="xdx_803_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_znWLWfEz3wa3" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0pt 0pt 1pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;9. &lt;span id="xdx_82D_zkmK2j23iWy9" style="line-height: inherit;"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 1pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;line-height: 1.2;"&gt;We have a 401(k) Savings Retirement Plan
(the &#x201c;401(k) Plan&#x201d;) that covers substantially all full-time employees who meet the 401(k) Plan&#x2019;s eligibility requirements and
provides for an employee elective contribution. The 401(k) Plan provides for employer matching contributions. Employer contributions are
discretionary and determined annually by the Board of Directors. During the years ended &lt;span id="fs_RPMK4G8M3K00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_7M9HS9KJW000000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, employer contributions
to the 401(k) Plan totaled $&lt;span id="xdx_907_eus-gaap--DefinedBenefitPlanContributionsByEmployer_dm_c20230101__20231231_zOxMa1nmUDAd" style="line-height: inherit;" title="Employer contributions to plan"&gt;0.2 million&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DefinedBenefitPlanContributionsByEmployer_dm_c20220101__20221231_zROWR5Qhpolf" style="line-height: inherit;" title="Employer contributions to plan"&gt;&lt;span style="border-left: none; border-right: none;"&gt;0.2&lt;/span&gt;&#160;million&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;























</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="D20251231"
      decimals="-5"
      id="Tag100"
      unitRef="USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="D20241231"
      decimals="-5"
      id="Tag101"
      unitRef="USD">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D20251231" id="Tag664">
&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zT64ZK8673w8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;10. &lt;span id="xdx_822_zK7w9sj9Duk4"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Equity Incentive Plans&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The Vivani Medical, Inc. &lt;span id="fs_7U9TWCS1FK00000000000000000000fs" style="display: inline;"&gt;2022&lt;/span&gt; Omnibus Incentive Plan (the &#x201c;&lt;span id="fs_YBIRTI0YZK00000000000000000000fs" style="display: inline;"&gt;2022&lt;/span&gt; Plan&#x201d;) became effective on August 30, 2022. &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlansMember_zxqU2ERkb8i8" title="Description of equity incentive plans"&gt;&lt;span style="border-left: none; border-right: none;"&gt;Under the &lt;span id="fs_KNP2AMITR400000000000000000000fs"&gt;2022&lt;/span&gt; Plan, 10,033,333 shares were authorized for issuance at its effective date. &lt;span style="border-left: none; border-right: none;"&gt;The maximum number of shares with respect to which stock awards could be granted is offset and reduced by stock awards previously granted under the Plan. As of &lt;span id="fs_DT41RGY0Z400000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20221231_zfSO7zIpMcee" title="Issuance shares of common stock"&gt;&lt;span style="border-left: none; border-right: none;"&gt;503,839&lt;/span&gt;&lt;/span&gt; shares of common stock were available for future issuance under the &lt;span id="fs_EB6FJZJ74W00000000000000000000fs"&gt;2022&lt;/span&gt; Plan pursuant to stock awards that had not previously been granted.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;For stock option grants, the option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date. Generally, the &lt;span id="xdx_909_ecustom--DescriptionOfStockOptionGrant_c20230101__20231231__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_ztqPkcZMAbXa" title="Description of stock option grant"&gt;&lt;span style="border-left: none; border-right: none;"&gt;options vest ratably over four years and expire ten years from the grant date&lt;/span&gt;&lt;/span&gt;. The &lt;span id="fs_JVPL3DLFGW00000000000000000000fs" style="display: inline;"&gt;2022&lt;/span&gt; plan provides for accelerated vesting if there is a change of control, as defined in the &lt;span id="fs_TELT9M0CDS00000000000000000000fs" style="display: inline;"&gt;2022&lt;/span&gt; Plan.&lt;/span&gt;&lt;br/&gt;&lt;/p&gt;

&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 10pt 0pt 0pt; text-align: justify; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo34eeeff5753a4e82b0eb2566d6c81167"&gt;
&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvOm3qdzhhNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;A summary of stock option activity is presented below (in thousands, except per share and contractual life data).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 274px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Remaining&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Exercise&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Contractual&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Life&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 17px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; vertical-align: bottom; height: 17px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Per Share&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 17px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(in Years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="width: 61%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options outstanding at &lt;span id="fs_AYURJU6TU800000000000000000000FM"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za3pri9f8d6d" style="width: 10%; text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,091&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQo2T6klCcDf" style="width: 10%; text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.60&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6.96&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvzLzJBvnLBi" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,093&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSk4DN95xkY7" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.57&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMOsZfUn4p6f" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fo84801262836b44e999bca60acd4f8c67"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUaNlR94a7h2" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="foa0fb7d39b6904dd68293d1133f4909ff"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9Ta8OhpDvC7" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(375&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG68z0obUO9a" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.19&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options outstanding at &lt;span id="fs_JFBN97320W00000000000000000000FM"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxFHYHkn6y" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,809&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJkkXXkIG3lj" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.52&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6.55&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztWswWsTLtK4" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,881&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOeX3PI8S6Rh" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQvmDnN3T4rh" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="foa500a60a7c83488095130c4fe80152a0"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd5HH8xaMaCf" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="focd117e81a3414616a259aee25e86aa89"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgm1JqUluxa6" style="text-align: right; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(324&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; height: 16px; box-shadow: none; text-align: left;"&gt;&lt;span style="padding: 0px 0px 0.5px; height: 16px; box-shadow: none; text-align: left;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zABwL8Bsjv53" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.78&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 17px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options outstanding, vested and expected to vest as of &lt;span id="fs_PPDO55R4C000000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; border-bottom: 2.8pt double #000000; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHoGElP3YBGj" style="text-align: right; height: 17px; border-bottom: 2.8pt double #000000; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;8,366&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5mfYEgkY5ej" style="text-align: right; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.23&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbHivuMcd9d7" style="text-align: right; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6.09&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options exercisable as of &lt;span id="fs_XQ8MSLZ7CW00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX6kQQeMMV78" style="text-align: right; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;5,830&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pip0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjBgNn02r6Cj" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.65&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk1QMRYtnhT9" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;4.95&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;p id="xdx_8A0_zZqpCrbyoBxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; color: red;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The estimated aggregate intrinsic value of stock options exercisable as of &lt;span id="fs_XQNNXRJEBK00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; was $0.4&#160;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_dm_c20231231_zobAml22NrGb" title="Stock options exercisable"&gt;million&lt;/span&gt;.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;i&gt;Restricted Stock Units (RSUs)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo248842eafe8b4f83903cf0140a9547c9"&gt;
&lt;p id="xdx_895_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zZpZM5qR32s1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B2_zvvQOHx8nmff" style="font-family: 'times new roman', times;"&gt;A summary of restricted stock activity and related information (in thousands, except per share data):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 117px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 38px;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 38px; box-shadow: none; border-bottom-color: black !important;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Number&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;of Shares&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 38px; box-shadow: none; border-bottom-color: black !important;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Weighted&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Average Grant&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Date Fair Value&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Per Share&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: justify; background-color: #cceeff; height: 16px; box-shadow: none; width: 74%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Outstanding as of &lt;span id="fs_1NWD3XAHHC00000000000000000000FM"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW3fB4v2oU09" style="text-align: right; background-color: #cceeff; height: 16px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;695&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIHeQgNSKH45" style="text-align: right; background-color: #cceeff; height: 16px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: justify; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlUZJcbEqk2f" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;293&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOA1jpmlxO34" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;0.87&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: justify; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztophoiuY2Z3" style="text-align: right; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fo65945eb6eea84ca38ae9d6ecdabd82f8"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc5aZxfcXFvk" style="text-align: right; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="d412d0aa-84ab-42e9-91a4-9fe791203be5"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 1pt; border-bottom-style: solid; height: 16px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBw0s08VO2ph" style="text-align: right; border-bottom-width: 1pt; border-bottom-style: solid; height: 16px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(188&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYkrG01BgNOg" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Outstanding as of &lt;span id="fs_5GKW42WUWG00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: 2.8pt double #000000; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1pIRmoHVQQg" style="text-align: right; border-bottom: 2.8pt double #000000; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;800&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcmUGItsl0qj" style="text-align: right; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.15&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;p id="xdx_8A3_z9BQoM8QMPX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: red;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;During the years ended &lt;span id="fs_LQT0KH5T4W00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&#160;and &lt;span id="fs_XDL3TLS8V400000000000000000000FM"&gt;2024&lt;/span&gt;, the Company granted &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_pid_uShares_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrQB5QoOC2Pk"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;292,500&lt;/span&gt;&#160;and 292,500&lt;/span&gt;&lt;/span&gt; RSUs, respectively, subject to market conditions which required our stock price to exceed $&lt;span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_uUSDPShares_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOhHMZVWcSZ9" title="Options exercisable (in dollars per share)"&gt;3.15&lt;/span&gt; per share for three consecutive days in the &lt;span style="border-left: none; border-right: none;"&gt;four years&lt;/span&gt; from grant date for the RSUs to vest.&#160;&lt;/span&gt;&lt;span style="font-size: 10.0pt;"&gt;Upon achievement of the market condition, &lt;span&gt;&lt;span style="-sec-ix-hidden:Tag12"&gt;&lt;span style="display: inline;"&gt;&lt;span id="fs_U0YPODATR400000000000000000000fs"&gt;one&lt;/span&gt;&lt;/span&gt;-third&lt;/span&gt;&lt;/span&gt; of the award will vest, and thereafter, &lt;span&gt;&lt;span style="-sec-ix-hidden:Tag13"&gt;&lt;span style="display: inline;"&gt;&lt;span id="fs_XMNKENS8Z400000000000000000000fs"&gt;one&lt;/span&gt;&lt;/span&gt;-third&lt;/span&gt;&lt;/span&gt; of the award will vest on the first and second anniversary of the achievement date, subject to the recipient&#x2019;s continued service through each applicable vesting date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0px; text-align: left;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Stock-Based Compensation Expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo72af9f222ee746e0be73dc55e82772b6"&gt;
&lt;p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zuFmQdKlrUl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The following table summarizes total stock-based compensation expense for stock options and RSUs, which is included in the statements of operations (in thousands).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 71px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 10px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Year Ended &lt;span id="fs_79B6VBTGOG00000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_WE5JGDDLLC00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_589HS88GQ800000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 68%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Research and development&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zeObiswLzpRj" style="text-align: right; height: 15px; box-shadow: none; width: 13%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;833&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbeRt4FTGX52" style="text-align: right; height: 15px; box-shadow: none; width: 13%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,001&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zURiv2eTHBfj" style="text-align: right; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;651&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwAWRq5UEBp5" style="text-align: right; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;609&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zSsgADCNEhQe" style="text-align: right; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,484&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231_zAEu7R9Ci34g" style="text-align: right; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,610&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 8pt; text-indent: 18pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;As of &lt;span id="fs_ANXUBTYJEO00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, there was $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zR3K9ZjzZHSf" title="Unrecognized compensation cost"&gt;2.0&lt;/span&gt; million of total unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over a weighted average period of &lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zyjn1nRq753a" title="Weighted average period (in years)::XDX::P1Y2M12D"&gt;1.5&lt;/span&gt;&#160;years. As of &lt;span id="fs_GYOAGV4B0G00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, there was $&lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z06khya0u7Ud" title="Unrecognized compensation cost"&gt;0.2&lt;/span&gt; million of total unrecognized compensation expense related to outstanding RSUs that will be recognized over a weighted average period of &lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7lVDKMZ6D74" title="Weighted average period (in years)::XDX::P0Y1M6D"&gt;1.4&lt;/span&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 8pt; text-indent: 0pt;"&gt;&lt;span style="font-weight: bold;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 8pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;i&gt;Stock Options (Service Vesting)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;div id="fo6ab63305cd4e4c679793ff954bbe0d74"&gt;
&lt;p id="xdx_898_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_zadq4clprso4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;The weighted-average grant-date fair value of options granted during the year ended December 31, 2025 and 2024 were $0.92 and $1.26, respectively. The assumptions used in the Black-Scholes model for stock options are as follows:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="height: 75px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="vertical-align: middle; height: 15px; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; vertical-align: middle; text-align: center; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: black !important; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_ZWL18FAK5S00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center; height: 15px; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; vertical-align: middle; text-align: center; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: black !important; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_GPAB667KXC00000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; vertical-align: middle; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: black !important; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zrVyI2wxX7h2" title="Risk-free interest rate"&gt;3.81&lt;/span&gt;% to &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z9TC14Vs8uJe" title="Risk-free interest rate"&gt;4.39&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zec0cOVOfEF4" title="Risk-free interest rate"&gt;3.79&lt;/span&gt;% &#x2013; &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z2UARH1Ja8Vf" title="Risk-free interest rate"&gt;5.53&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zUQZefBn2Zm3" title="Expected dividend yield"&gt;&lt;span id="fo0d797e0534c249bdb110f7f41b259bf7"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z6SlCGr3ANqc" title="Expected dividend yield"&gt;&lt;span id="fo438947879e8f4b8390feb7975a5922a2"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zPiRhJApXgc2" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zNs8s78D4VV9" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Expected term&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zufPMDCxUa3g" title="Expected term::XDX::P4Y"&gt;5.25&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_znYjPks8oNY2" title="Expected term::XDX::P6Y2M12D"&gt;6.08&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z36XRQzXgN0c" title="Expected term::XDX::P4Y2M30D"&gt;5.04&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zV4bkNBawPL1" title="Expected term::XDX::P6Y0M29D"&gt;6.08&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;div style="margin: 0pt 0pt 0pt; text-indent: 0pt;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0pt 0pt 0pt; text-indent: 0pt; font: 10pt 'Times New Roman', Times, serif;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;i&gt;Restricted Stock Units (RSUs)&lt;/i&gt;&lt;/span&gt;&lt;/div&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt; text-indent: 18pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fs_7BF8ZUNTGG00000000000000000000B" style="margin: 0pt 0pt 0pt; text-indent: 0pt;"&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;The assumptions used to estimate the fair value of the performance-based restricted stock units granted during the year&lt;span&gt;s ended &lt;span id="fs_7HMVMBP3KG00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&#160;and &lt;span&gt;&lt;span id="fs_NCA553A4KW00000000000000000000fs"&gt;2024&lt;/span&gt;&lt;/span&gt; and valued using a Monte Carlo simulation were as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;div id="t_ft_SCA5Q1NNO000000000000000000000b"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="height: 96px; width: 100%; border-collapse: collapse; font-family: 'times new roman'; font-size: 10pt; margin: 0px; text-indent: 0px;" width="100%"&gt;
&lt;tbody&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td colspan="3" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="text-align: center; margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;b&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt;&lt;span style="border-right: none; border-left: none; font-family: 'times new roman', times;"&gt;Year Ended &lt;span id="fs_MUBKTO1VV400000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="text-align: center; margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span style="color: #000000;"&gt;&lt;span id="fs_RTP2TICWLC00000000000000000000fs"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;b&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="text-align: center; margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&lt;span style="color: #000000;"&gt;&lt;span id="fs_TPZOJ0LLTC00000000000000000000fs"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px; background-color: #cceeff;"&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; RSUs&#160;Granted &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px; text-align: center;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt; 292,500 &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 9pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; text-align: center; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt; 292,500 &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none; width: 66%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; Valuation date stock price &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none; width: 16%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px; text-align: center;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;$1.03&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none; width: 1%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 9pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; width: 16%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; text-align: center; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;$1.81&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 12px; background-color: #cceeff;"&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; Risk-free interest rate &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px; text-align: center;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt; &lt;span style="border-left: none; border-right: none;"&gt;3.99%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 9pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; text-align: center; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt; &lt;span style="border-left: none; border-right: none;"&gt;4.53%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 12px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Expected divided yield&lt;/span&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 17px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px; background-color: #cceeff;"&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;Simulation term&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;4&#160;years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;4&#160;y&lt;span style="color: #000000; font-family: 'times new roman', times; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;ears&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 17px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;


 &lt;/div&gt;


 &lt;/div&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt; text-indent: 18pt; color: #171717;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 8pt; text-indent: 18pt; color: #171717;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The steps involved in utilizing the Monte Carlo simulation in order to value the performance-based RSUs included the following:&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;



 &lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 8pt 18pt; color: #171717; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_W0OS7Q8CF400000000000000000000fs"&gt;1&lt;/span&gt;&lt;/span&gt;. Projection of the Company&#x2019;s Common Stock Value. &lt;/b&gt;The performance-based RSUs were measured based on the Company&#x2019;s underlying common stock value over the performance period (&lt;span style="border-left: none; border-right: none;"&gt;four years&lt;/span&gt; following the Valuation Date).&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 8pt; font-size: 12pt; font-family: 'Times New Roman', serif; line-height: 1.2;"&gt;&lt;span style="font-size: 10pt; color: #171717; margin: 0pt 0pt 8pt; text-indent: 18pt; line-height: inherit;"&gt;&lt;span style="font-family: 'times new roman', times; color: black; line-height: inherit;"&gt;Additionally, the Company considered the &lt;span style="-sec-ix-hidden:Tag52"&gt;two-year&lt;/span&gt; vesting period following achievement of the performance condition. Accordingly, the Company&#x2019;s common stock value was simulated over a &lt;span style="-sec-ix-hidden:Tag51"&gt;six-year&lt;/span&gt; period to capture iterations through which the performance condition was satisfied on the Performance Period End Date. The analysis involved projecting the Company&#x2019;s common stock value starting with its current common stock value. The forecasted stock price was based on the Geometric Brownian motion (&#x201c;GBM&#x201d;), and the Monte Carlo simulation generated rando&lt;/span&gt;m variables using the GBM to forecast our stock price on a daily basis over the specified period assuming 252 trading days per year. The Monte Carlo simulation for the PSO utilized the following assumptions:&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_MUCFECXJPC00000000000000000000b" style="margin: 0pt 0pt 8pt; text-indent: 0pt;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: justify; width: 0.5in; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0px 23px; box-shadow: none;"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Beginning Stock Price.&#160; &lt;/b&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000;"&gt;As of the Valuation Date, the Company is a publicly traded company with an observable share price. Therefore, the publicly traded share price as of the Valuation Date was utilized as the beginning stock value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;div id="t_ft_CJI9RS0Z8000000000000000000000b" style="margin: 0pt 0pt 8pt; text-indent: 0pt;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0px 23px; box-shadow: none;"&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Drift Rate. &lt;/b&gt;In determining the value of the instrument in the risk-neutral framework, risk free rates were estimated based on the applicable treasury rate for the projection period. For each simulation, the term of the risk-free rate was based on the term from the Valuation Date through the latest date on which the award could vest (i.e., &lt;span style="border-left: none; border-right: none;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_ONTG96750G00000000000000000000fs"&gt;two&lt;/span&gt; years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; following the Performance Period End Date). Please note that, for the purposes of calculating the service period associated with the Subject Interest, the Company's cost of equity was utilized as the drift rate.&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;div id="t_ft_2J6PULDI0G00000000000000000000b" style="margin: 0pt 0pt 8pt; text-indent: 0pt;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0px 23px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Volatility. &lt;/b&gt;The total equity volatility (standard deviation) was based on a total equity volatility analysis.&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;div id="t_ft_BYL7TPQIKW00000000000000000000b" style="margin: 0pt 0pt 8pt; text-indent: 0pt;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 0.5in; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0px 23px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Period. &lt;/b&gt;The period was measured as the number of years from the Valuation Date through the latest date on which the award could vest.&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;div id="t_ft_TLV4V03EM800000000000000000000b" style="margin: 0pt 0pt 0pt; text-indent: 0pt;"&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; width: 100%;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 0.5in; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0px 23px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;Dividends. &lt;/b&gt;The Company has not historically paid dividends nor do we expect to pay dividends going forward. As such, no dividends were considered in the analysis.&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 0pt 18pt; color: #171717; text-indent: 0pt;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 8pt 18pt; color: #171717; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_BDZXMQR0ZK00000000000000000000fs"&gt;2&lt;/span&gt;&lt;/span&gt;. Consideration of the Performance-Vesting Schedule. &lt;/b&gt;As previously discussed, the Company's publicly traded common share price must equal or exceed the Stock Price Hurdle amount of $3.15 over a three-consecutive-trading-day rolling period on or before the Performance Period End Date. If such performance condition is achieved, &lt;span style="-sec-ix-hidden:Tag9"&gt;&lt;span style="display: inline;"&gt;&lt;span id="fs_842I9A15VK00000000000000000000fs"&gt;one&lt;/span&gt;&lt;/span&gt;-third&lt;/span&gt; of the award shall vest on the Hurdle Achievement Date, &lt;span style="-sec-ix-hidden:Tag10"&gt;&lt;span style="display: inline;"&gt;&lt;span id="fs_DWDGM44PFK00000000000000000000fs"&gt;one&lt;/span&gt;&lt;/span&gt;-third&lt;/span&gt; of the award shall vest &lt;span id="fs_0W1GGEX4GW00000000000000000000fs" style="display: inline;"&gt;one&lt;/span&gt; year following the Hurdle Achievement Date, and &lt;span style="-sec-ix-hidden:Tag11"&gt;&lt;span style="display: inline;"&gt;&lt;span id="fs_OSC98AP2S000000000000000000000fs"&gt;one&lt;/span&gt;&lt;/span&gt;-third&lt;/span&gt; of the award shall vest &lt;span id="fs_I1EPNWASCG00000000000000000000fs" style="display: inline;"&gt;two&lt;/span&gt; years following the Hurdle Achievement Date.&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0pt 0pt 18pt; color: #171717; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span id="fs_ZK4HWGGN9C00000000000000000000fs"&gt;3&lt;/span&gt;&lt;/span&gt;. Performance-Based RSU Value Conclusion&lt;/b&gt;.&#160; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; color: #171717; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;The proceeds from the vesting of common shares were then discounted to the Valuation Date using the applicable risk-free rate, which is consistent with the assumption utilized to project stock prices in the Monte Carlo simulation. For the purposes of calculating the weighted service period associated with the Subject Interest, a separate simulation was performed using the Company&#x2019;s cost of equity as the drift rate. The service period was then determined based on the median Hurdle Achievement Date.&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;


 </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="I20251231_EquityIncentivePlansMember"
      decimals="0"
      id="Tag674"
      unitRef="Shares">10033333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="I20251231_EquityIncentivePlansMember"
      decimals="0"
      id="Tag675"
      unitRef="Shares">503839</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="D20251231_EquityIncentivePlansMember_EmployeeStockOptionMember"
      id="Tag676">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="D20251231_EquityIncentivePlansMember_EmployeeStockOptionMember"
      id="Tag677">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="D20251231" id="Tag659">
&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvOm3qdzhhNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;A summary of stock option activity is presented below (in thousands, except per share and contractual life data).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 274px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Weighted&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Average&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Remaining&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Exercise&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Contractual&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Number of&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Price&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Life&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 17px;"&gt;
&lt;td style="height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 17px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Shares&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; vertical-align: bottom; height: 17px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Per Share&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 17px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(in Years)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 17px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="width: 61%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options outstanding at &lt;span id="fs_AYURJU6TU800000000000000000000FM"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za3pri9f8d6d" style="width: 10%; text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,091&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQo2T6klCcDf" style="width: 10%; text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.60&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6.96&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvzLzJBvnLBi" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,093&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSk4DN95xkY7" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.57&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMOsZfUn4p6f" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fo84801262836b44e999bca60acd4f8c67"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUaNlR94a7h2" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="foa0fb7d39b6904dd68293d1133f4909ff"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9Ta8OhpDvC7" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(375&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG68z0obUO9a" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.19&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options outstanding at &lt;span id="fs_JFBN97320W00000000000000000000FM"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxFHYHkn6y" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,809&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJkkXXkIG3lj" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.52&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6.55&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztWswWsTLtK4" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,881&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOeX3PI8S6Rh" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px; background-color: #cceeff;"&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pn3n3_di_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQvmDnN3T4rh" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="foa500a60a7c83488095130c4fe80152a0"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zd5HH8xaMaCf" style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="focd117e81a3414616a259aee25e86aa89"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgm1JqUluxa6" style="text-align: right; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(324&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; height: 16px; box-shadow: none; text-align: left;"&gt;&lt;span style="padding: 0px 0px 0.5px; height: 16px; box-shadow: none; text-align: left;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zABwL8Bsjv53" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.78&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 17px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options outstanding, vested and expected to vest as of &lt;span id="fs_PPDO55R4C000000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; border-bottom: 2.8pt double #000000; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHoGElP3YBGj" style="text-align: right; height: 17px; border-bottom: 2.8pt double #000000; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;8,366&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5mfYEgkY5ej" style="text-align: right; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.23&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbHivuMcd9d7" style="text-align: right; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6.09&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 17px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Options exercisable as of &lt;span id="fs_XQ8MSLZ7CW00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX6kQQeMMV78" style="text-align: right; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;5,830&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pip0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjBgNn02r6Cj" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2.65&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zk1QMRYtnhT9" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;4.95&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="I20231231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag709"
      unitRef="Shares">6091000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="I20231231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag715"
      unitRef="USDPerShare">2.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="D20231231_EmployeeStockOptionMember"
      id="Tag731">P6Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20241231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag710"
      unitRef="Shares">1093000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20241231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag716"
      unitRef="USDPerShare">1.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="D20241231_EmployeeStockOptionMember"
      id="Tag729"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="D20241231_EmployeeStockOptionMember"
      id="Tag728"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="D20241231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag739"
      unitRef="Shares">375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="D20241231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag717"
      unitRef="USDPerShare">1.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="I20241231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag711"
      unitRef="Shares">6809000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="I20241231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag718"
      unitRef="USDPerShare">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="D20241231_EmployeeStockOptionMember"
      id="Tag730">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20251231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag712"
      unitRef="Shares">1881000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20251231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag719"
      unitRef="USDPerShare">1.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="D20251231_EmployeeStockOptionMember"
      id="Tag738"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="D20251231_EmployeeStockOptionMember"
      id="Tag737"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="D20251231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag727"
      unitRef="Shares">324000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="D20251231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag720"
      unitRef="USDPerShare">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="I20251231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag713"
      unitRef="Shares">8366000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="I20251231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag721"
      unitRef="USDPerShare">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="D20251231_EmployeeStockOptionMember"
      id="Tag681">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="I20251231_EmployeeStockOptionMember"
      decimals="-3"
      id="Tag714"
      unitRef="Shares">5830000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="I20251231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag722"
      unitRef="USDPerShare">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="D20251231_EmployeeStockOptionMember"
      id="Tag680">P4Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="I20251231"
      decimals="-5"
      id="Tag749"
      unitRef="USD">400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="D20251231" id="Tag660">
&lt;p id="xdx_895_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zZpZM5qR32s1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B2_zvvQOHx8nmff" style="font-family: 'times new roman', times;"&gt;A summary of restricted stock activity and related information (in thousands, except per share data):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 117px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 38px;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 38px; box-shadow: none; border-bottom-color: black !important;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Number&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;of Shares&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 38px; box-shadow: none; border-bottom-color: black !important;"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Weighted&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Average Grant&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Date Fair Value&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;Per Share&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 38px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: justify; background-color: #cceeff; height: 16px; box-shadow: none; width: 74%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Outstanding as of &lt;span id="fs_1NWD3XAHHC00000000000000000000FM"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW3fB4v2oU09" style="text-align: right; background-color: #cceeff; height: 16px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;695&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIHeQgNSKH45" style="text-align: right; background-color: #cceeff; height: 16px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: justify; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlUZJcbEqk2f" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;293&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOA1jpmlxO34" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;0.87&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: justify; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztophoiuY2Z3" style="text-align: right; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fo65945eb6eea84ca38ae9d6ecdabd82f8"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc5aZxfcXFvk" style="text-align: right; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="d412d0aa-84ab-42e9-91a4-9fe791203be5"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Forfeited and canceled&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 1pt; border-bottom-style: solid; height: 16px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBw0s08VO2ph" style="text-align: right; border-bottom-width: 1pt; border-bottom-style: solid; height: 16px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(188&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYkrG01BgNOg" style="text-align: right; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Outstanding as of &lt;span id="fs_5GKW42WUWG00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: 2.8pt double #000000; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_uShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1pIRmoHVQQg" style="text-align: right; border-bottom: 2.8pt double #000000; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;800&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcmUGItsl0qj" style="text-align: right; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1.15&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; background-color: #cceeff; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20241231_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Tag723"
      unitRef="Shares">695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20241231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag679"
      unitRef="USDPerShare">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Tag748"
      unitRef="Shares">293000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag725"
      unitRef="USDPerShare">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag740"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag743"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Tag745"
      unitRef="Shares">188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag742"
      unitRef="USDPerShare">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20251231_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Tag724"
      unitRef="Shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag726"
      unitRef="USDPerShare">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag746"
      unitRef="Shares">292500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20241231_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag668"
      unitRef="Shares">292500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <vani:ShareBasedPaymentAwardPerformanceVestingCriteriaStockPriceTrigger
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag673"
      unitRef="USDPerShare">3.15</vani:ShareBasedPaymentAwardPerformanceVestingCriteriaStockPriceTrigger>
    <vani:ShareBasedPaymentAwardPerformanceVestingCriteriaThresholdConsecutiveTradingDays
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag732"
      unitRef="Pure">3</vani:ShareBasedPaymentAwardPerformanceVestingCriteriaThresholdConsecutiveTradingDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag670">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D20251231" id="Tag661">
&lt;p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zuFmQdKlrUl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The following table summarizes total stock-based compensation expense for stock options and RSUs, which is included in the statements of operations (in thousands).&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 71px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 10px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Year Ended &lt;span id="fs_79B6VBTGOG00000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_WE5JGDDLLC00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; border-bottom-color: black !important; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_589HS88GQ800000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 68%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Research and development&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zeObiswLzpRj" style="text-align: right; height: 15px; box-shadow: none; width: 13%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;833&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbeRt4FTGX52" style="text-align: right; height: 15px; box-shadow: none; width: 13%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,001&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zURiv2eTHBfj" style="text-align: right; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;651&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zwAWRq5UEBp5" style="text-align: right; border-bottom-width: 1pt; border-bottom-style: solid; height: 15px; box-shadow: none; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;609&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zSsgADCNEhQe" style="text-align: right; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,484&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231_zAEu7R9Ci34g" style="text-align: right; height: 16px; border-bottom: 2.8pt double #000000; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,610&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20251231_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Tag703"
      unitRef="USD">833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20241231_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Tag706"
      unitRef="USD">1001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20251231_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Tag704"
      unitRef="USD">651000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20241231_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Tag707"
      unitRef="USD">609000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag705"
      unitRef="USD">1484000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag708"
      unitRef="USD">1610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="I20251231_StockCompensationPlanMember"
      decimals="-5"
      id="Tag671"
      unitRef="USD">2000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="D20251231_StockCompensationPlanMember"
      id="Tag662">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="I20251231_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Tag672"
      unitRef="USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag663">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="D20251231" id="Tag678">
&lt;p id="xdx_898_ecustom--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTableTextBlock_zadq4clprso4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt; &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;The weighted-average grant-date fair value of options granted during the year ended December 31, 2025 and 2024 were $0.92 and $1.26, respectively. The assumptions used in the Black-Scholes model for stock options are as follows:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="height: 75px; width: 80%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: 0.25in;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="vertical-align: middle; height: 15px; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; vertical-align: middle; text-align: center; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: black !important; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_ZWL18FAK5S00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-align: center; height: 15px; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; vertical-align: middle; text-align: center; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: black !important; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_GPAB667KXC00000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; vertical-align: middle; text-align: center; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: black !important; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zrVyI2wxX7h2" title="Risk-free interest rate"&gt;3.81&lt;/span&gt;% to &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_z9TC14Vs8uJe" title="Risk-free interest rate"&gt;4.39&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zec0cOVOfEF4" title="Risk-free interest rate"&gt;3.79&lt;/span&gt;% &#x2013; &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z2UARH1Ja8Vf" title="Risk-free interest rate"&gt;5.53&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zUQZefBn2Zm3" title="Expected dividend yield"&gt;&lt;span id="fo0d797e0534c249bdb110f7f41b259bf7"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_z6SlCGr3ANqc" title="Expected dividend yield"&gt;&lt;span id="fo438947879e8f4b8390feb7975a5922a2"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zPiRhJApXgc2" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; background-color: #cceeff; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zNs8s78D4VV9" title="Expected volatility"&gt;100&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; background-color: #cceeff; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: middle; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; width: 65.9443%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Expected term&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zufPMDCxUa3g" title="Expected term::XDX::P4Y"&gt;5.25&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_znYjPks8oNY2" title="Expected term::XDX::P6Y2M12D"&gt;6.08&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 1.03199%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 15.9959%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_z36XRQzXgN0c" title="Expected term::XDX::P4Y2M30D"&gt;5.04&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zV4bkNBawPL1" title="Expected term::XDX::P6Y0M29D"&gt;6.08&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; width: 1.03199%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20251231_StockOptionsWithServiceVestingMember"
      decimals="2"
      id="Tag735"
      unitRef="USDPerShare">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20241231_StockOptionsWithServiceVestingMember"
      decimals="2"
      id="Tag736"
      unitRef="USDPerShare">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20251231_MinimumMember_EmployeeStockOptionMember"
      decimals="4"
      id="Tag693"
      unitRef="Pure">0.0381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20251231_MaximumMember_EmployeeStockOptionMember"
      decimals="4"
      id="Tag694"
      unitRef="Pure">0.0439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20241231_MinimumMember_EmployeeStockOptionMember"
      decimals="4"
      id="Tag698"
      unitRef="Pure">0.0379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20241231_MaximumMember_EmployeeStockOptionMember"
      decimals="4"
      id="Tag699"
      unitRef="Pure">0.0553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20251231_EmployeeStockOptionMember"
      id="Tag741"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20241231_EmployeeStockOptionMember"
      id="Tag734"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="D20251231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag695"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="D20241231_EmployeeStockOptionMember"
      decimals="2"
      id="Tag700"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D20251231_MinimumMember_EmployeeStockOptionMember"
      id="Tag696">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D20251231_MaximumMember_EmployeeStockOptionMember"
      id="Tag697">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D20241231_MinimumMember_EmployeeStockOptionMember"
      id="Tag701">P5Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D20241231_MaximumMember_EmployeeStockOptionMember"
      id="Tag702">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <vani:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitsValuationAssumptionsTableTextBlock contextRef="D20251231" id="Tag665">
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;The assumptions used to estimate the fair value of the performance-based restricted stock units granted during the year&lt;span&gt;s ended &lt;span id="fs_7HMVMBP3KG00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&#160;and &lt;span&gt;&lt;span id="fs_NCA553A4KW00000000000000000000fs"&gt;2024&lt;/span&gt;&lt;/span&gt; and valued using a Monte Carlo simulation were as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; t; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;div id="t_ft_SCA5Q1NNO000000000000000000000b"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="height: 96px; width: 100%; border-collapse: collapse; font-family: 'times new roman'; font-size: 10pt; margin: 0px; text-indent: 0px;" width="100%"&gt;
&lt;tbody&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td colspan="3" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="text-align: center; margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;b&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt;&lt;span style="border-right: none; border-left: none; font-family: 'times new roman', times;"&gt;Year Ended &lt;span id="fs_MUBKTO1VV400000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="text-align: center; margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;b&gt;&lt;span style="color: #000000;"&gt;&lt;span id="fs_RTP2TICWLC00000000000000000000fs"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;b&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="text-align: center; margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;b&gt;&lt;span style="color: #000000;"&gt;&lt;span id="fs_TPZOJ0LLTC00000000000000000000fs"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px; background-color: #cceeff;"&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; RSUs&#160;Granted &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px; text-align: center;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt; 292,500 &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 9pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; text-align: center; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt;"&gt; 292,500 &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none; width: 66%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; Valuation date stock price &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none; width: 16%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px; text-align: center;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;$1.03&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none; width: 1%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 9pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 10px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; width: 16%;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; text-align: center; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;$1.81&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 12px; background-color: #cceeff;"&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt; Risk-free interest rate &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px; text-align: center;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt; &lt;span style="border-left: none; border-right: none;"&gt;3.99%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="font-size: 9pt; color: #000000;"&gt; &#160; &lt;/span&gt;&lt;/p&gt;


&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 12px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;" valign="bottom"&gt;
&lt;p style="margin: 0px; font-size: 10pt; t; font-family: 'Times New Roman', serif; text-align: center; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt; &lt;span style="border-left: none; border-right: none;"&gt;4.53%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 12px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Expected divided yield&lt;/span&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 17px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px; background-color: #cceeff;"&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; height: 10px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background: #cceeff; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;Simulation term&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; text-align: center; box-shadow: none;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;4&#160;years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; height: 17px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;4&#160;y&lt;span style="color: #000000; font-family: 'times new roman', times; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;ears&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; padding: 0px; text-align: center; margin: 0px; text-indent: 0px; box-shadow: none; height: 17px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;


 &lt;/div&gt;


 </vani:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag747"
      unitRef="Shares">292500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20241231_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag688"
      unitRef="Shares">292500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag686"
      unitRef="USDPerShare">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="D20241231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag687"
      unitRef="USDPerShare">1.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="4"
      id="Tag682"
      unitRef="Pure">0.0399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20241231_RestrictedStockUnitsRSUMember"
      decimals="4"
      id="Tag692"
      unitRef="Pure">0.0453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag683"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20241231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag689"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag684"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="D20241231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag690"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag685">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D20241231_RestrictedStockUnitsRSUMember"
      id="Tag691">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      id="Tag669">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <vani:ShareBasedPaymentAwardForecastedStockPriceSpecifiedPeriodPerYear
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag744"
      unitRef="ITEM">252</vani:ShareBasedPaymentAwardForecastedStockPriceSpecifiedPeriodPerYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="-6"
      id="Tag666"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <vani:ShareBasedPaymentAwardPerformanceVestingCriteriaStockPriceTrigger
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Tag667"
      unitRef="USDPerShare">3.15</vani:ShareBasedPaymentAwardPerformanceVestingCriteriaStockPriceTrigger>
    <vani:ShareBasedPaymentAwardPerformanceVestingCriteriaThresholdConsecutiveTradingDays
      contextRef="D20251231_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag733"
      unitRef="Pure">3</vani:ShareBasedPaymentAwardPerformanceVestingCriteriaThresholdConsecutiveTradingDays>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="D20251231" id="Tag552">
&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_ztEPYdWPUMXi" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;11. &lt;span id="xdx_82A_zBmx9vDehCWc" style="line-height: inherit;"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt; &lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Due to the net losses in &lt;span id="fs_4CT79YKJF400000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt; and &lt;span id="fs_QSZNXZVPDS00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, the provision for income taxes consists only of minimum California franchise taxes presented in general and administrative expenses.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fs_G097OZAQGG00000000000000000000B"&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The loss from operations before income tax for the years ended &lt;span id="fs_7V133CILW000000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_G5MG482LQO00000000000000000000FM"&gt;2024&lt;/span&gt; are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_3IS49PRPSG00000000000000000000b"&gt;
&lt;table style="width: 100%; margin: 0px; border-collapse: collapse; height: 98px; font-family: 'times new roman'; font-size: 10pt; text-indent: 0px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; box-shadow: none; vertical-align: bottom; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_57EH2YGI8000000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; box-shadow: none; vertical-align: bottom; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_RW6O3TV2M800000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; box-shadow: none; vertical-align: bottom; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_IBRLVDD7A800000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px; background-color: #cceeff;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Pre-Tax Loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="width: 74%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;Domestic&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(24,910&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(22,450&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px; background-color: #cceeff;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;Foreign&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(1,699&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 0.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(1,037&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 0.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;Total&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;(26,609&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 1.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;(23,487&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 1.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;


 &lt;/div&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fs_R19JQLYVSG00000000000000000000B"&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The components of the income tax provision as for the year ended &lt;span id="fs_D2ZAAU05DS00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_PL4TJNHCKG00000000000000000000FM"&gt;2024&lt;/span&gt; are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_3PF49D1HZ400000000000000000000b"&gt;
&lt;table style="width: 100%; margin-left: 0.1px; border-collapse: collapse; height: 130px; font-family: 'times new roman'; font-size: 10pt;"&gt;
&lt;tbody&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="6" style="box-shadow: none; width: 24%; text-align: center; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_VW7LZTGHGW00000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td colspan="2" style="box-shadow: none; width: 11%; text-align: center; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_UPSMJP3AJK00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td colspan="2" style="box-shadow: none; width: 11%; text-align: center; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_033HN2VEWW00000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 10px;"&gt;
&lt;td style="box-shadow: none; width: 74%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;span style="font-weight: bold;"&gt;Income Tax Provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;Federal&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_K7ZFGL8N4W00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_MYHHXSEQ8000000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;Foreign&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_25DZPNVBF400000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_5OEH60QK4W00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;State&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_BY0P0BQKDS00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;2&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;Total&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_R3ZN27TYHS00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;2&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;


 &lt;/div&gt;


 &lt;/div&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;On July 4, 2025, the &lt;span id="fs_73BDMXQ7SW00000000000000000000fs"&gt;2025&lt;/span&gt; budget reconciliation bill, officially known as the &lt;span id="fs_3CUGP5FZSW00000000000000000000fs"&gt;One&lt;/span&gt; Big Beautiful Bill Act of &lt;span id="fs_L0LK763RY800000000000000000000fs"&gt;2025&lt;/span&gt; (the &#x201c;Act&#x201d;), was enacted into law. The Act includes a broad range of tax reforms such as deductions for domestic research and development expenditures and federal bonus depreciation. The Company has evaluated the provisions of the Act and determined that, because it maintains a full valuation allowance against its deferred tax assets, the Act does not have a material impact on the Company&#x2019;s condensed consolidated financial statements or effective tax rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fobda54c6b43f24f309d0607caf5be6d03"&gt;
&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzyFSfJrxEtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B1_zG1bURljiAY9" style="line-height: inherit; font-family: 'times new roman', times;"&gt;The components of deferred income assets and liabilities as of &lt;span id="fs_RZD75XJ3GW00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_WIK11ZTV6O00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 319px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_492_20231231_zGB0i75kRlUg" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td colspan="2" id="xdx_498_20221231_zlQDHO3CHDtl" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_FFEOE7SWG000000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_JNCL3NHRZ400000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_04T9EEI46O00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Deferred Tax:&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_iI_pn3n3_zRy1eW5MBpzj" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="width: 74%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;493&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;523&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_ziGffJAJYylc" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Capitalized R&amp;amp;E &#xa7;&lt;span id="fs_71OR5AIB5S00000000000000000000fs" style="display: inline;"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="foed5f4eaf2c1a4a10b4778d915adc99c7"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,722&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsRegulatoryAssetsAndLiabilities_iI_pn3n3_zNc6fJbtgk4g" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Lease ROU&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;455&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;379&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_z9ShI2DPS0ea" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,407&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,992&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_ztFF4pvFlBt7" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;65,351&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;52,588&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_z5ehlQkX0WJ3" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;R&amp;amp;D credit&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,261&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,459&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_zhx5BLwZgRc" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;77,967&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;71,663&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zbrzdhCa8eJc" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Investment in subsidiary&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(1,924&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(1,924&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredRevenueLeasesAccumulatedAmortization_iNI_pn3n3_di_zhhFEWMFDbae" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(216&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(158&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zoI9BiulhW6f" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(2,140&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(2,082&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zeicVnGtMKcl" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(75,827&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(69,581&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_zBHE39id6K8k" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total Deferred Tax Assets, Net&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fac967a0-f2a8-4b5f-9783-fe7dba559fcb"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn3n3_zhOa2A3hG7Sd" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Change in Valuation Allowance for the Year Ended&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,246&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;8,702&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;div id="fo5fb69b31ccc44a4380ceb0f156080c45"&gt;
&lt;p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zN1TxLyKnuLg" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B3_z8CEZ5Dkvgn7" style="line-height: inherit; font-family: 'times new roman', times;"&gt;The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands) for the year ended &lt;span id="fs_WYPRWUE05S00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_K45IJ7PGKG00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;:&lt;/span&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 183px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="14" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 51.3746%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;For the Year Ended &lt;span id="fs_5LEBBQGMKG00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="text-align: center; height: 10px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 24.5074%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_Q9PDJLHBGW00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 24.0649%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_ZGJU0NPZ9C00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="width: 46.9027%; text-align: left; padding: 0px 0px 1px; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Pre-tax loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_fKGEp_zhIFuC6iTgSd" style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(26,609&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.47493%; padding: 0px 0px 1.5px; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;)&lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1.76991%; padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231_fKGEp_zLKBKzh6yW57" style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(23,487&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.03245%; padding: 0px 0px 1.5px; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1.76991%; padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Federal tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20230101__20231231_zt1ht97xdRhb" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(5,588&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zfq3SwMwYqU8" style="line-height: inherit; font-family: 'times new roman', times;" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231_z8RhwcftPr59" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(4,932&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zwr4GpEi5jFd" style="line-height: inherit; font-family: 'times new roman', times;" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;State tax (benefit), net of federal tax benefit *&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20230101__20231231_zgPmm4ipullg" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fob0b265f9979e4dc7af1534de87fbda72"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.47493%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20230101__20231231_zuvLAJvjlokf" style="line-height: inherit; font-family: 'times new roman', times;" title="State tax (benefit), net of federal tax benefit (percent)"&gt;&lt;span id="foc1c573a97a5248f79a480009e910b1f1"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231_zNdl9MTOfg6e" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.03245%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zqCQi8s24d09" style="line-height: inherit; font-family: 'times new roman', times;" title="State tax (benefit), net of federal tax benefit (percent)"&gt;&lt;span id="fo6050a0ab3b244ed0a67bd9281bf9300f"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;R&amp;amp;D tax credit from current year&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20230101__20231231_zxrlaDZd4eKi" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;384&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20230101__20231231_zDPJs38wbrM5" style="line-height: inherit; font-family: 'times new roman', times;" title="R&amp;amp;D tax credit from current year (percent)"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231_ze5Yhmxow93j" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(1,911&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zUrTrsBLa5Sg" style="line-height: inherit; font-family: 'times new roman', times;" title="R&amp;amp;D tax credit from current year (percent)"&gt;8.1&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Non Deductible Items&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20230101__20231231_zp6VEgtvbPLk" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20230101__20231231_z4S9p3aD52j" style="line-height: inherit; font-family: 'times new roman', times;" title="Impact on effective rate of loss eliminated in consolidation (percent)"&gt;&lt;span style="border-left: none; border-right: none;"&gt;(0.1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231_zURGkFtaHCvl" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;14&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.03245%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20220101__20221231_zCZugICSd1N4" style="line-height: inherit; font-family: 'times new roman', times;" title="Impact on effective rate of loss eliminated in consolidation (percent)"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 46.9027%;"&gt;Foreign Tax Effects **&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;357&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.47493%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;(1.3)&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;218&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;(0.9)&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 46.9027%;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000;"&gt;Changes in unrecognized tax benefits&lt;/span&gt; &lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_9IVAUOUBU800000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.47493%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_B3USMI2L8G00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.76991%;"&gt;%&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_Q5DE3Z6WCW00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_G2J1OB6HM800000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.76991%;"&gt;%&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Other&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20230101__20231231_z4R5qEQunaTj" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(4&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt;)&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20230101__20231231_zSwyJCgves6j" style="line-height: inherit; font-family: 'times new roman', times;" title="Other (percent)"&gt;&lt;span id="fo698bd17ca2254d72b45f3440afe986e2"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231_z48dF0ZLk3uf" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(42&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt;)&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231_zLx4l3YJQyG" style="line-height: inherit; font-family: 'times new roman', times;" title="Other percent"&gt;0.2&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20230101__20231231_zSGLqZGU4igl" style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;4,839&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20230101__20231231_zdYh2eYv6lbf" style="line-height: inherit; font-family: 'times new roman', times;" title="Change in valuation allowance (percent)"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231_zaw6h6Th9JB9" style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,653&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231_zt5EbcIA3m6e" style="line-height: inherit; font-family: 'times new roman', times;" title="Change in valuation allowance (percent)"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20230101__20231231_zh1uKGKWrcq9" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_0XGAVOZZ5S00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20230101__20231231_zxtvuenSmCB7" style="line-height: inherit; font-family: 'times new roman', times;" title="Total provision for income taxes (percent)"&gt;&lt;span id="fo10785f988f954fc8bf3049809b0104ab"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231_zuezAPUohlK7" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zgLBnWDZfUkk" style="line-height: inherit; font-family: 'times new roman', times;" title="Total provision for income taxes (percent)"&gt;&lt;span id="fod40ed7e195af4d11870664170e99ec24"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2pt; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px; text-align: left;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px; text-align: left;"&gt;* State taxes in California comprised the majority (greater than &lt;span style="-sec-ix-hidden:Tag25"&gt;50&lt;/span&gt; percent) of the tax effect in this category&lt;br/&gt;** &lt;span&gt;&lt;span style="border-right: none; border-left: none;"&gt;&lt;span style="border-right: none; border-left: none;"&gt;&lt;span style="border-right: none; border-left: none;"&gt;Foreign tax in Switzerland comprised the majority (greater than &lt;span style="border-left: none; border-right: none;"&gt;50&lt;/span&gt; percent) of the tax effect in this category&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/div&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 10pt 0pt 0pt; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. Based on this evaluation, as of &lt;span id="fs_A4LYJH71S000000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_IUM4R3QP8W00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, a full valuation allowance&lt;span style="font-size: 10pt;"&gt; has been recorded because deferred tax assets have been assessed to be less than &#x201c;more likely than not&#x201d; to be realized.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 8pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo22c4a3d0623b4021b9fbb8fee7386828" style="line-height: 1.2;"&gt;
&lt;p id="xdx_895_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zbhF0zFXa6N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B8_z9jvU6y9Uxuk" style="line-height: inherit; font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10pt;"&gt;As&lt;/span&gt; of &lt;span id="fs_8L22OTOFIO00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;, we had federal and apportioned state net operating loss (&#x201c;NOL&#x201d;) and federal and state R&amp;amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 141px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20231231_zMHjNJDdZgic" style="white-space: nowrap; font-weight: bold; text-align: center; height: 10px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; vertical-align: bottom;" valign="bottom"&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_0PLM3ICGZK00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn3n3_zfRl0Yn34PO5" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Pre TCJA (Tax Cuts and Jobs Acts of &lt;span id="fs_IFIMPPEOTC00000000000000000000fs" style="display: inline;"&gt;2017&lt;/span&gt;) period federal NOL carry-forward, begin expiring &lt;span id="fs_891IRKHF9S00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;47,353&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn3n3_zsWm2Krl0cti" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 1px; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Post TCJA period federal NOL carry-forward, with no carry-forward limitation&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;206,727&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_ziw34Z7MKf5k" style="vertical-align: bottom; background-color: #cceeff; height: 10px;"&gt;
&lt;td style="text-align: left; padding: 0px; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total federal NOL carry-forward&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;254,080&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; width: 87%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; width: 10%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_zGEuwEhV2jH8" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt; State NOL carry-forward, begin expiring &lt;span id="fs_W9BD5FXPWW00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;167,590&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_zHLlbo8OovKf" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Federal R&amp;amp;D tax credit carry-forward, begin expiring in &lt;span id="fs_QTCEZPLL4000000000000000000000fs" style="display: inline;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;4,428&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_zYc9tMWen8K8" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;State R&amp;amp;D carry-forward, no expiration date&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,048&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt; Reserve for uncertain income tax positions&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_VE3AUVROTS00000000000000000000fs"&gt;&lt;span id="fs_WLPI4EEWOW00000000000000000000fs"&gt;Nil&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;As of &lt;span id="fs_F8XCQ5C3KW00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, the Company has Federal and California research and development credit carryforwards of $4.4 &lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsOther_iI_dm_c20231231_zh8CtU036Kni" style="line-height: inherit;" title="Research tax credit carryfowarrds for federal state"&gt;million&lt;/span&gt; and $9.0 &lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_dm_c20231231_zFvQR1i3eHHi" style="line-height: inherit;" title="Research tax credit carryfowarrds for california state"&gt;million&lt;/span&gt;, respectively. The Federal research and development credit carryforwards will expire beginning in 2036 if not utilized. The California research and development credits have no expiration date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-align: justify; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Under recently enacted U.S. tax legislation, although the treatment of tax losses generated in taxable years ending before December 31, 2017, has generally not changed, tax losses generated in taxable years beginning after December 31, 2017, may only be utilized to offset &lt;span id="fs_2OYBDD3WJ400000000000000000000fs" style="display: inline;"&gt;80&lt;/span&gt;% of taxable income annually. This change may require NPM and Legacy SSMP to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;To the extent that each of the tax filers continue to generate taxable losses, unused losses will carry-forward to offset future taxable income, if any, until these unused losses expire. However, the tax filers may be unable to use these losses to offset taxable income before our unused losses expire at various dates that range from &lt;span id="fs_IBYMZUU6DC00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt; through &lt;span id="fs_KRBEH5Y6DC00000000000000000000fs" style="display: inline;"&gt;2037&lt;/span&gt; for federal net operating losses ("NOLs") generated before &lt;span id="fs_4ITDSJT0SG00000000000000000000fs" style="display: inline;"&gt;2018&lt;/span&gt;. Federal net operating losses generated for year &lt;span id="fs_H191MUU8CG00000000000000000000fs" style="display: inline;"&gt;2018&lt;/span&gt; and forward do not expire. State net operating losses expire from &lt;span id="fs_8Q92LABXNK00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt; through &lt;span id="fs_LXK34PAV6800000000000000000000fs" style="display: inline;"&gt;2042&lt;/span&gt;. Under Section &lt;span id="fs_VAEY9N9YFK00000000000000000000fs" style="display: inline;"&gt;382&lt;/span&gt; of the Internal Revenue Code of &lt;span id="fs_C6BENK8FCW00000000000000000000fs" style="display: inline;"&gt;1986&lt;/span&gt;, as amended, or the Code, if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than &lt;span id="fs_KH001QFT5C00000000000000000000fs" style="display: inline;"&gt;50&lt;/span&gt; percentage point change (by value) in its equity ownership over a &lt;span id="fs_BIGDAFHS9C00000000000000000000fs" style="display: inline;"&gt;three&lt;/span&gt;-year period, the corporation&#x2019;s ability to use its pre-change NOL carry-forwards to offset its post-change taxable income may be limited. Limitations may also apply to the utilization of other pre-change tax attributes as a result of an ownership change.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt; &lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Second Sight Medical Products, Inc. experienced an &#x201c;ownership change&#x201d; within the meaning of Section &lt;span id="fs_E6PBJX55WG00000000000000000000fs" style="display: inline;"&gt;382&lt;/span&gt;(g) of the Code during the third quarter of &lt;span id="fs_S787N2LHB400000000000000000000fs" style="display: inline;"&gt;2022&lt;/span&gt; as a result of the merger. The ownership change will subject its net operating loss carry-forwards to an annual limitation, which will significantly restrict its ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the Internal Revenue Service. We have not yet fully analyzed the available information to determine the amount of the annual limitation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fo48eee52353034624b62d702f17f847d6" style="line-height: 1.2;"&gt;
&lt;p id="xdx_89F_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zCraDt5ndhE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_8B1_z470o8qIzTy1" style="line-height: inherit;"&gt;The Company has the following activity relating to unrecognized tax benefits (in thousands):&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 117px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_495_20230101__20231231_zpLYYSd1vgj1" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td colspan="3" id="xdx_49F_20220101__20221231_ztqTc920eqD" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Year Ended &lt;span id="fs_K16J547GZK00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_SW3UEYNFDC00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_L08GAX6QWG00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefits_iS_zgRwX3QcT144" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,364&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,692&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zCjyLg9a6Tob" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="width: 74%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Increases based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;299&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;648&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zZL9WmFXqs5a" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Increases based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(348&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;24&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_zZSSD90u2mrg" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Reductions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefits_iE_zdFGLR6YBwVe" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding: 0px 0px 2px; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,315&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,364&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;

&lt;p id="xdx_8AC_zcn1JFiw6tql" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt; &lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;As of &lt;span id="fs_C2Y5566VUO00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;, the Company had $2.3 million of unrecognized tax benefits which are comprised of federal of $0.9 million and California of $1.4 million. The Company&#x2019;s unrecognized gross tax benefits would not reduce its annual effective tax rate if recognized because the Company has recorded a full valuation allowance on deferred tax assets. The Company does not foresee any material changes to its gross unrecognized tax benefit within the next &lt;span id="fs_XEFZ3B24Y800000000000000000000fs" style="display: inline;"&gt;12&lt;/span&gt; months. The Company recognizes interest and/or penalties related to income tax matters in income tax expense. The Company did not recognize any accrued interest and penalties related to gross unrecognized tax benefits related to the year ended &lt;span id="fs_K955C4OQAO00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_B02I0C97RK00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;. All years are open for examination by federal and state authorities. The Company currently has no federal or state tax examinations in progress. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Beginning January 1, 2022, we are required to capitalize certain research and development expenditures in accordance with section &lt;span id="fs_Z8Q1D8SVQO00000000000000000000fs" style="display: inline;"&gt;174&lt;/span&gt; of the Internal Revenue Code, as amended by the Tax Cuts and Jobs Act of &lt;span id="fs_H3736BAGY800000000000000000000fs" style="display: inline;"&gt;2017&lt;/span&gt;, instead of previously being allowed to expense. Amortization of such capitalized expenditures are allowed over a &lt;span id="fs_W2RC69VC5C00000000000000000000fs" style="display: inline;"&gt;5&lt;/span&gt;-year period if incurred in the U.S. or a &lt;span id="fs_HB2B80WLM800000000000000000000fs" style="display: inline;"&gt;15&lt;/span&gt;-year period if incurred outside the United States.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt; &lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;We file income tax returns in the U.S. federal jurisdiction and various states and are subject to income tax examinations by federal tax authorities for tax years ended &lt;span id="fs_1Z56IXKPFK00000000000000000000fs" style="display: inline;"&gt;2017&lt;/span&gt; and later and by state authorities for tax years ended &lt;span id="fs_VACAW84G8W00000000000000000000fs" style="display: inline;"&gt;2016&lt;/span&gt; and later. We currently are not under examination by any tax authority. Our policy is to record interest and penalties on uncertain tax positions as income tax expense. As of &lt;span id="fs_9ORVLXDK1C00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_DTKCG7ZQAO00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, we have &lt;span id="xdx_900_eus-gaap--UnrecognizedTaxBenefitsPeriodIncreaseDecrease_do_c20230101__20231231_zMMqWOKbbQxj" style="line-height: inherit;" title="Uncertain tax positions"&gt;&lt;span id="xdx_905_eus-gaap--UnrecognizedTaxBenefitsPeriodIncreaseDecrease_do_c20220101__20221231_zMOhfcwaioB3" style="line-height: inherit;" title="Uncertain tax positions"&gt;no&lt;/span&gt;&lt;/span&gt; accrued interest or penalties related to uncertain tax positions. Second Sight Switzerland, our foreign subsidiary, has not had any taxable income in the prior and current years.&lt;/span&gt;&lt;/p&gt;


 </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="D20251231" id="Tag555">
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The loss from operations before income tax for the years ended &lt;span id="fs_7V133CILW000000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_G5MG482LQO00000000000000000000FM"&gt;2024&lt;/span&gt; are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_3IS49PRPSG00000000000000000000b"&gt;
&lt;table style="width: 100%; margin: 0px; border-collapse: collapse; height: 98px; font-family: 'times new roman'; font-size: 10pt; text-indent: 0px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; box-shadow: none; vertical-align: bottom; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_57EH2YGI8000000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; box-shadow: none; vertical-align: bottom; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_RW6O3TV2M800000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; box-shadow: none; vertical-align: bottom; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_IBRLVDD7A800000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding-left: 0px; padding-right: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px; background-color: #cceeff;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Pre-Tax Loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 10px;"&gt;
&lt;td style="width: 74%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;Domestic&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(24,910&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(22,450&lt;/td&gt;
&lt;td style="width: 1%; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px; background-color: #cceeff;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;Foreign&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(1,699&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 0.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;(1,037&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 0.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 17px;"&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;Total&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;(26,609&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 1.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; vertical-align: bottom; padding: 0px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;" valign="bottom"&gt;(23,487&lt;/td&gt;
&lt;td style="box-shadow: none; padding: 0px 0px 1.5px; margin: 0px; text-indent: 0px; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;


 </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="D20251231"
      decimals="-3"
      id="Tag604"
      unitRef="USD">-24910000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="D20241231"
      decimals="-3"
      id="Tag605"
      unitRef="USD">-22450000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="D20251231"
      decimals="-3"
      id="Tag603"
      unitRef="USD">-1699000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="D20241231"
      decimals="-3"
      id="Tag606"
      unitRef="USD">-1037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20251231"
      decimals="-3"
      id="Tag639"
      unitRef="USD">-26609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20241231"
      decimals="-3"
      id="Tag607"
      unitRef="USD">-23487000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="D20251231" id="Tag556">
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The components of the income tax provision as for the year ended &lt;span id="fs_D2ZAAU05DS00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_PL4TJNHCKG00000000000000000000FM"&gt;2024&lt;/span&gt; are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_3PF49D1HZ400000000000000000000b"&gt;
&lt;table style="width: 100%; margin-left: 0.1px; border-collapse: collapse; height: 130px; font-family: 'times new roman'; font-size: 10pt;"&gt;
&lt;tbody&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="6" style="box-shadow: none; width: 24%; text-align: center; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_VW7LZTGHGW00000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td colspan="2" style="box-shadow: none; width: 11%; text-align: center; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_UPSMJP3AJK00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;/td&gt;
&lt;td colspan="2" style="box-shadow: none; width: 11%; text-align: center; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span id="fs_033HN2VEWW00000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 10px;"&gt;
&lt;td style="box-shadow: none; width: 74%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;span style="font-weight: bold;"&gt;Income Tax Provision&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 10px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;Federal&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_K7ZFGL8N4W00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_MYHHXSEQ8000000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;Foreign&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_25DZPNVBF400000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; text-align: right; margin-left: 0.1px; height: 15px;"&gt;&lt;span id="fs_5OEH60QK4W00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;State&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_BY0P0BQKDS00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;2&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; background-color: #cceeff; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="margin-left: 0.1px; height: 15px;"&gt;
&lt;td style="box-shadow: none; width: 74%; margin-left: 0.1px; height: 15px;"&gt;Total&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_R3ZN27TYHS00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; width: 10%; text-align: right; margin-left: 0.1px; height: 15px; border-top-width: 1pt; border-top-style: solid; border-top-color: #000000 !important; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;2&lt;/td&gt;
&lt;td style="box-shadow: none; width: 1%; margin-left: 0.1px; height: 15px;"&gt;&lt;br/&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 &lt;/div&gt;


 </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="D20251231"
      id="Tag623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="D20241231"
      id="Tag611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="D20251231"
      id="Tag622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="D20241231"
      id="Tag610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="D20251231"
      id="Tag638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="D20241231"
      decimals="-3"
      id="Tag608"
      unitRef="USD">2000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20251231"
      id="Tag637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20241231"
      decimals="-3"
      id="Tag609"
      unitRef="USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="D20251231" id="Tag550">
&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzyFSfJrxEtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B1_zG1bURljiAY9" style="line-height: inherit; font-family: 'times new roman', times;"&gt;The components of deferred income assets and liabilities as of &lt;span id="fs_RZD75XJ3GW00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_WIK11ZTV6O00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt; are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 319px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_492_20231231_zGB0i75kRlUg" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td colspan="2" id="xdx_498_20221231_zlQDHO3CHDtl" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_FFEOE7SWG000000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_JNCL3NHRZ400000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_04T9EEI46O00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Deferred Tax:&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_iI_pn3n3_zRy1eW5MBpzj" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="width: 74%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;493&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;523&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_ziGffJAJYylc" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Capitalized R&amp;amp;E &#xa7;&lt;span id="fs_71OR5AIB5S00000000000000000000fs" style="display: inline;"&gt;174&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="foed5f4eaf2c1a4a10b4778d915adc99c7"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,722&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsRegulatoryAssetsAndLiabilities_iI_pn3n3_zNc6fJbtgk4g" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Lease ROU&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;455&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;379&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_z9ShI2DPS0ea" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,407&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,992&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_ztFF4pvFlBt7" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;65,351&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;52,588&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_z5ehlQkX0WJ3" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;R&amp;amp;D credit&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,261&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,459&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_iI_pn3n3_zhx5BLwZgRc" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;77,967&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;71,663&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_iNI_pn3n3_di_zbrzdhCa8eJc" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Investment in subsidiary&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(1,924&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(1,924&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredRevenueLeasesAccumulatedAmortization_iNI_pn3n3_di_zhhFEWMFDbae" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(216&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(158&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNI_pn3n3_di_zoI9BiulhW6f" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(2,140&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(2,082&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_zeicVnGtMKcl" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Valuation Allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(75,827&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 15px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(69,581&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iI_pn3n3_zBHE39id6K8k" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total Deferred Tax Assets, Net&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fac967a0-f2a8-4b5f-9783-fe7dba559fcb"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pn3n3_zhOa2A3hG7Sd" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Change in Valuation Allowance for the Year Ended&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,246&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;8,702&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="I20251231"
      decimals="-3"
      id="Tag582"
      unitRef="USD">493000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="I20241231"
      decimals="-3"
      id="Tag569"
      unitRef="USD">523000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="I20251231"
      id="Tag624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="I20241231"
      decimals="-3"
      id="Tag563"
      unitRef="USD">6722000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="I20251231"
      decimals="-3"
      id="Tag583"
      unitRef="USD">455000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="I20241231"
      decimals="-3"
      id="Tag570"
      unitRef="USD">379000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="I20251231"
      decimals="-3"
      id="Tag584"
      unitRef="USD">2407000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="I20241231"
      decimals="-3"
      id="Tag567"
      unitRef="USD">1992000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:OperatingLossCarryforwards
      contextRef="I20251231"
      decimals="-3"
      id="Tag585"
      unitRef="USD">65351000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="I20241231"
      decimals="-3"
      id="Tag568"
      unitRef="USD">52588000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="I20251231"
      decimals="-3"
      id="Tag586"
      unitRef="USD">9261000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="I20241231"
      decimals="-3"
      id="Tag565"
      unitRef="USD">9459000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="I20251231"
      decimals="-3"
      id="Tag587"
      unitRef="USD">77967000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="I20241231"
      decimals="-3"
      id="Tag564"
      unitRef="USD">71663000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="I20251231"
      decimals="-3"
      id="Tag617"
      unitRef="USD">1924000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="I20241231"
      decimals="-3"
      id="Tag577"
      unitRef="USD">1924000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="I20251231"
      decimals="-3"
      id="Tag618"
      unitRef="USD">216000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="I20241231"
      decimals="-3"
      id="Tag579"
      unitRef="USD">158000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="I20251231"
      decimals="-3"
      id="Tag616"
      unitRef="USD">2140000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="I20241231"
      decimals="-3"
      id="Tag578"
      unitRef="USD">2082000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="I20251231"
      decimals="-3"
      id="Tag651"
      unitRef="USD">75827000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="I20241231"
      decimals="-3"
      id="Tag571"
      unitRef="USD">69581000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="I20251231"
      id="Tag625"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="I20241231"
      id="Tag580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="I20251231"
      decimals="-3"
      id="Tag650"
      unitRef="USD">6246000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="I20241231"
      decimals="-3"
      id="Tag562"
      unitRef="USD">8702000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="D20251231" id="Tag549">
&lt;p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zN1TxLyKnuLg" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B3_z8CEZ5Dkvgn7" style="line-height: inherit; font-family: 'times new roman', times;"&gt;The reconciliation of income tax computed at the expected U.S. federal statutory tax rate of 21% to income tax expense (benefit) and the corresponding rate from operations consist of the following (in thousands) for the year ended &lt;span id="fs_WYPRWUE05S00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_K45IJ7PGKG00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;:&lt;/span&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 183px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="14" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 51.3746%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;For the Year Ended &lt;span id="fs_5LEBBQGMKG00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="text-align: center; height: 10px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 24.5074%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_Q9PDJLHBGW00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; width: 24.0649%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_ZGJU0NPZ9C00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: center; height: 15px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="height: 15px; box-shadow: none; width: 11%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="width: 46.9027%; text-align: left; padding: 0px 0px 1px; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Pre-tax loss&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_fKGEp_zhIFuC6iTgSd" style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(26,609&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.47493%; padding: 0px 0px 1.5px; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;)&lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1.76991%; padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20220101__20221231_fKGEp_zLKBKzh6yW57" style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(23,487&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.03245%; padding: 0px 0px 1.5px; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1.03245%; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;
&lt;td style="width: 1.76991%; padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none; background-color: #cceeff;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 46.9027%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 16px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; box-shadow: none; width: 10%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none; width: 1.76991%;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Federal tax (benefit) at statutory rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20230101__20231231_zt1ht97xdRhb" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(5,588&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zfq3SwMwYqU8" style="line-height: inherit; font-family: 'times new roman', times;" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_c20220101__20221231_z8RhwcftPr59" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(4,932&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zwr4GpEi5jFd" style="line-height: inherit; font-family: 'times new roman', times;" title="Federal tax (benefit) at statutory rate (percent)"&gt;21.0&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;State tax (benefit), net of federal tax benefit *&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20230101__20231231_zgPmm4ipullg" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fob0b265f9979e4dc7af1534de87fbda72"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.47493%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20230101__20231231_zuvLAJvjlokf" style="line-height: inherit; font-family: 'times new roman', times;" title="State tax (benefit), net of federal tax benefit (percent)"&gt;&lt;span id="foc1c573a97a5248f79a480009e910b1f1"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_pn3n3_c20220101__20221231_zNdl9MTOfg6e" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.03245%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_c20220101__20221231_zqCQi8s24d09" style="line-height: inherit; font-family: 'times new roman', times;" title="State tax (benefit), net of federal tax benefit (percent)"&gt;&lt;span id="fo6050a0ab3b244ed0a67bd9281bf9300f"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;R&amp;amp;D tax credit from current year&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20230101__20231231_zxrlaDZd4eKi" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;384&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20230101__20231231_zDPJs38wbrM5" style="line-height: inherit; font-family: 'times new roman', times;" title="R&amp;amp;D tax credit from current year (percent)"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_pn3n3_c20220101__20221231_ze5Yhmxow93j" style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(1,911&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;)&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_c20220101__20221231_zUrTrsBLa5Sg" style="line-height: inherit; font-family: 'times new roman', times;" title="R&amp;amp;D tax credit from current year (percent)"&gt;8.1&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Non Deductible Items&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20230101__20231231_zp6VEgtvbPLk" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20230101__20231231_z4S9p3aD52j" style="line-height: inherit; font-family: 'times new roman', times;" title="Impact on effective rate of loss eliminated in consolidation (percent)"&gt;&lt;span style="border-left: none; border-right: none;"&gt;(0.1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_pn3n3_c20220101__20221231_zURGkFtaHCvl" style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;14&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.03245%;"&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; width: 10%;"&gt;&lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_pid_dp_uPure_c20220101__20221231_zCZugICSd1N4" style="line-height: inherit; font-family: 'times new roman', times;" title="Impact on effective rate of loss eliminated in consolidation (percent)"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 16px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 46.9027%;"&gt;Foreign Tax Effects **&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;357&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.47493%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;(1.3)&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;218&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; background-color: #cceeff; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; background-color: #cceeff; width: 10%;"&gt;(0.9)&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 46.9027%;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman', serif; color: #000000;"&gt;Changes in unrecognized tax benefits&lt;/span&gt; &lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_9IVAUOUBU800000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.47493%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_B3USMI2L8G00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.76991%;"&gt;%&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_Q5DE3Z6WCW00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="box-shadow: none; height: 16px; width: 1.03245%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1%;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; box-shadow: none; height: 16px; width: 10%;"&gt;&lt;span id="fs_G2J1OB6HM800000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; box-shadow: none; height: 16px; width: 1.76991%;"&gt;%&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Other&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20230101__20231231_z4R5qEQunaTj" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(4&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt;)&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20230101__20231231_zSwyJCgves6j" style="line-height: inherit; font-family: 'times new roman', times;" title="Other (percent)"&gt;&lt;span id="fo698bd17ca2254d72b45f3440afe986e2"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--IncomeTaxReconciliationTaxContingenciesOther_pn3n3_c20220101__20221231_z48dF0ZLk3uf" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(42&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt;)&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%;"&gt;&lt;span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_pid_dp_uPure_c20220101__20221231_zLx4l3YJQyG" style="line-height: inherit; font-family: 'times new roman', times;" title="Other percent"&gt;0.2&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 10px; box-shadow: none; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20230101__20231231_zSGLqZGU4igl" style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;4,839&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20230101__20231231_zdYh2eYv6lbf" style="line-height: inherit; font-family: 'times new roman', times;" title="Change in valuation allowance (percent)"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_c20220101__20221231_zaw6h6Th9JB9" style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;6,653&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; width: 10%; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span id="xdx_907_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_pid_dp_uPure_c20220101__20221231_zt5EbcIA3m6e" style="line-height: inherit; font-family: 'times new roman', times;" title="Change in valuation allowance (percent)"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff; width: 46.9027%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20230101__20231231_zh1uKGKWrcq9" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="fs_0XGAVOZZ5S00000000000000000000FM"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.47493%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20230101__20231231_zxtvuenSmCB7" style="line-height: inherit; font-family: 'times new roman', times;" title="Total provision for income taxes (percent)"&gt;&lt;span id="fo10785f988f954fc8bf3049809b0104ab"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_pn3n3_c20220101__20221231_zuezAPUohlK7" style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none; background-color: #cceeff; width: 1.03245%;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; background-color: #cceeff; width: 1%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; background-color: #cceeff; width: 10%; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_zgLBnWDZfUkk" style="line-height: inherit; font-family: 'times new roman', times;" title="Total provision for income taxes (percent)"&gt;&lt;span id="fod40ed7e195af4d11870664170e99ec24"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2pt; height: 10px; box-shadow: none; background-color: #cceeff; width: 1.76991%;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;%&lt;/span&gt;&lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px; text-align: left;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px; text-align: left;"&gt;* State taxes in California comprised the majority (greater than &lt;span style="-sec-ix-hidden:Tag25"&gt;50&lt;/span&gt; percent) of the tax effect in this category&lt;br/&gt;** &lt;span&gt;&lt;span style="border-right: none; border-left: none;"&gt;&lt;span style="border-right: none; border-left: none;"&gt;&lt;span style="border-right: none; border-left: none;"&gt;Foreign tax in Switzerland comprised the majority (greater than &lt;span style="border-left: none; border-right: none;"&gt;50&lt;/span&gt; percent) of the tax effect in this category&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;


 </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="D20241231"
      decimals="2"
      id="Tag14"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="D20251231"
      decimals="2"
      id="Tag553"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20251231"
      decimals="-3"
      id="Tag648"
      unitRef="USD">-26609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20241231"
      decimals="-3"
      id="Tag649"
      unitRef="USD">-23487000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="D20251231"
      decimals="-3"
      id="Tag588"
      unitRef="USD">-5588000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="D20251231"
      decimals="3"
      id="Tag599"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="D20241231"
      decimals="-3"
      id="Tag566"
      unitRef="USD">-4932000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="D20241231"
      decimals="3"
      id="Tag576"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="D20251231"
      id="Tag635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="D20251231"
      id="Tag628"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="D20241231"
      decimals="-3"
      id="Tag621"
      unitRef="USD">2000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="D20241231"
      id="Tag629"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="D20251231"
      decimals="-3"
      id="Tag619"
      unitRef="USD">-384000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="D20251231"
      decimals="3"
      id="Tag620"
      unitRef="Pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="D20241231"
      decimals="-3"
      id="Tag597"
      unitRef="USD">1911000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="D20241231"
      decimals="3"
      id="Tag598"
      unitRef="Pure">-0.081</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag612"
      unitRef="USD">12000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="D20251231"
      decimals="3"
      id="Tag613"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag614"
      unitRef="USD">14000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="D20241231"
      decimals="3"
      id="Tag615"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="D20251231"
      decimals="-3"
      id="Tag654"
      unitRef="USD">357000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="D20251231"
      decimals="3"
      id="Tag655"
      unitRef="Pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="D20241231"
      decimals="-3"
      id="Tag656"
      unitRef="USD">218000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="D20241231"
      decimals="3"
      id="Tag657"
      unitRef="Pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="D20251231"
      id="Tag626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="D20251231"
      id="Tag627"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="D20241231"
      id="Tag633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies
      contextRef="D20241231"
      id="Tag632"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="D20251231"
      decimals="-3"
      id="Tag644"
      unitRef="USD">-4000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="D20251231"
      id="Tag647"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="D20241231"
      decimals="-3"
      id="Tag645"
      unitRef="USD">-42000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="D20241231"
      decimals="3"
      id="Tag646"
      unitRef="Pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="D20251231"
      decimals="-3"
      id="Tag602"
      unitRef="USD">4839000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="D20251231"
      decimals="3"
      id="Tag642"
      unitRef="Pure">-0.182</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="D20241231"
      decimals="-3"
      id="Tag600"
      unitRef="USD">6653000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="D20241231"
      decimals="3"
      id="Tag643"
      unitRef="Pure">-0.283</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="D20251231"
      id="Tag636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="D20251231"
      id="Tag630"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="D20241231"
      decimals="-3"
      id="Tag601"
      unitRef="USD">2000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="D20241231"
      id="Tag631"
      unitRef="Pure"
      xsi:nil="true"/>
    <vani:DescriptionOfEffectiveIncomeTaxRateReconciliationForeignJuridictionContributionGreaterThan50PercentTaxEffect contextRef="D20251231_CH_1" id="Tag658">Foreign tax in Switzerland comprised the majority (greater than 50 percent) of the tax effect in this category </vani:DescriptionOfEffectiveIncomeTaxRateReconciliationForeignJuridictionContributionGreaterThan50PercentTaxEffect>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="D20251231" id="Tag551">
&lt;p id="xdx_895_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zbhF0zFXa6N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B8_z9jvU6y9Uxuk" style="line-height: inherit; font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10pt;"&gt;As&lt;/span&gt; of &lt;span id="fs_8L22OTOFIO00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;, we had federal and apportioned state net operating loss (&#x201c;NOL&#x201d;) and federal and state R&amp;amp;D credit carry-forwards available to offset future taxable income and income taxes as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 141px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20231231_zMHjNJDdZgic" style="white-space: nowrap; font-weight: bold; text-align: center; height: 10px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; vertical-align: bottom;" valign="bottom"&gt;
&lt;p style="margin-top: 0; margin-bottom: 0;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_0PLM3ICGZK00000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


 &lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn3n3_zfRl0Yn34PO5" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Pre TCJA (Tax Cuts and Jobs Acts of &lt;span id="fs_IFIMPPEOTC00000000000000000000fs" style="display: inline;"&gt;2017&lt;/span&gt;) period federal NOL carry-forward, begin expiring &lt;span id="fs_891IRKHF9S00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;47,353&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn3n3_zsWm2Krl0cti" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding: 0px 0px 1px; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Post TCJA period federal NOL carry-forward, with no carry-forward limitation&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;206,727&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_ziw34Z7MKf5k" style="vertical-align: bottom; background-color: #cceeff; height: 10px;"&gt;
&lt;td style="text-align: left; padding: 0px; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Total federal NOL carry-forward&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;254,080&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; width: 87%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 16px; width: 10%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsStateTaxes_iI_pn3n3_zGEuwEhV2jH8" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt; State NOL carry-forward, begin expiring &lt;span id="fs_W9BD5FXPWW00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;167,590&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_iI_pn3n3_zHLlbo8OovKf" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Federal R&amp;amp;D tax credit carry-forward, begin expiring in &lt;span id="fs_QTCEZPLL4000000000000000000000fs" style="display: inline;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;4,428&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_zYc9tMWen8K8" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;State R&amp;amp;D carry-forward, no expiration date&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;9,048&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt; Reserve for uncertain income tax positions&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_VE3AUVROTS00000000000000000000fs"&gt;&lt;span id="fs_WLPI4EEWOW00000000000000000000fs"&gt;Nil&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt; &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 </us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="I20251231"
      decimals="-3"
      id="Tag589"
      unitRef="USD">47353000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="I20251231"
      decimals="-3"
      id="Tag590"
      unitRef="USD">206727000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="I20251231"
      decimals="-3"
      id="Tag591"
      unitRef="USD">254080000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="I20251231"
      decimals="-3"
      id="Tag592"
      unitRef="USD">167590000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="I20251231"
      decimals="-3"
      id="Tag593"
      unitRef="USD">4428000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="I20251231"
      decimals="-3"
      id="Tag594"
      unitRef="USD">9048000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="I20251231"
      id="Tag560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="I20251231_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Tag652"
      unitRef="USD">4400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="I20251231_CaliforniaFranchiseTaxBoardMember"
      decimals="-5"
      id="Tag653"
      unitRef="USD">9000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <vani:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpiryPeriod
      contextRef="D20251231_InternalRevenueServiceIRSMember"
      id="Tag554">beginning in 2036</vani:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentExpiryPeriod>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="D20251231" id="Tag548">
&lt;p id="xdx_89F_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zCraDt5ndhE4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="xdx_8B1_z470o8qIzTy1" style="line-height: inherit;"&gt;The Company has the following activity relating to unrecognized tax benefits (in thousands):&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 117px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td id="xdx_495_20230101__20231231_zpLYYSd1vgj1" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td colspan="3" id="xdx_49F_20220101__20221231_ztqTc920eqD" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="6" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Year Ended &lt;span id="fs_K16J547GZK00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_SW3UEYNFDC00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 10px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span id="fs_L08GAX6QWG00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 10px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--UnrecognizedTaxBenefits_iS_zgRwX3QcT144" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,364&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;1,692&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zCjyLg9a6Tob" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="width: 74%; text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Increases based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;299&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="width: 10%; text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;648&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zZL9WmFXqs5a" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Increases based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;(348&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;24&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_zZSSD90u2mrg" style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Reductions based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt; &lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 1pt; border-bottom-style: solid; border-bottom-color: black !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefits_iE_zdFGLR6YBwVe" style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="font-weight: bold; text-align: left; padding: 0px 0px 2px; height: 15px; box-shadow: none;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,315&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt; &lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;$&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none; border-bottom-width: 2.8pt; border-bottom-style: double; border-bottom-color: #000000 !important;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;2,364&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt; &lt;/td&gt;


 &lt;/tr&gt;


 &lt;/tbody&gt;


 &lt;/table&gt;


 </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I20241231"
      decimals="-3"
      id="Tag572"
      unitRef="USD">2364000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I20231231"
      decimals="-3"
      id="Tag581"
      unitRef="USD">1692000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="D20251231"
      decimals="-3"
      id="Tag595"
      unitRef="USD">299000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="D20241231"
      decimals="-3"
      id="Tag574"
      unitRef="USD">648000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <vani:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="D20251231"
      decimals="-3"
      id="Tag640"
      unitRef="USD">-348000</vani:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <vani:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="D20241231"
      decimals="-3"
      id="Tag641"
      unitRef="USD">24000</vani:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="D20251231"
      id="Tag634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="D20241231"
      id="Tag575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I20251231"
      decimals="-3"
      id="Tag596"
      unitRef="USD">2315000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I20241231"
      decimals="-3"
      id="Tag573"
      unitRef="USD">2364000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I20251231"
      decimals="-5"
      id="Tag557"
      unitRef="USD">2300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I20251231_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Tag558"
      unitRef="USD">900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="I20251231_CaliforniaFranchiseTaxBoardMember"
      decimals="-5"
      id="Tag559"
      unitRef="USD">1400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="D20241231"
      decimals="0"
      id="Tag53"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="D20251231"
      decimals="-6"
      id="Tag561"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="D20251231" id="Tag515">
&lt;p id="xdx_801_ecustom--RightOfUseAssetsAndOperatingLeaseLiabilitiesTextBlock_z0kmDrXXz0G6" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0pt 0pt 1pt; text-indent: 0pt;"&gt;&lt;b&gt;12. &lt;span id="xdx_82D_zxwOrUkKbJp7" style="line-height: inherit;"&gt;Right-of-use Assets and Operating Lease Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 1pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;The Company &lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;leases certain office, laboratory, research and development space for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. &lt;span style="color: #000000;"&gt;Operating lease cost for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&#160;The lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of the &lt;span style="mso-spacerun: yes;"&gt;&#160;&lt;/span&gt;leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.&lt;/span&gt; &lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="line-height: inherit;"&gt;On November 21, 2022, Vivani entered into a triple net lease agreement for a single building with 43,645 square feet of space in Alameda, California. &lt;span id="xdx_90D_eus-gaap--LessorOperatingLeaseLeaseNotYetCommencedOptionToTerminate_c20221119__20221121__us-gaap--LeaseContractualTermAxis__custom--AlamedaCAMember_zXRu4FaIVXdb" style="line-height: inherit;" title="Lease terminates"&gt;The stated term of the lease commenced on June 1, 2023 and terminates on September 30, 2033, ten years and 4 months. The lease term is based on the non-cancellable period in the lease agreement. There are two options to extend the lease, each for a term of five years; however, the extension options were not included in the measurement of the ROU asset and lease liability since it is not reasonably certain that the Company will exercise such extension options.&lt;/span&gt; &lt;span id="xdx_90F_eus-gaap--LessorOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions_c20230928__20230930__us-gaap--LeaseContractualTermAxis__custom--ValenciaCAMember_z0fKA53ZuLoa" style="line-height: inherit;" title="Net lease agreement description"&gt;Payments increase annually from $2,676,311 to $3,596,784, or 124 monthly payments less the first four which are abated, totaling approximately $31.0 million. Vivani will be responsible for insurance, property taxes and common area maintenance charges. Vivani deposited $1.3 million to guarantee a letter of credit to secure the lease and this amount is included in long-term assets on the balance sheet as of December 31, 2025 and&#160;&lt;span style="border-right: none; border-left: none; line-height: inherit;"&gt;2024&lt;/span&gt;.&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;















&lt;span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;On February 1, 2023, the Company entered into a
lease agreement, effective March 1, 2023, to sublease office space to replace
Cortigent&#x2019;s existing headquarters. Rental payments amount to $22,158 per month
plus operating expenses, to lease 14,823 square feet of office space at 27200
Tourney Road, Valencia, California 91355. The sublease had a term of two years
and two months. The sublease expired on April 30, 2025. The Company also
entered into a lease for storage space on January 25, 2023, in the same
building at a cost of $6,775 per month for a term of two years and one
month.The lease expired on March 31, 2025.&#160;The Company did not renew the
current office lease. However, the Company entered into another lease in the
same building for a smaller space at a cost of $1,700 per month for six months.
The lease of the storage unit was renewed. &lt;span style="color: #000000;"&gt;These new
and renewal leases are short-term leases with immaterial monthly costs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;On July 3, 2024, the Company entered into a short-term sublease agreement for access to manufacturing facility which terminated on June 30, 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;On October 1, 2025, the Company entered into a long-term sublease agreement for access to a manufacturing facility that will support, among other activities, Good Manufacturing Practices (GMP) with the Company's clinical study test article. The stated term of the sublease commenced on October 1, 2025 and terminates on April 30, 2028.&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&#160;The Company's rental payment amounts to $&lt;/span&gt;35,000&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;span&gt;&#160;&lt;/span&gt;per month plus operating expenses.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="color: #000000; font-family: 'Times New Roman', serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;
&lt;div id="focb0de726d66d43739c0bf5a3d2c6e70f" style="line-height: 1.2;"&gt;
&lt;p id="xdx_89C_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zwfvNoj0Pnci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B0_zcVcYDY3ehLa" style="line-height: inherit;"&gt;The following table summarizes supplemental balance sheet information related to the Company&#x2019;s operating leases (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 107px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 15px; box-shadow: none;"&gt;&lt;span id="fs_87C1MAJJGG00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; height: 16px; box-shadow: none;"&gt;Balance Sheet Classification&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_GTS0QD2ES000000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_JO99E89FV400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="text-decoration: underline; line-height: inherit;"&gt;Assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="width: 30%; text-align: left; padding-left: 0.25in; height: 15px; box-shadow: none;"&gt;Non-current assets&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 39%; text-align: left; height: 15px; box-shadow: none;"&gt;Right-of-use assets&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_z9a2ZvlklOQ9" style="width: 12%; text-align: right; height: 15px; box-shadow: none;"&gt;17,230&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231_zcyiyF03ZEoj" style="width: 12%; text-align: right; height: 15px; box-shadow: none;"&gt;17,957&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-decoration: underline; font-weight: bold; height: 15px; box-shadow: none;"&gt;Liabilities&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in; height: 15px; box-shadow: none;"&gt;Current&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;Current operating lease liabilities&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20231231_zTBqBRB441fk" style="text-align: right; height: 15px; box-shadow: none;"&gt;1,794&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20221231_zJYyU32QheDa" style="text-align: right; height: 15px; box-shadow: none;"&gt;1,348&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in; height: 15px; box-shadow: none;"&gt;Long-term&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;Long-term operating lease liabilities&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--LiabilitiesOtherThanLongtermDebtNoncurrent_iI_pn3n3_c20231231_zwKWiLoT6gHj" style="text-align: right; height: 15px; box-shadow: none;"&gt;17,061&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--LiabilitiesOtherThanLongtermDebtNoncurrent_iI_pn3n3_c20221231_zFiICn8r2Axe" style="text-align: right; height: 15px; box-shadow: none;"&gt;17,965&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;








 &lt;/tbody&gt;








 &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;








 &lt;/div&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;Operating lease cost was $&lt;span id="xdx_90C_eus-gaap--OperatingLeaseCost_pn5n6_c20230101__20231231_zkPjImyIFsii" style="line-height: inherit;" title="Operating lease cost"&gt;3.2&lt;/span&gt; million and $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseCost_pn5n6_c20220101__20221231_zLdOmURfqZyg" style="line-height: inherit;"&gt;3.3&lt;/span&gt; million during &lt;span id="fs_5ZYJCFGTCG00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt; and &lt;span id="fs_5L2UHT8O0G00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively. Variable lease cost, comprising primarily of common area maintenance charges and taxes, for the operating lease was $&lt;span id="xdx_90C_eus-gaap--UtilitiesOperatingExpenseMaintenance_pn5n6_c20230101__20231231_zssuu8sczMm5" style="line-height: inherit;" title="Operating lease maintenance charges"&gt;0.6 &lt;/span&gt;million and $&lt;span id="xdx_90A_eus-gaap--UtilitiesOperatingExpenseMaintenance_pn5n6_c20220101__20221231_ziYMHI3IUk02" style="line-height: inherit;" title="Operating lease maintenance charges"&gt;0.4&lt;/span&gt; million during &lt;span id="fs_2ESAYIHP8G00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt; and &lt;span id="fs_9YNMEWM99S00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;, respectively. Short-term sublease costs were $205,000 during &lt;span id="fs_0S53VFJBG000000000000000000000FM"&gt;2025&lt;/span&gt;.&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&#160;&lt;/p&gt;
&lt;div id="foeb8d39ea386846bd93167667164bc1a7"&gt;
&lt;p id="xdx_89E_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z7irvRFL7ick" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8BC_zSo9XStRaigb" style="line-height: inherit;"&gt;The following table summarizes a maturity analysis of our lease liabilities showing the aggregate lease payments as of &lt;span id="fs_QYB7EDN1A800000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; (in thousands except weighted average data):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto; height: 163px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 11px;"&gt;
&lt;td style="text-align: left; height: 11px; box-shadow: none;"&gt;&lt;span style="text-decoration: underline; line-height: inherit;"&gt;Year Ending &lt;span id="fs_NS797HY4Y800000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="width: 76%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_UUL4BHZ2M800000000000000000000fs" style="display: inline;"&gt;2026&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_pn3n3_c20230101__20231231_zV5RECWR426l" style="width: 10%; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;3,298&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span id="fs_CIQXRWI57K00000000000000000000fs" style="display: inline;"&gt;2027&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearFour_pn3n3_c20230101__20231231_zgDAoAANdFz2" style="text-align: right; height: 15px; box-shadow: none;"&gt;3,395&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_4QWKJK2K3K00000000000000000000fs" style="display: inline;"&gt;2028&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearFive_pn3n3_c20230101__20231231_z2NzpxJVdQ6l" style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;3,207&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span id="fs_FFZDQK0ZDS00000000000000000000fs" style="display: inline;"&gt;2029&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearSix_pn3n3_c20230101__20231231_zkillqTzwdW3" style="text-align: right; height: 15px; box-shadow: none;"&gt;3,156&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_YGXPDH0UKG00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearSeven_pn3n3_c20230101__20231231_zeLmVoi8WIsc" style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;3,251&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;Thereafter&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearEight_pn3n3_c20230101__20231231_zq7q4rs8IwT1" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;9,453&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;Total lease payments&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_zbfxjRdRhER7" style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;25,760&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;Less imputed interest&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FinanceLeaseInterestExpense_iN_pn3n3_di_c20230101__20231231_zLrhq0EAShEb" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;(6,905&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 16px; box-shadow: none;"&gt;)&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;Total lease liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-bottom-color: black !important; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--LeaseCost_pn3n3_c20230101__20231231_z8xipiRNQLfe" style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-bottom-color: black !important; box-shadow: none;"&gt;18,855&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;Weighted average remaining lease term&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dxL_c20231231_zJbs4mNlqwK1" style="text-align: right; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;7.49&lt;/span&gt;&#160;years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;








 &lt;/tbody&gt;








 &lt;/table&gt;








 &lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div id="fs_EFHYEGQZPC00000000000000000000B"&gt;
&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zKMpsShh1uBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B8_zWRL8gDXHiDf" style="line-height: inherit;"&gt;Other information related to leases are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_XXCKP4SOLS00000000000000000000b"&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 79px; width: 90%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: auto; margin-right: auto;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20230101__20231231_zQcRoZ9Xxrvl" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" id="xdx_491_20220101__20221231_zitVmPI8LOw3" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Year ended &lt;span id="fs_AD5SF546W000000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_3DOUVH5I1C00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_VCEHFREQQO00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--CashPaidForOperatingLeaseLiabilities_pn3n3_d0_znLViHCoXOE2" style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; width: 68%; box-shadow: none;"&gt;Cash paid for operating lease liabilities&lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; width: 13%; box-shadow: none;"&gt;2,934&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; width: 13%; box-shadow: none;"&gt;3,070&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;8.32&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;%&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;8.40&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;%&lt;/td&gt;








 &lt;/tr&gt;








 &lt;/tbody&gt;








 &lt;/table&gt;








 &lt;/div&gt;








 &lt;/div&gt;








 </us-gaap:LesseeOperatingLeasesTextBlock>
    <vani:MaximumPeriodForLeaseTermWhichAreNotRecordedOnBalanceSheet contextRef="D20251231" id="Tag539">P12M</vani:MaximumPeriodForLeaseTermWhichAreNotRecordedOnBalanceSheet>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I20221121_AlamedaCAMember"
      decimals="0"
      id="Tag517"
      unitRef="SquareFoot">43645</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LessorOperatingLeaseLeaseNotYetCommencedOptionToTerminate contextRef="D20221121_AlamedaCAMember" id="Tag510">The stated term of the lease commenced on June 1, 2023 and terminates on September 30, 2033, ten years and 4 months. The lease term is based on the non-cancellable period in the lease agreement. There are two options to extend the lease, each for a term of five years; however, the extension options were not included in the measurement of the ROU asset and lease liability since it is not reasonably certain that the Company will exercise such extension options.</us-gaap:LessorOperatingLeaseLeaseNotYetCommencedOptionToTerminate>
    <us-gaap:LessorOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions contextRef="D20221121_ValenciaCAMember" id="Tag511">Payments increase annually from $2,676,311 to $3,596,784, or 124 monthly payments less the first four which are abated, totaling approximately $31.0 million. Vivani will be responsible for insurance, property taxes and common area maintenance charges. Vivani deposited $1.3 million to guarantee a letter of credit to secure the lease and this amount is included in long-term assets on the balance sheet as of December 31, 2025 and&#160;2024.</us-gaap:LessorOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions>
    <vani:LeaseEffectiveDate contextRef="D20230201_LessorMember" id="Tag540">2023-03-01</vani:LeaseEffectiveDate>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20230201_LessorMember"
      decimals="-3"
      id="Tag541"
      unitRef="USD">22158000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LessorOperatingLeaseDescription contextRef="D20230201_1" id="Tag542">to lease 14,823 square feet of office space at 27200
Tourney Road, Valencia, California 91355</us-gaap:LessorOperatingLeaseDescription>
    <us-gaap:LesseeFinanceSubleaseOptionToExtend contextRef="D20230201_1" id="Tag543">The sublease had a term of two years
and two months. The sublease expired on April 30, 2025. The Company also
entered into a lease for storage space on January 25, 2023, in the same
building at a cost of $6,775 per month for a term of two years and one
month.</us-gaap:LesseeFinanceSubleaseOptionToExtend>
    <us-gaap:LeaseExpirationDate1
      contextRef="D20230201_SubleaseStorageSpaceMember"
      id="Tag544">2025-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20251231_LessorMember"
      decimals="-3"
      id="Tag545"
      unitRef="USD">1700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="I20251231_LessorMember" id="Tag546">P6M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1 contextRef="D20240703" id="Tag516">2025-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LessorOperatingLeaseDescription
      contextRef="D20251001_SubleaseForManufacturingFacilityMember"
      id="Tag518">On October 1, 2025, the Company entered into a long-term sublease agreement for access to a manufacturing facility that will support, among other activities, Good Manufacturing Practices (GMP) with the Company's clinical study test article. The stated term of the sublease commenced on October 1, 2025 and terminates on April 30, 2028.</us-gaap:LessorOperatingLeaseDescription>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20251001_SubleaseForManufacturingFacilityMember"
      decimals="-3"
      id="Tag519"
      unitRef="USD">35000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="D20251231" id="Tag505">
&lt;p id="xdx_89C_eus-gaap--OperatingLeaseLeaseIncomeTableTextBlock_zwfvNoj0Pnci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B0_zcVcYDY3ehLa" style="line-height: inherit;"&gt;The following table summarizes supplemental balance sheet information related to the Company&#x2019;s operating leases (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; border-collapse: collapse; width: 100%; height: 107px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 15px; box-shadow: none;"&gt;&lt;span id="fs_87C1MAJJGG00000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; font-weight: bold; height: 16px; box-shadow: none;"&gt;Balance Sheet Classification&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_GTS0QD2ES000000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_JO99E89FV400000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&lt;span style="text-decoration: underline; line-height: inherit;"&gt;Assets&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="width: 30%; text-align: left; padding-left: 0.25in; height: 15px; box-shadow: none;"&gt;Non-current assets&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 39%; text-align: left; height: 15px; box-shadow: none;"&gt;Right-of-use assets&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_z9a2ZvlklOQ9" style="width: 12%; text-align: right; height: 15px; box-shadow: none;"&gt;17,230&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20221231_zcyiyF03ZEoj" style="width: 12%; text-align: right; height: 15px; box-shadow: none;"&gt;17,957&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-decoration: underline; font-weight: bold; height: 15px; box-shadow: none;"&gt;Liabilities&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in; height: 15px; box-shadow: none;"&gt;Current&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;Current operating lease liabilities&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20231231_zTBqBRB441fk" style="text-align: right; height: 15px; box-shadow: none;"&gt;1,794&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_c20221231_zJYyU32QheDa" style="text-align: right; height: 15px; box-shadow: none;"&gt;1,348&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff; height: 15px;"&gt;
&lt;td style="text-align: left; padding-left: 0.25in; height: 15px; box-shadow: none;"&gt;Long-term&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;Long-term operating lease liabilities&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--LiabilitiesOtherThanLongtermDebtNoncurrent_iI_pn3n3_c20231231_zwKWiLoT6gHj" style="text-align: right; height: 15px; box-shadow: none;"&gt;17,061&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--LiabilitiesOtherThanLongtermDebtNoncurrent_iI_pn3n3_c20221231_zFiICn8r2Axe" style="text-align: right; height: 15px; box-shadow: none;"&gt;17,965&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;








 &lt;/tbody&gt;








 &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red;"&gt;&lt;br/&gt;&lt;/p&gt;








 </us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I20251231"
      decimals="-3"
      id="Tag533"
      unitRef="USD">17230000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I20241231"
      decimals="-3"
      id="Tag534"
      unitRef="USD">17957000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag535"
      unitRef="USD">1794000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag537"
      unitRef="USD">1348000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="I20251231"
      decimals="-3"
      id="Tag536"
      unitRef="USD">17061000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent
      contextRef="I20241231"
      decimals="-3"
      id="Tag521"
      unitRef="USD">17965000</us-gaap:LiabilitiesOtherThanLongtermDebtNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="D20251231"
      decimals="-5"
      id="Tag507"
      unitRef="USD">3200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D20241231"
      decimals="-5"
      id="Tag509"
      unitRef="USD">3300000</us-gaap:OperatingLeaseCost>
    <us-gaap:UtilitiesOperatingExpenseMaintenance
      contextRef="D20251231"
      decimals="-5"
      id="Tag508"
      unitRef="USD">600000</us-gaap:UtilitiesOperatingExpenseMaintenance>
    <us-gaap:UtilitiesOperatingExpenseMaintenance
      contextRef="D20241231"
      decimals="-5"
      id="Tag506"
      unitRef="USD">400000</us-gaap:UtilitiesOperatingExpenseMaintenance>
    <us-gaap:OperatingLeaseCost
      contextRef="D20251231_LessorMember"
      decimals="-3"
      id="Tag514"
      unitRef="USD">205000000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="D20251231" id="Tag512">
&lt;p id="xdx_89E_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_z7irvRFL7ick" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8BC_zSo9XStRaigb" style="line-height: inherit;"&gt;The following table summarizes a maturity analysis of our lease liabilities showing the aggregate lease payments as of &lt;span id="fs_QYB7EDN1A800000000000000000000FM" style="line-height: inherit;"&gt;December 31, 2025&lt;/span&gt; (in thousands except weighted average data):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'times new roman'; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto; height: 163px;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 11px;"&gt;
&lt;td style="text-align: left; height: 11px; box-shadow: none;"&gt;&lt;span style="text-decoration: underline; line-height: inherit;"&gt;Year Ending &lt;span id="fs_NS797HY4Y800000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 11px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="width: 76%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_UUL4BHZ2M800000000000000000000fs" style="display: inline;"&gt;2026&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree_pn3n3_c20230101__20231231_zV5RECWR426l" style="width: 10%; text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;3,298&lt;/td&gt;
&lt;td style="width: 1%; text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span id="fs_CIQXRWI57K00000000000000000000fs" style="display: inline;"&gt;2027&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearFour_pn3n3_c20230101__20231231_zgDAoAANdFz2" style="text-align: right; height: 15px; box-shadow: none;"&gt;3,395&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_4QWKJK2K3K00000000000000000000fs" style="display: inline;"&gt;2028&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearFive_pn3n3_c20230101__20231231_z2NzpxJVdQ6l" style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;3,207&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span id="fs_FFZDQK0ZDS00000000000000000000fs" style="display: inline;"&gt;2029&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearSix_pn3n3_c20230101__20231231_zkillqTzwdW3" style="text-align: right; height: 15px; box-shadow: none;"&gt;3,156&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span id="fs_YGXPDH0UKG00000000000000000000fs" style="display: inline;"&gt;2030&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearSeven_pn3n3_c20230101__20231231_zeLmVoi8WIsc" style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;3,251&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;Thereafter&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearEight_pn3n3_c20230101__20231231_zq7q4rs8IwT1" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;9,453&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 15px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;Total lease payments&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_zbfxjRdRhER7" style="text-align: right; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;25,760&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; box-shadow: none;"&gt;Less imputed interest&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: 1pt solid black; text-align: left; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FinanceLeaseInterestExpense_iN_pn3n3_di_c20230101__20231231_zLrhq0EAShEb" style="border-bottom: 1pt solid black; text-align: right; height: 16px; box-shadow: none;"&gt;(6,905&lt;/td&gt;
&lt;td style="padding: 0px 0px 0.5px; text-align: left; height: 16px; box-shadow: none;"&gt;)&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;Total lease liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-bottom-color: black !important; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--LeaseCost_pn3n3_c20230101__20231231_z8xipiRNQLfe" style="text-align: right; height: 10px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-bottom-color: black !important; box-shadow: none;"&gt;18,855&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px;"&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 10px; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;Weighted average remaining lease term&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dxL_c20231231_zJbs4mNlqwK1" style="text-align: right; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;&lt;span style="border-left: none; border-right: none; line-height: inherit;"&gt;7.49&lt;/span&gt;&#160;years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 10px; background-color: #cceeff; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;








 &lt;/tbody&gt;








 &lt;/table&gt;








 </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="I20251231"
      decimals="-3"
      id="Tag523"
      unitRef="USD">3298000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="I20251231"
      decimals="-3"
      id="Tag524"
      unitRef="USD">3395000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="I20251231"
      decimals="-3"
      id="Tag525"
      unitRef="USD">3207000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="I20251231"
      decimals="-3"
      id="Tag526"
      unitRef="USD">3156000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="I20251231"
      decimals="-3"
      id="Tag527"
      unitRef="USD">3251000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="I20251231"
      decimals="-3"
      id="Tag528"
      unitRef="USD">9453000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="I20251231"
      decimals="-3"
      id="Tag529"
      unitRef="USD">25760000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="I20251231"
      decimals="-3"
      id="Tag547"
      unitRef="USD">6905000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="I20251231"
      decimals="-3"
      id="Tag530"
      unitRef="USD">18855000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="I20251231" id="Tag538">P7Y5M26D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="D20251231" id="Tag513">
&lt;p id="xdx_89E_eus-gaap--LeaseCostTableTextBlock_zKMpsShh1uBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in;"&gt;&lt;span id="xdx_8B8_zWRL8gDXHiDf" style="line-height: inherit;"&gt;Other information related to leases are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;div id="t_ft_XXCKP4SOLS00000000000000000000b"&gt;
&lt;table cellpadding="0" cellspacing="0" style="height: 79px; width: 90%; font: 10pt 'times new roman'; border-collapse: collapse; margin-left: auto; margin-right: auto;"&gt;
&lt;tbody&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20230101__20231231_zQcRoZ9Xxrvl" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" id="xdx_491_20220101__20221231_zitVmPI8LOw3" style="font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="text-align: center; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;Year ended &lt;span id="fs_AD5SF546W000000000000000000000FM" style="line-height: inherit;"&gt;December 31,&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="vertical-align: bottom; height: 16px;"&gt;
&lt;td style="height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_3DOUVH5I1C00000000000000000000FM" style="line-height: inherit;"&gt;2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: bold; text-align: center; height: 16px; box-shadow: none;"&gt;&lt;span id="fs_VCEHFREQQO00000000000000000000FM" style="line-height: inherit;"&gt;2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold; height: 16px; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--CashPaidForOperatingLeaseLiabilities_pn3n3_d0_znLViHCoXOE2" style="vertical-align: bottom; background-color: #cceeff; height: 16px;"&gt;
&lt;td style="text-align: left; height: 16px; width: 68%; box-shadow: none;"&gt;Cash paid for operating lease liabilities&lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; width: 13%; box-shadow: none;"&gt;2,934&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 16px; width: 13%; box-shadow: none;"&gt;3,070&lt;/td&gt;
&lt;td style="text-align: left; height: 16px; width: 1%; box-shadow: none;"&gt;&#160;&lt;/td&gt;








 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;8.32&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;%&lt;/td&gt;
&lt;td style="height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; box-shadow: none;"&gt;8.40&lt;/td&gt;
&lt;td style="text-align: left; height: 15px; box-shadow: none;"&gt;%&lt;/td&gt;








 &lt;/tr&gt;








 &lt;/tbody&gt;








 &lt;/table&gt;








 &lt;/div&gt;








 </us-gaap:LeaseCostTableTextBlock>
    <vani:CashPaidForOperatingLeaseLiabilities
      contextRef="D20251231"
      decimals="-3"
      id="Tag522"
      unitRef="USD">2934000</vani:CashPaidForOperatingLeaseLiabilities>
    <vani:CashPaidForOperatingLeaseLiabilities
      contextRef="D20241231"
      decimals="-3"
      id="Tag520"
      unitRef="USD">3070000</vani:CashPaidForOperatingLeaseLiabilities>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="I20251231"
      decimals="4"
      id="Tag531"
      unitRef="Pure">0.0832</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="I20241231"
      decimals="4"
      id="Tag532"
      unitRef="Pure">0.084</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="D20251231" id="Tag109">
&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_za6es3wy4sU" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;b&gt;13. &lt;span id="xdx_82F_zEUwoXq42Wl3" style="line-height: inherit;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;b&gt;Indemnification Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;The Company maintains indemnification agreements with its directors and officers that may require it to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 0.25in;"&gt;&lt;span style="font-size: 10pt; text-indent: 0px;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&lt;b&gt;Clinical Trial Agreements&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;Based upon FDA approval of Argus II, which was obtained in February 2013, the Company was required to collect follow-up data from subjects enrolled in our pre-approval trial for a period of up to &lt;span id="fs_O7RIFGHLHC00000000000000000000fs"&gt;ten&lt;/span&gt; years post-implant, which was extended through the year &lt;span id="fs_Z3KBOSFPF400000000000000000000fs"&gt;2019&lt;/span&gt;. This requirement to collect follow-up data was halted in &lt;span id="fs_G44L01W63K00000000000000000000fs"&gt;2020&lt;/span&gt; with FDA approval. In addition, the Company conducted &lt;span id="fs_8V23QTPNHC00000000000000000000fs"&gt;three&lt;/span&gt; post-market studies to comply with U.S. FDA, French, and European post-market surveillance regulations and requirements and are conducting an early feasibility clinical study of Orion. The Company has contracted with various universities, hospitals, and medical practices to provide these services. Payments are based on procedures performed for each subject and are charged to clinical and regulatory expense as incurred. Total amounts expensed for the year ended December 31, 2025 and &lt;span id="fs_0W1XMT266800000000000000000000fs"&gt;2024&lt;/span&gt; were $35,000&#160;and $17,000, respectively.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0px; text-indent: 0px;"&gt;&#160;&lt;b&gt;Litigation, Claims and Assessments&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;One opposition filed by Pixium Vision SA (&#x201c;Pixium&#x201d;)
was pending in the European Patent Office challenging the validity of a
European patent owned by Cortigent. The Company decided to allow the patent to
be abandoned by the EPO, which occurred in February 2025. As a result, this
opposition is no longer pending. While this abandonment could impact our
ability to protect Cortigent&#x2019;s neurostimulation technology in Europe related to
this patent, the Company does not believe that it will have a material effect
on our ability to manufacture and sell our products, or otherwise have a
material effect on Cortigent&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;






 &lt;/div&gt;
&lt;p style="text-align: justify; text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;As described in the Company&#x2019;s 10-K for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (&#x201c;MOU&#x201d;) for a proposed business combination with Pixium. In response to a press release by Pixium dated March 24, 2021, and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium was not in the best interest of our stockholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an amicable resolution will be reached. We accrued $1,000,000 of liquidated damages as contemplated by the MOU in accounts payable as of March 31, 2021 and remitted that amount to Pixium in April 2021. Pixium indicated that it considered this termination wrongful, rejected the Company&#x2019;s offers, but retained the $&lt;span id="fs_V6EOOMJR6800000000000000000000fs" style="display: inline;"&gt;1,000,000&lt;/span&gt; payment. On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately &#x20ac;&lt;span id="fs_W8MMFP317K00000000000000000000fs" style="display: inline;"&gt;5.1&lt;/span&gt; million or about $&lt;span id="fs_ULKTBM1CCG00000000000000000000fs" style="display: inline;"&gt;5.6&lt;/span&gt; million. We believe we have fulfilled our obligations to Pixium with the liquidated damages payment of $&lt;span id="fs_F9ORQFWSV400000000000000000000fs" style="display: inline;"&gt;1,000,000&lt;/span&gt;. On December 8, 2022, the Company received notice that the Paris Commercial Court has rendered its judgment, including finding that the Company&#x2019;s termination of the MOU was not valid. In the judgment, the Company was ordered to pay to Pixium the amount of &#x20ac;&lt;span id="fs_J30T3JKCKW00000000000000000000fs" style="display: inline;"&gt;2,500,000&lt;/span&gt; minus a &#x20ac;&lt;span id="fs_FUE6RZVPGW00000000000000000000fs" style="display: inline;"&gt;947,780&lt;/span&gt; credit for the $&lt;span id="fs_EKWBGT46TS00000000000000000000fs" style="display: inline;"&gt;1,000,000&lt;/span&gt; already paid for, a net amount payable of approximately &#x20ac;&lt;span id="fs_FPEUKW0UO000000000000000000000fs" style="display: inline;"&gt;1,552,220&lt;/span&gt;. On May 24, 2023, the Company filed an appeal against the judgment from the Paris Commercial Court except in so far as such prior judgment dismissed (i) Pixium&#x2019;s claim for the Company to pay it a sum of &#x20ac;&lt;span id="fs_KGCH947TVK00000000000000000000fs" style="display: inline;"&gt;480,693&lt;/span&gt; relating to the alleged time spent by its teams, (ii) Pixium&#x2019;s application to order the Company to pay it a sum of &#x20ac;&lt;span id="fs_8DICCU9NSW00000000000000000000fs" style="display: inline;"&gt;1,500,000&lt;/span&gt; in respect to alleged loss of opportunity and (iii) deducted the sum of $&lt;span id="fs_QZRDIVNV1C00000000000000000000fs" style="display: inline;"&gt;1,000,000&lt;/span&gt; that we already paid Pixium and which Pixium retained converted into euros at the date of the judgment. Thereafter Pixium filed its brief with Paris Court of Appeal and filed a cross-appeal on January 18, 2024. Meanwhile, the Company received notice that the Paris Commercial Court had opened safeguard proceedings against Pixium by judgment dated October 9, 2023, then in its judgment dated November 13, 2023, converted safeguard proceedings into receivership, and in its judgment dated January 31, 2024, converted Pixium&#x2019;s receivership proceedings to liquidation proceedings, the transfer plan being rejected. As a result, Pixium&#x2019;s liquidator intervened on behalf of Pixium in the pending proceedings before the Paris Court of Appeal and filed its brief on March 21, 2024. The Company filed its brief in reply with the Paris Court of Appeal on April 17, 2024. Proceedings before the Paris Court of Appeal are pending. In parallel, since the Company has failed to enforce the judgment, Pixium has requested the pre-trial judge to strike out the Company's appeal for failure to enforce the judgment. The hearing took place on June 4, 2024 and on October 23, 2024, the pre-trial judge issued his order, striking out Vivani's appeal for failure to enforce the decision. Within &lt;span id="fs_BJM7920HR400000000000000000000fs" style="display: inline;"&gt;two&lt;/span&gt; years, Vivani&#160;will have to request that the case be reinstated on the court's docket, providing evidence that the judgment has been fully enforced or, at the very least, that an agreement has been reached. Failing this, the appeal proceedings will lapse.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;The Company recorded a charge of $1,675,000 for the year ended December 31, 2022, related to this matter but plans to continue its appeal against the preliminary judgment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 1.2; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;On January 26, 2024, Oppenheimer &amp;amp; Co. Inc. (&#x201c;Oppenheimer&#x201d;) filed a complaint asserting breach of contract and other claims against the Company and a party unrelated to the Company, ThinkEquity LLC&#160;(the &#x201c;Third Party&#x201d;), arising from a placement agent agreement dated November 5, 2020, executed by and between the Company and Pixium in connection with a proposed business combination transaction with Pixium.&#160; The complaint, filed in the Supreme Court of the State of New York, County of New York, Index No. &lt;span id="fs_790WLHU2Y800000000000000000000fs" style="line-height: inherit; display: inline;"&gt;650421&lt;/span&gt;/&lt;span id="fs_8KZMN9VPKW00000000000000000000fs" style="line-height: inherit; display: inline;"&gt;2024&lt;/span&gt;, seeks recovery of no less than $1,625,000 in damages, plus costs and fees. On April 3, 2024, the Company filed a motion to dismiss the complaint. On May 3, 2024, the Third Party filed its own motion to dismiss. On June 12, 2025, the Court granted the Company&#x2019;s motion in part and denied it in part, dismissing all claims except the&#160;first&#160;cause of action for breach of contract (the &#x201c;Claim&#x201d;), and the Court dismissed the complaint as against the Third Party.&#160;Oppenheimer&#160;and the Company are now commencing discovery on the Claim, which seeks the monetary damages referenced above. Each of the Company and Oppenheimer have filed notices of appeal.&#160; The Company&#160;has defenses to the Claim and intends to defend itself vigorously,&#160;but there can be no assurance as to the outcome of the litigation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations, however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.&lt;/span&gt;&lt;/p&gt;





 </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vani:ClinicalAndRegulatoryExpense
      contextRef="D20251231"
      decimals="0"
      id="Tag115"
      unitRef="USD">35000</vani:ClinicalAndRegulatoryExpense>
    <vani:ClinicalAndRegulatoryExpense
      contextRef="D20241231"
      decimals="0"
      id="Tag116"
      unitRef="USD">17000</vani:ClinicalAndRegulatoryExpense>
    <vani:LiquidatedDamagesPaidValue
      contextRef="I20210401"
      decimals="0"
      id="Tag110"
      unitRef="USD">1000000</vani:LiquidatedDamagesPaidValue>
    <us-gaap:ContractTerminationClaimsDescription contextRef="D20251231" id="Tag111">Pixium indicated that it considered this termination wrongful, rejected the Company&#x2019;s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately &#x20ac;5.1 million or about $5.6 million. We believe we have fulfilled our obligations to Pixium with the liquidated damages payment of $1,000,000.</us-gaap:ContractTerminationClaimsDescription>
    <us-gaap:LossContingencySettlementAgreementCourt contextRef="D20221208" id="Tag112">On December 8, 2022, the Company received notice that the Paris Commercial Court has rendered its judgment, including finding that the Company&#x2019;s termination of the MOU was not valid. In the judgment, the Company was ordered to pay to Pixium the amount of &#x20ac;2,500,000 minus a &#x20ac;947,780 credit for the $1,000,000 already paid for, a net amount payable of approximately &#x20ac;1,552,220. On May 24, 2023, the Company filed an appeal against the judgment from the Paris Commercial Court except in so far as such prior judgment dismissed (i) Pixium&#x2019;s claim for the Company to pay it a sum of &#x20ac;480,693 relating to the alleged time spent by its teams, (ii) Pixium&#x2019;s application to order the Company to pay it a sum of &#x20ac;1,500,000 in respect to alleged loss of opportunity and (iii) deducted the sum of $1,000,000 that we already paid Pixium and which Pixium retained converted into euros at the date of the judgment. Thereafter Pixium filed its brief with Paris Court of Appeal and filed a cross-appeal on January 18, 2024. Meanwhile, the Company received notice that the Paris Commercial Court had opened safeguard proceedings against Pixium by judgment dated October 9, 2023, then in its judgment dated November 13, 2023, converted safeguard proceedings into receivership, and in its judgment dated January 31, 2024, converted Pixium&#x2019;s receivership proceedings to liquidation proceedings, the transfer plan being rejected. As a result, Pixium&#x2019;s liquidator intervened on behalf of Pixium in the pending proceedings before the Paris Court of Appeal and filed its brief on March 21, 2024. The Company filed its brief in reply with the Paris Court of Appeal on April 17, 2024. Proceedings before the Paris Court of Appeal are pending. In parallel, since the Company has failed to enforce the judgment, Pixium has requested the pre-trial judge to strike out the Company's appeal for failure to enforce the judgment. The hearing took place on June 4, 2024 and on October 23, 2024, the pre-trial judge issued his order, striking out Vivani's appeal for failure to enforce the decision. Within two years, Vivani&#160;will have to request that the case be reinstated on the court's docket, providing evidence that the judgment has been fully enforced or, at the very least, that an agreement has been reached. Failing this, the appeal proceedings will lapse.</us-gaap:LossContingencySettlementAgreementCourt>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="D20221231_3"
      decimals="0"
      id="Tag113"
      unitRef="USD">1675000</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="D20240126"
      decimals="0"
      id="Tag114"
      unitRef="USD">1625000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="D20251231" id="Tag791">
&lt;div style="font-family: 'times new roman', times; font-size: 10pt; margin: 0px; text-indent: 0px;"&gt;
&lt;p style="margin: 0px; text-indent: 0px;"&gt;&lt;b style="font-size: 10pt; text-indent: 1.66667px;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;&lt;span style="border-left: none; border-right: none;"&gt;14&lt;/span&gt;&lt;/span&gt;. Segment Information&#160;&lt;/b&gt;&lt;/p&gt;





 &lt;/div&gt;
&lt;p style="margin: 0px; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0px; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;Operating segments are defined as components of an enterprise for which separate financial information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and assess performance. The Company has two operating and reporting segments, the Biopharm Division and the Neurostimulation Division. The Company&#x2019;s CODM is its Chief Executive Officer who reviews the Company between Biopharm and Cortigent. Our primary focus is the Biopharm Division. We are trying to spin off Cortigent. The measure of segment loss is reported on the Consolidated Statements of Operations and Comprehensive Loss as net loss. The measure of segment assets is reported on the Consolidated Balance Sheets as total assets.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0px; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="margin: 0px; text-indent: 0.25in; line-height: 1.2; font-size: 10pt; font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;The Company has not generated any product revenue to date. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it is a clinical stage biopharmaceutical company.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font-family: 'times new roman'; font-size: 10pt; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10pt; color: #000000;"&gt;During the year ended &lt;span id="fs_WWK3UI9A3400000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, the&#160;&lt;/span&gt;&lt;span style="font-size: 10.0pt;"&gt;Biopharm&lt;span style="color: #000000;"&gt;&#160;Division and&#160;&lt;/span&gt;Neurostimulation&lt;span style="color: #000000;"&gt;&#160;Division incurred operating expenses of $24.9&lt;/span&gt;&lt;span style="color: #000000;"&gt;&#160;million and $2.6&lt;/span&gt;&lt;span style="color: #000000;"&gt;&#160;million, respectively. During the year ended &lt;span id="fs_AO969XCSZK00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, net loss for the&#160;&lt;/span&gt;Biopharm&lt;span style="color: #000000;"&gt;&#160;Division was $&lt;/span&gt;24.1&lt;span style="color: #000000;"&gt;&#160;million and for the&#160;&lt;/span&gt;Neurostimulation&lt;span style="color: #000000;"&gt;&#160;Division was $&lt;/span&gt;2.5&lt;span style="color: #000000;"&gt;&#160;million.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; line-height: 12pt; margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;span style="font-size: 10.0pt;"&gt;As of &lt;span id="fs_EQ4UXAFJY800000000000000000000FM"&gt;December 31, 2025&lt;/span&gt;, total assets for the Biopharm Division and the Neurostimulation Division were $38.9 million and $0.5 million, respectively.&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font-family: 'times new roman'; font-size: 10pt; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div style="font-family: 'times new roman', times; font-size: 10pt;"&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;div id="t_ft_D7KXCHI9DS00000000000000000000b"&gt;
&lt;p style="margin: 0px; line-height: 1.2; font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;The following table provides information related to our operating segments based upon the Company's net loss for the years ended &lt;span id="fs_05WIYL62SG00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_WN6P2CKL7400000000000000000000fs"&gt;2024&lt;/span&gt; (in thousands): &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font-family: 'times new roman'; font-size: 10pt; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table style="height: 200px; width: 100%; font: 10pt 'times new roman'; border-collapse: collapse; margin: 0px; text-indent: 0px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 16px; box-shadow: none;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="22" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; font-weight: bold;"&gt;Year Ended &lt;span id="fs_FUTBTVGHQ800000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 16px; box-shadow: none;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="10" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; font-weight: bold;"&gt;&lt;span id="fs_7KKHNJTZSG00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="10" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; font-weight: bold;"&gt;&lt;span id="fs_60TLUGEMCW00000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 16px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Biopharm&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Neurostimulation&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding: 0px; margin: 0px; text-indent: 0px; text-align: center; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Biopharm&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Neurostimulation&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;Division&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;&#160;Division&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;Division&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;Division&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Operating expenses:&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;Personnel and related expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;10,275&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;1,139&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;11,414&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;10,053&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;1,752&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;11,805&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none; width: 35%;" valign="bottom"&gt;Office space rental related expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;4,213&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;319&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;4,532&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;3,999&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_21263512MO00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;3,999&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;Development expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,329&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_ZVJDMTQTVK00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="border-left: none; border-right: none;"&gt;4,329&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;2,765&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;294&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;3,059&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Professional services and insurance&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,911&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;836&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;5,747&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,600&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_027NGI16IO00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,600&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 15px; box-shadow: none;"&gt;Depreciation&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;411&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;13&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;424&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;378&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;30&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;408&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Other general and administrative expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;785&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;325&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;1,110&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;806&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_GQDP7BPTAO00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;806&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;Other (income) expense, net&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(821&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(126&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(947&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(1,347&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;156&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(1,191&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 17px; background-color: #cceeff;"&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Segment net loss&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;24,103&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;2,506&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;26,609&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;21,254&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;2,232&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;23,486&lt;/td&gt;
&lt;td style="height: 17px; margin: 0px; text-indent: 0px; padding: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;





 &lt;/tr&gt;





 &lt;/tbody&gt;





 &lt;/table&gt;





 &lt;/div&gt;





 &lt;/div&gt;





 &lt;/div&gt;





 </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="D20251231"
      decimals="0"
      id="Tag797"
      unitRef="SEGMENT">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:OperatingExpenses
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-5"
      id="Tag798"
      unitRef="USD">24900000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-5"
      id="Tag799"
      unitRef="USD">2600000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-5"
      id="Tag796"
      unitRef="USD">-24100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-5"
      id="Tag795"
      unitRef="USD">-2500000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets
      contextRef="I20251231_BiopharmDivisionMember_1"
      decimals="-5"
      id="Tag793"
      unitRef="USD">38900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="I20251231_NeurostimulationDivisionMember_1"
      decimals="-5"
      id="Tag794"
      unitRef="USD">500000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="D20251231" id="Tag792">
&lt;p style="margin: 0px; line-height: 1.2; font-size: 10pt; text-indent: 0.25in; font-family: 'times new roman', times;"&gt;&lt;span style="font-size: 10pt; font-family: 'times new roman', times; line-height: inherit;"&gt;The following table provides information related to our operating segments based upon the Company's net loss for the years ended &lt;span id="fs_05WIYL62SG00000000000000000000FM"&gt;December 31, 2025&lt;/span&gt; and &lt;span id="fs_WN6P2CKL7400000000000000000000fs"&gt;2024&lt;/span&gt; (in thousands): &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin: 0px; font-family: 'times new roman'; font-size: 10pt; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;table style="height: 200px; width: 100%; font: 10pt 'times new roman'; border-collapse: collapse; margin: 0px; text-indent: 0px;"&gt;
&lt;tbody&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 16px; box-shadow: none;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="22" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; font-weight: bold;"&gt;Year Ended &lt;span id="fs_FUTBTVGHQ800000000000000000000FM"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 16px; box-shadow: none;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="10" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; font-weight: bold;"&gt;&lt;span id="fs_7KKHNJTZSG00000000000000000000FM"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="10" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; font-weight: bold;"&gt;&lt;span id="fs_60TLUGEMCW00000000000000000000FM"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 16px;"&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 16px; box-shadow: none;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Biopharm&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Neurostimulation&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="padding: 0px; margin: 0px; text-indent: 0px; text-align: center; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Biopharm&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="color: #000000; font-family: 'times new roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: bold; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;Neurostimulation&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 16px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; text-align: center; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;Division&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;&#160;Division&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;Division&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="font-size: 10pt;"&gt;&#160;Division&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 1pt; border-bottom-style: solid; box-shadow: none; border-bottom-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-size: 10pt; font-weight: bold;"&gt;Total&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Operating expenses:&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;Personnel and related expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;10,275&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;1,139&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;11,414&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;10,053&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;1,752&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;11,805&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none; width: 35%;" valign="bottom"&gt;Office space rental related expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;4,213&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;319&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;4,532&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;3,999&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_21263512MO00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 8%; vertical-align: bottom;" valign="bottom"&gt;3,999&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; width: 1%; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;Development expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,329&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_ZVJDMTQTVK00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="border-left: none; border-right: none;"&gt;4,329&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;2,765&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;294&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;3,059&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Professional services and insurance&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,911&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;836&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;5,747&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,600&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_027NGI16IO00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;4,600&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; height: 15px; box-shadow: none;"&gt;Depreciation&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;411&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;13&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;424&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;378&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;30&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; text-align: right; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;408&lt;/td&gt;
&lt;td style="padding: 0px; margin: 0px; text-indent: 0px; height: 15px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px; background-color: #cceeff;"&gt;
&lt;td style="height: 15px; padding: 0px 0px 0px 15px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Other general and administrative expenses&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;785&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;325&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;1,110&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;806&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;span id="fs_GQDP7BPTAO00000000000000000000fs"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;806&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 15px;"&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; box-shadow: none;" valign="bottom"&gt;Other (income) expense, net&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="text-align: right; height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(821&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(126&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(947&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(1,347&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;156&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 15px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;(1,191&lt;/td&gt;
&lt;td style="height: 15px; padding: 0px 0px 1px; margin: 0px; text-indent: 0px; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;)&lt;/td&gt;





 &lt;/tr&gt;
&lt;tr style="height: 17px; background-color: #cceeff;"&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; vertical-align: bottom; background-color: #cceeff; box-shadow: none;" valign="bottom"&gt;Segment net loss&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;24,103&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;2,506&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;26,609&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;21,254&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;2,232&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="height: 17px; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;$&lt;/td&gt;
&lt;td style="height: 17px; text-align: right; padding: 0px; margin: 0px; text-indent: 0px; border-bottom-width: 2.8pt; border-bottom-style: double; background-color: #cceeff; border-top-width: 1pt; border-top-style: solid; box-shadow: none; border-bottom-color: #000000 !important; border-top-color: #000000 !important; vertical-align: bottom;" valign="bottom"&gt;23,486&lt;/td&gt;
&lt;td style="height: 17px; margin: 0px; text-indent: 0px; padding: 0px; background-color: #cceeff; box-shadow: none; vertical-align: bottom;" valign="bottom"&gt;&lt;/td&gt;





 &lt;/tr&gt;





 &lt;/tbody&gt;





 &lt;/table&gt;





 </us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:LaborAndRelatedExpense
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag802"
      unitRef="USD">10275000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-3"
      id="Tag804"
      unitRef="USD">1139000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag800"
      unitRef="USD">11414000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag805"
      unitRef="USD">10053000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="D20241231_NeurostimulationDivisionMember"
      decimals="-3"
      id="Tag807"
      unitRef="USD">1752000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag808"
      unitRef="USD">11805000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag814"
      unitRef="USD">4213000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-3"
      id="Tag838"
      unitRef="USD">319000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag818"
      unitRef="USD">4532000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag817"
      unitRef="USD">3999000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20241231_NeurostimulationDivisionMember"
      id="Tag816"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag815"
      unitRef="USD">3999000</us-gaap:OperatingLeaseExpense>
    <vani:DevelopmentExpense
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag819"
      unitRef="USD">4329000</vani:DevelopmentExpense>
    <vani:DevelopmentExpense
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      id="Tag846"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:DevelopmentExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag820"
      unitRef="USD">4329000</vani:DevelopmentExpense>
    <vani:DevelopmentExpense
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag821"
      unitRef="USD">2765000</vani:DevelopmentExpense>
    <vani:DevelopmentExpense
      contextRef="D20241231_NeurostimulationDivisionMember"
      decimals="-3"
      id="Tag822"
      unitRef="USD">294000</vani:DevelopmentExpense>
    <vani:DevelopmentExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag823"
      unitRef="USD">3059000</vani:DevelopmentExpense>
    <vani:ProfessionalServicesAndInsuranceExpense
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag824"
      unitRef="USD">4911000</vani:ProfessionalServicesAndInsuranceExpense>
    <vani:ProfessionalServicesAndInsuranceExpense
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-3"
      id="Tag837"
      unitRef="USD">836000</vani:ProfessionalServicesAndInsuranceExpense>
    <vani:ProfessionalServicesAndInsuranceExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag825"
      unitRef="USD">5747000</vani:ProfessionalServicesAndInsuranceExpense>
    <vani:ProfessionalServicesAndInsuranceExpense
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag826"
      unitRef="USD">4600000</vani:ProfessionalServicesAndInsuranceExpense>
    <vani:ProfessionalServicesAndInsuranceExpense
      contextRef="D20241231_NeurostimulationDivisionMember"
      id="Tag827"
      unitRef="USD"
      xsi:nil="true"/>
    <vani:ProfessionalServicesAndInsuranceExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag828"
      unitRef="USD">4600000</vani:ProfessionalServicesAndInsuranceExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag829"
      unitRef="USD">411000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-3"
      id="Tag832"
      unitRef="USD">13000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="D20251231"
      decimals="-3"
      id="Tag834"
      unitRef="USD">424000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag830"
      unitRef="USD">378000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="D20241231_NeurostimulationDivisionMember"
      decimals="-3"
      id="Tag833"
      unitRef="USD">30000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="D20241231"
      decimals="-3"
      id="Tag835"
      unitRef="USD">408000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag803"
      unitRef="USD">785000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-3"
      id="Tag836"
      unitRef="USD">325000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag801"
      unitRef="USD">1110000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag806"
      unitRef="USD">806000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="D20241231_NeurostimulationDivisionMember"
      id="Tag810"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag809"
      unitRef="USD">806000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag844"
      unitRef="USD">821000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-3"
      id="Tag847"
      unitRef="USD">126000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20251231"
      decimals="-3"
      id="Tag845"
      unitRef="USD">947000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag840"
      unitRef="USD">1347000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20241231_NeurostimulationDivisionMember"
      decimals="-3"
      id="Tag831"
      unitRef="USD">-156000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20241231"
      decimals="-3"
      id="Tag839"
      unitRef="USD">1191000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_BiopharmDivisionMember_1"
      decimals="-3"
      id="Tag842"
      unitRef="USD">-24103000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231_NeurostimulationDivisionMember_1"
      decimals="-3"
      id="Tag841"
      unitRef="USD">-2506000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20251231"
      decimals="-3"
      id="Tag843"
      unitRef="USD">-26609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231_BiopharmDivisionMember"
      decimals="-3"
      id="Tag813"
      unitRef="USD">-21254000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231_NeurostimulationDivisionMember"
      decimals="-3"
      id="Tag812"
      unitRef="USD">-2232000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20241231"
      decimals="-3"
      id="Tag811"
      unitRef="USD">-23486000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="D20251231" id="Tag102">
&lt;div style="font-family: 'times new roman', times; font-size: 10pt;"&gt;
&lt;div style="border-left: none; border-right: none;"&gt;
&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zudvhUhjCxz2" style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 1.25pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&lt;b&gt;15. &lt;span id="xdx_827_zkB7v3BJs30j" style="line-height: inherit;"&gt;Subsequent Event&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt 0px; text-indent: 1.25pt;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt / 1.2 'Times New Roman', Times, serif; margin: 0pt; text-indent: 0.25in;"&gt;&lt;span style="font-family: 'times new roman', times;"&gt;The Company evaluated subsequent events for recognition and disclosure through the date the financial statements were issued or filed. Nothing has occurred outside normal operations that required recognition or disclosure in these financial statements except as follows:&lt;/span&gt;&lt;/p&gt;

 &lt;/div&gt;

 &lt;/div&gt;
&lt;div&gt;
&lt;p style="margin: 0px; text-indent: 0px; line-height: 1.2;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0px; line-height: 1.2;"&gt;&lt;span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"&gt;&lt;i&gt;Private Sale Transaction&#160;&lt;/i&gt;&lt;/span&gt;&lt;i&gt;&lt;span style="font-size: 10pt; line-height: inherit;"&gt;and Registered Direct Offering&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0px; line-height: 1.2;"&gt;&lt;i&gt;&lt;/i&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.25in; margin: 0px; line-height: 1.2;"&gt;&lt;span style="color: #000000; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="line-height: inherit;"&gt;O&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-family: 'times new roman', times; line-height: inherit;"&gt;&lt;span style="color: #000000; line-height: inherit;"&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;n January 25, 2026,&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; line-height: inherit;"&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;the Company entered into a share purchase agreement with an entity affiliated with&#160;&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-right: none; border-left: none; line-height: inherit;"&gt;&lt;span style="cursor: default; line-height: inherit;"&gt;&lt;span id="fs_SP1V8XT7E800000000000000000000fs"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;of its &lt;span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;"&gt;independent&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;directors for the purchase of an aggregate of&#160;1,351,351&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;shares of common stock of the Company at a purchase price of $1.48&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;per share, the last reported sale price of the common stock on January 23, 2026. This private placement of common stock resulted in gross proceeds of approximately $2.0&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;million to the Company. Concurrent with the private placement, the Company also entered into a Placement Agency Agreement with&#160;&lt;/span&gt;ThinkEquity,&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;LLC relating to the sale by the Company of&#160;1,689,200&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;shares of the Company&#x2019;s common stock in a registered direct offering, also at a purchase price of $1.48&#160;per share. The gross proceeds from the Registered Offering were approximately $2.5&lt;/span&gt;&lt;span style="color: #000000; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; line-height: inherit; display: inline !important;"&gt;&#160;million, before placement agent fees and other estimated offering expenses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

 &lt;/div&gt;

 </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharesIssued
      contextRef="I20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="0"
      id="Tag103"
      unitRef="Shares">1351351</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="I20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="2"
      id="Tag104"
      unitRef="USDPerShare">1.48</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20260125_CommonStockMember_SubsequentEventMember_EntityAffiliatedWithDirectorMember_PrivatePlacementMember"
      decimals="-5"
      id="Tag105"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <vani:SaleOfCommonStockAtDirectOfferingAuthorizedShares
      contextRef="I20260125_SubsequentEventMember_ThinkEquityLlcMember_PlacementAgencyAgreementMember"
      decimals="0"
      id="Tag106"
      unitRef="Shares">1689200</vani:SaleOfCommonStockAtDirectOfferingAuthorizedShares>
    <vani:SaleOfCommonStockAtDirectOfferingPricePerShare
      contextRef="D20260125_SubsequentEventMember_PlacementAgencyAgreementMember_ThinkEquityLlcMember"
      decimals="2"
      id="Tag107"
      unitRef="USDPerShare">1.48</vani:SaleOfCommonStockAtDirectOfferingPricePerShare>
    <vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingGross
      contextRef="D20260125_SubsequentEventMember_PlacementAgencyAgreementMember_ThinkEquityLlcMember"
      decimals="-5"
      id="Tag108"
      unitRef="USD">2500000</vani:ProceedsFromIssuanceOfCommonStockInConnectionWithDirectOfferingGross>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tag635"
          xlink:label="Tag635"
          xlink:type="locator"/>
        <link:footnote id="footnote0" xlink:label="footnote0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">State taxes in California comprised the majority (greater than <xhtml:span style="-sec-ix-hidden:Tag25">50</xhtml:span> percent) of the tax effect in this category</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag635"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag628"
          xlink:label="Tag628"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag628"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag621"
          xlink:label="Tag621"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag621"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag629"
          xlink:label="Tag629"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag629"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag654"
          xlink:label="Tag654"
          xlink:type="locator"/>
        <link:footnote id="footnote1" xlink:label="footnote1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="border-right: none; border-left: none;"><xhtml:span style="border-right: none; border-left: none;">Foreign tax in Switzerland comprised the majority (greater than <xhtml:span style="border-left: none; border-right: none;">50</xhtml:span> percent) of the tax effect in this category</xhtml:span></xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag654"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag655"
          xlink:label="Tag655"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag655"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag656"
          xlink:label="Tag656"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag656"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag657"
          xlink:label="Tag657"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag657"
          xlink:to="footnote1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
